WO2006103399A1 - Hiv integrase inhibitors - Google Patents

Hiv integrase inhibitors Download PDF

Info

Publication number
WO2006103399A1
WO2006103399A1 PCT/GB2006/001062 GB2006001062W WO2006103399A1 WO 2006103399 A1 WO2006103399 A1 WO 2006103399A1 GB 2006001062 W GB2006001062 W GB 2006001062W WO 2006103399 A1 WO2006103399 A1 WO 2006103399A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
hydroxy
fluorobenzyl
methyl
carboxamide
Prior art date
Application number
PCT/GB2006/001062
Other languages
French (fr)
Other versions
WO2006103399A8 (en
Inventor
Giuseppe Cecere
Maria Del Rosario Rico Ferreira
Philip Jones
Paola Pace
Alessia Petrocchi
Vincenzo Summa
Original Assignee
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa filed Critical Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa
Priority to AU2006228278A priority Critical patent/AU2006228278C1/en
Priority to CN200680009660XA priority patent/CN101146811B/en
Priority to JP2008503572A priority patent/JP5116660B2/en
Priority to EP06726483A priority patent/EP1866313A1/en
Priority to CA2600832A priority patent/CA2600832C/en
Priority to US11/887,305 priority patent/US7981879B2/en
Publication of WO2006103399A1 publication Critical patent/WO2006103399A1/en
Publication of WO2006103399A8 publication Critical patent/WO2006103399A8/en
Priority to US13/172,393 priority patent/US20110257162A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Definitions

  • the present invention is directed tetrahydropyrazinopyrimidine carboxamides and related compounds and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of the HTV integrase enzyme.
  • the compounds and pharmaceutically acceptable salts thereof of the present invention are useful for the prophylaxis or treatment of infection by HTV and for the prophylaxis, treatment, or delay in the onset of AIDS.
  • a retrovirus designated human immunodeficiency virus is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system.
  • This virus was previously known as LAV, HTLV-III, or ARV.
  • a common feature of retrovirus replication is the insertion by virally-encoded integrase of +proviral DNA into the host cell genome, a required step in FHV replication in human T-lymphoid and monocytoid cells.
  • Integration is believed to be mediated by integrase in three steps: assembly of a stable nucleoprotein complex with viral DNA sequences; cleavage of two nucleotides from the 3' termini of the linear proviral DNA; covalent joining of the recessed 3' OH termini of the proviral DNA at a staggered cut made at the host target site.
  • the fourth step in the process, repair synthesis of the resultant gap may be accomplished by cellular enzymes.
  • Nucleotide sequencing of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277(1985)].
  • Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, integrase and an HTV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M.D. et al., Science, 231, 1567 (1986); Pearl, L.H. et al., Nature, 329, 351 (1987)]. All three enzymes have been shown to be essential for the replication of BQV.
  • antiviral compounds which act as inhibitors of HIV replication are effective agents in the treatment of AIDS and similar diseases, including reverse transcriptase inhibitors such as azidothymidine (AZT) and efavirenz and protease inhbitors such as indinavir and nelfmavir.
  • the compounds of this invention are inhibitors of HIV integrase and inhibitors of HIV replication.
  • the inhibition of integrase in vitro and HtV replication in cells is a direct result of inhibiting the strand transfer reaction catalyzed by the recombinant integrase in vitro in HTV infected cells.
  • the particular advantage of the present invention is highly specific inhibition of HTV integrase and HTV replication.
  • US 2003/0229079 discloses l-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)- 1, 3 -propanediones useful as BDV integrase inhibitors.
  • US 2003/0055071 (corresponding to WO 02/30930), US 2004/0034221 (corresponding to WO 02/30426), and US 2004/0044207 (corresponding to WO 02/55079) each disclose certain 8-hydroxy-l,6-naphthyridine-7-carboxamides as HTV integrase inhibitors.
  • US 2005/010048 (corresponding to WO 02/036734) discloses certain aza- and polyaza- naphthalenyl ketones to be HIV integrase inhibitors.
  • US2004/229909 (corresponding to WO 2003/016275) discloses certain compounds having integrase inhibitory activity.
  • WO 03/35076 discloses certain 5,6-dihydroxypyrimidine-4-carboxamides as HTV integrase inhibitors
  • US 2005/025774 discloses certain N- substituted 5-hydroxy-6-oxo-l,6-dihydropyrimidine-4-carboxamides as HTV integrase inhibitors
  • WO 03/062204 discloses certain hydroxynaphthyridinone carboxamides that are useful as HTV integrase inhibitors.
  • WO 2004/096128 disclose certain pyrimidine carboxamides that are useful as HTV integrase inhibitors.
  • WO 2005/016927 discloses certain nitrogenous condensed ring compounds that are HIV integrase inhibitors.
  • WO 2005/061490 discloses certain hydroxypyrimidinone derivatives having HTV integrase inhibitory activity.
  • Various pyrimidinone compounds useful as HTV integrase inhibitors are also disclosed in WO 2005/115398, WO 2005/118589, WO 2005/118590, WO 2005/118593, and US 2005/0256109.
  • the present invention is directed to tetrahydropyrazinopyrimidine carboxamides and related compounds. These compounds are useful in the inhibition of HTV integrase, the prophylaxis or treatment of infection by HIV, and the prophylaxis, treatment, or delay in the onset of AIDS and/or ARC, either as compounds or their pharmaceutically acceptable salts or hydrates (when appropriate), or as pharmaceutical composition ingredients, whether or not in combination with other HIV antivirals, anti- infectives, immunomodulators, antibiotics or vaccines. More particularly, the present invention includes compounds of Formula I, and pharmaceutically acceptable salts thereof:
  • X is N(RK) 5 O, S, S(O), S(0)2, where each * denotes the point of attachment to the rest of the molecule;
  • RK is:
  • Ci_6 alkyl substituted with T wherein T is C ⁇ 2R A , CN, S ⁇ 2R A , N(RD)RE,
  • n and n are each independently integers equal to zero, 1, or 2, with the proviso that m + n is zero, 1, or 2;
  • Rl is: (1) H,
  • Ci-6 alkyl substituted with V wherein V is OH, O-Ci-6 alkyl, O-Ci-6 haloalkyl, SRA, S(O)RA, SO2RA, N(RD)RE, C(0)N(RD)RE N(RA)-C(O)C(O)-N(RD)RE, N(RA)-C(O)RB, N(RA)-SO 2 RB, N(RA)-C 1-6 alkylene-SO 2 RB, N(RA)C(O)-C i_6 alkylene-SO 2 RB, N(RA)-SO 2 N(RD)RE, N(RA)_CO 2 RB, or N(RA)-C(0)N(RD)RE,
  • C 1 _6 alkyl substituted with W wherein W is CycA, AryA, HetA, O-C 1 -6 alkylene-CycA, O-Ci-6 alkylene-AryA, O-Ci-6 alkylene-HetA, S(O)j-Ci-6 alkylene-CycA, S(0)j-Ci_6 alkylene-AryA, S(0)j-Ci-6 alkylene-HetA, N(RA)-C(O)-AryA, or N(RA)-C(O)-HetA,
  • each j is independently an integer equal to zero, 1, or 2;
  • R2 is H or Cl _6 alkyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form (i) a 3- to 7-membered saturated carbocyclic ring or (ii) a 4- to 7-membered saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from N, O and S, where independently each N is optionally substituted with C ⁇ . ⁇ alkyl and each S is optionally oxidized to S(O) or S(O)2; ( note: the ring formed by the joining of Rl and R2 provides a spiro ring system)
  • each R.3 is independently H or Ci -6 alkyl, and each R4 is independently H or Cl -6 alkyl; or alternatively R3 and R4 attached to the same carbon atom together form oxo or thioxo;
  • each R5 is independently H or Ci_6 alkyl, and each R6 is independently H or Ci -6 alkyl; or alternatively R5 and R6 attached to the same carbon atom together form oxo or thioxo; R7 is H or C 1-6 alkyl;
  • R.8 is H or C ⁇ . ⁇ alkyl; or alternatively R? and R ⁇ together form oxo or thioxo;
  • R9 is H or alkyl
  • RlO is C ⁇ -6 alkyl substituted with CycC, AryC or HetC;
  • each RA is independently H or Ci_ ⁇ alkyl
  • each RB is independently H or C ⁇ . ⁇ alkyl
  • RC is C l_6 alkyl substituted with CycA, AryA, or HetA; or alternatively, when X is N(RK) and Rl includes the N(RC) moiety, RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- to 7-membered diazacycloalkyl ring, wherein the portion of the fused ring obtained from RC and RK is a 1- to 4- membered methylene chain optionally substituted with oxo or C ⁇ . ⁇ alkyl;
  • each RD and RE are each independently H or C ⁇ . ⁇ alkyl, or together with the nitrogen to which they are both attached form a 4- to 7-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to RD and RE selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently C ⁇ . ⁇ alkyl or S(O)2-Ci_6 alkyl;
  • RF is C 1-6 alkyl, or alternatively, when X is N(RK) and Rl is 8RF or ORF, RF and RK together with (i) the N atom to which RK is attached, (ii) the S or O atom to which RF is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused S- to 7-membered oxyazacycloalkyl or thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is a 1- to 4-membered methylene chain;
  • each CycA is independently C3.8 cycloalkyl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
  • CycB and CycC each independently have the same definition as CycA;
  • each AryA is independently aryl which is optionally substituted with a total of from 1 to 5 substituents, wherein:
  • Ci-6 alkyl (2) Ci_6 alkyl substituted with OH, O-Ci-6 alkyl, O-Cl-6 haloalkyl, CN, NO2,
  • AryB and AryC each independently have the same definition as AryA;
  • each HetA is independently a heteroaryl which is optionally substituted with a total of from 1 to 5 substituents, wherein:
  • HetB and HetC each independently have the same definition as HetA;
  • each CycD is independently a C3_8 cycloalkyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, Ci_6 alkyl, OH, O-Ci-6 alkyl, or Ci_6 haloalkyl;
  • each AryD is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 5 substituents each of which is independently any one of the substituents (1) to (25) as set forth above in part (i) of the definition of AryA;
  • each HetD is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, Ci _6 alkyl, C ⁇ s haloalkyl, O-Ci_ ⁇ alkyl, O-Ci_6 haloalkyl, or hydroxy;
  • each aryl is independently (i) phenyl, (ii) a 9- or 10-membered bicyclic, fused carbocyclic ring system in which at least one ring is aromatic, or (iii) an 11- to 14-membered tricyclic, fused carbocyclic ring system in which at least one ring is aromatic;
  • each heteroaryl is independently (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, or (ii) a 9- or 10-membered bicyclic, fused ring system containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein either one or both of the rings contain one or more of the heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2;
  • the present invention also includes pharmaceutical compositions containing a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention further includes methods for the treatment of AIDS, the delay in the onset of AIDS, the prophylaxis of ADDS, the prophylaxis of infection by HIV, and the treatment of infection by HTV.
  • the present invention includes compounds of Formula I above, and pharmaceutically acceptable salts thereof. These compounds and their pharmaceutically acceptable salts are HTV integrase inhibitors (e.g., HIV-I integrase inhibitors).
  • a first embodiment of the present invention (i.e., Embodiment El) is a compound of
  • Ci_6 alkyl substituted with T wherein T is CO2RA, CN, S ⁇ 2R A , N(RD)RE 5 C(O)N(RD)RE 5 or N(RA)-C(O)RB, (4) Ci_6 haloalkyl,
  • V is S(O)RA 5 N(RA)-C(O)C(O)-N(RD)RE 5 N(RA)-SO2R B , N(RA)-CI_ 6 alkylene-S02R B , N(RA)C(O)-C i_6 alkylene-SO2RB, N(RA)-S02N(RD)RE S N(RA)-C ⁇ 2RB, or N(RA)-C(O)N(RD)RE w h en N(RA)-C(O)N(RD)RE is other than NH-C(0)NH2,
  • W is O-Ci-6 alkylene-CycA, O-Ci-6 alkylene-AryA, O-C ⁇ 6 alkylene-HetA, S(0)j-Ci_6 alkylene-CycA, S(0)j-Ci-6 alkylene-AryA, S(0)j-Ci_6 alkylene-HetA, N(RA)-C(O)-AryA, or N(RA)_c(O)-HetA, (7) N(RA)-SO2N(RD)RE w hen RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring,
  • a second embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as originally defined, and provided that:
  • O-Ci-6 alkylene-AryA O-Ci-6 alkylene-HetA
  • S(0)j-Ci-6 alkylene-CycA S(0)j-Ci_6 alkylene-AryA
  • S(O)j-Ci_6 alkylene-HetA S(O)j-Ci_6 alkylene-HetA
  • CycA (21) N(RA)-C(O)-HetA, (22) N(RA)-C(O)-N(RD)RE w h e n RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring, (23) N(RC)-C(O)-CycA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring, (24) N(RC)-C(O)-AryA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
  • a third embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as originally defined, and provided that:
  • a fourth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the integer m is equal to 1 and the integer n is equal to 1, or m is zero and n is 2, or m is zero and n is 1, or m is 1 and n is zero, or m is zero and n is zero; and all other variables are as originally defined (i.e., as defined for Formula I in the Summary of the Invention) or as defined in any of the preceding embodiments.
  • a fifth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X is N(RK) or O; and all other variables are as originally defined or as defined in any of the preceding embodiments.
  • X is N(RK).
  • a sixth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R9 is H or Cl -.4 alkyl; RlO is:
  • CH2-phenyl or CH2-HetC wherein the phenyl is optionally substituted with a total of from 1 to 3 substituents, wherein (i) from zero to 3 substituents are each independently bromo, chloro, fluoro, C1-4 alkyl, CF3, C(O)NH2, C(O)NH(CM alkyl), C(O)N(Ci_4 alkyl)2, S-C1-4 alkyl, SO2-C1-4 alkyl, or S ⁇ 2N(Ci_4 alkyl)2, and (ii) from zero to 1 substituent is a heteroaromatic selected from the group consisting of imidazolyl, triazolyl, oxadiazolyl, pyrrolyl, and pyrazolyl, wherein the heteroaomatic ring is optionally substituted with 1 or 2 substituents each of which is independently Cl, Br, F,
  • HetC is a heteroaryl which is (i) a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero to 1 O atom, and zero to 1 S atom, or (ii) a 9 or 10-membered bicyclic, fused ring system in which one ring is a benzene ring and the other ring is a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from zero to 3 N atoms, zero to 1 O atom, and zero to 1 S atom, wherein the heteroaryl is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, or Ci_4 alkyl; and all other variables are as originally defined or as defined in any one of the preceding embodiments.
  • R.9 is H and the definition of RlO j s unchanged.
  • a seventh embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R? is H or C 1.4 alkyl; RlO is: (1) CH2-phenyl wherein the phenyl is optionally substituted with a total of from 1 to 2 substituents wherein (i) from zero to 2 substituents are each independently bromo, chloro, fluoro, CH3, CF3, C(O)NH2, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or S ⁇ 2N(CH3)2, and (ii) from zero to 1 substituent is oxadiazolyl optionally substituted with CH3, or (2) CH2-HetC, wherein HetC is a heteroaryl which is quinolinyl, indazolyl, benzoxazolyl, isoquinolinyl, cinnolinyl, quinazolinyl, benzopyranyl, wherein the heteroaryl is
  • An eighth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R9 is H; RlO is 4-fluorobenzyl, 3- chloro-4-fluorobenzyl, 3-chloro-4-methylbenzyl, 4-fluoro-3-methylbenzyl, 3-chlorobenzyl, 4-fluoro-2- methylsulfonylbenzyl, 3-bromo-4-fluorobenzyl, 4-fluoro-2-[(methylamino)carbonyl]benzyl, 2- methylthiobenzyl, 4-fluoro-2-[(3-methyl)-l,2,4-oxadiazol-5-yl]benzyl, or [(5-fluoro)quinolin-8- yljmethyl; and all other variables are as originally defined or as defined in any one of the preceding embodiments.
  • a ninth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R9 is H; RlO is 4-fluorobenzyl; and all other variables are as originally defined or as defined in any one of the preceding embodiments.
  • a tenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
  • X is N(RK) or O
  • RK is:
  • Ci-4 alkyl substituted with T wherein T is C ⁇ 2R A , CN, N(RD)RE, or C(O)N(RD)RE, (4) C(O)RA,
  • Ci_4 alkyl substituted with U wherein U is CycB, AryB, or HetB, or
  • V is OH, O-C1.4 alkyl, SRA, S(O)RA, SO 2 RA,
  • N(RD)RE 5 C(O)N(RD)RE, N(RA)-C(O)C(O)-N(RD)RE, N(RA)-C(O)RB,
  • N(RA)-SO 2 RB N(RA)-Ci-4 alkylene-SO 2 RB, N(RA)C(O)-Ci .4 alkylene-SO 2 RB,
  • W is CycA, AryA, HetA, O-Ci-4 alkylene-AryA, O-Ci_4 alkylene-HetA, or N(RA)-C(O)-HetA,
  • R2 is H or C 1-4 alkyl; or alternatively Rl and R ⁇ together with the ring carbon atom to which they are both attached form (i) a 3- to 6-membered saturated carbocyclic ring or (ii) a 6-membered saturated heterocyclic ring containing 1 heteroatom selected from N, O and S, where the N is optionally substituted with C 1-4 alkyl and the S is optionally oxidized to S(O) or S(O)2;
  • each R 3 is independently H or C 1.4 alkyl, and each R4 is independently H or C 1.4 alkyl; or alternatively R3 and R4 attached to the same carbon atom together form oxo;
  • each R5 is independently H or Ci_4 alkyl, and each Rfi is independently H or Ci_4 alkyl; or alternatively R5 and R ⁇ attached to the same carbon atom together form oxo;
  • R? is H or C 1-4 alkyl
  • R8 is H or C 1-4 alkyl; or alternatively R7 and R ⁇ together form oxo;
  • R9 is H or Ci-4 alkyl
  • RlO is C 1-4 alkyl substituted with CycC, AryC or HetC;
  • each RA is independently H or Ci .4 alkyl
  • each RB is independently H or Ci .4 alkyl
  • RC is C I_4 alkyl substituted with CycA, AryA, or HetA; or alternatively, when X is N(RK) and Rl includes the N(RC) moiety, RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered diazacycloalkyl ring; wherein the portion of the fused ring obtained from RC and RK is a 1- to 3- membered methylene chain optionally substituted with oxo or C 1.4 alkyl;
  • each RD and RE are independently H or C 1.4 alkyl, or together with the nitrogen to which they are both attached form a 5- or 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently Ci .4 alkyl or S(O)2-Ci_4 alkyl;
  • RF is Ci-4 alkyl, or alternatively, when X is N(RK) and Rl is SRF, RF and RK together with (i) the N atom to which RK is attached, (ii) the S atom to which RF is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is a 1- to 3-membered methylene chain;
  • each CycA is independently a C3.6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl, OH, or O-C1.4 alkyl;
  • CycB is a C3.6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl, OH, or O-C1.4 alkyl;
  • CycC is a C3-6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl, OH, or O-C1.4 alkyl;
  • each AryA is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 3 substituents each of which is independently:
  • C i-4 alkyl which is optionally substituted with OH, O-C1.4 alkyl, O-C1.4 haloalkyl, CN 5 N(RA)RB 3 C(O)N(RA)RB 5 C(O)RA, CO2RA, SRA S(O)RA, SO2RA, or
  • AryB independently has the same definition as AryA;
  • AryC is phenyl or naphthyl, wherein the phenyl or naphthyl is: (i) optionally substituted with from 1 to 3 substituents each of which is independently any one of the substituents (1) to (17) as set forth above in the definition of AryA, and (ii) optionally substituted with:
  • each HetA is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, C 1.4 alkyl, or OH;
  • HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, C 1.4 alkyl, or OH;
  • HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is:
  • each CycD is independently a C3.6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently Ci .4 alkyl, OH, or O-C1.4 alkyl;
  • each AryD is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 3 substituents each of which is independently any one of the substituents (1) to (17) as set forth above in the definition of AryA; and
  • each HetD is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, C 1.4 alkyl, or OH.
  • An eleventh embodiment of the present invention is a compound of Formula I wherein the variables are as defined in Embodiment ElO, and provided that: (A) when m is zero and X is O, then Rl is not H or C 1.4 alkyl;
  • T is C ⁇ 2R A , CN, N(RD)RE 5 or C(O)N(RD)RE,
  • U is CH2-HetB
  • HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group, and m is zero and the -C(R5R6) n C(R7R8). moiety is -CH2CH2-), then Rl is:
  • V is S(O)RA, N(RA)-C(O)C(O)-N(RD)RE 3 N(RA)-SO2RB, N(RA)-CI_4 alkylene-S02R B , N(RA)C(O)-Ci -4 alkylene-SO2R B , N(RA)-SO2N(RD)RE, O ⁇ N(RA)-CO2RB,
  • N(RA)-C(O)-HetA N(RC)-C(O)-N(RD)RE when (i) RD and RE together with the N to which they are both attached form a optionally substituted saturated heterocyclic ring or (ii) RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring), (15) N(RA)-C(O)C(O)-N(RD)RE or (16) N(RC)-C(O)C(O)-N(RD)RE ; or
  • a twelfth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined in Embodiment ElO, and provided that:
  • Ci_4 alkyl (3) Ci-4 alkyl substituted with T, wherein T is C ⁇ 2R A , CN, N(RD)RE, or
  • Ci_4 alkyl substituted with V wherein V is S(O)RA, N(RA)-C(O)C(O)-N(RD)RE 5 N(RA)-SO 2 RB, N(RA)-Ci_4 alkylene-SO2RB, N(RA)C(O)-Ci -4 alkylene-SO2RB, N(RA)-SO2N(RD)RE 5 orN(RA)-CO2R B , (4) C 1-4 alkyl substituted with W, wherein W is O-C i_4 alkylene-AryA,
  • O-Ci-4 alkylene-HetA or N(RA)-C(O)-HetA,
  • a thirteenth embodiment of the present invention is a compound of
  • a fourteenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is a compound of Formula II, HI, IV, V, VI, orV ⁇ :
  • a fifteenth embodiment of the present invention is a compound of any one of Formulas ⁇ , DI, IV, V and VI, or a pharmaceutically acceptable salt thereof, wherein: Rl and R2 are both methyl (except in Formula IV where Rl and R2 are both H); R 5 , R6, RV and R ⁇ are each H; RlO is 4-fluorobenzyl; RK is CH 2 -HetB; and HetB is a 5-membered heteroaromatic ring containing from
  • the compound is a compound of Formula ⁇ , or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula DI, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula IV, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula V, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula VI, or a pharmaceutically acceptable salt thereof.
  • a sixteenth embodiment of the present invention is a compound of any one of Formulas II, IH, V, VI and VD, or a pharmaceutically acceptable salt thereof, wherein: Rl is N(RA)-C(O)C(O)-N(RD)RE or N(RC)-C(O)C(O)-N(RD)RE; R2 i s H; and all other variables are as defined in Embodiment ElO.
  • the compound is a compound of Formula H, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula DI, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula V, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula VI, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula V ⁇ , or a pharmaceutically acceptable salt thereof.
  • a seventeenth embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
  • X is N(RK) or O
  • RK is:
  • Ci_4 alkyl (3) (CH2)l-2-T, wherein T is C ⁇ 2R A , CN, N(RD)RE, O r C(O)N(RD)RE,
  • R2 is H or C I_4 alkyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form cyclopropyl, cyclobutyl, cyclopenryl, cyclohexyl, or oxacyclohexyl (alternatively known in the art as tetrahydropyranyl); each R ⁇ is H, and each R.4 is H; or alternatively R ⁇ and R.4 attached to the same carbon atom together form oxo;
  • each R ⁇ is H, and each R6 is H; or alternatively R ⁇ and R ⁇ attached to the same carbon atom together form oxo;
  • R7 is H
  • R8 is H; or alternatively R7 and R ⁇ together form oxo;
  • R9 is H
  • RlO is CH2-CycC, CH2-AryC or Clfe-HetC;
  • each RA is independently H or C 1-4 alkyl
  • each RB is independently H or C 1.4 alkyl
  • RC is (CH2) l -2-CycA, (CH2) 1 -2-AryA, or (CH2) 1 -2-HetA; or alternatively, when X is N(RK), RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered diazacycloalkyl ring; wherein the portion of the fused ring obtained from RC and RK is a 1- to 3-membered methylene chain optionally substituted with oxo;
  • each RD and RE are independently H or C 1.4 alkyl, or together with the nitrogen to which they are both attached form a 5- or 6-membered saturated heterocyclic ring selected from the group consisting of *— N ⁇ I *-N ) *-N p *-N S *-N S(O) *-N S(O) 2
  • RF is C 1-4 alkyl, or alternatively, when X is N(RK) and Rl is SRF, RF and RK together with (i) the N atom to which RK is attached, (ii) the S atom to which RF is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is a 1- to 3-membered methylene chain;
  • each CycA is independently a C3_6 cycloalkyl
  • CycB is a C3.6 cycloalkyl
  • CycC is a C ⁇ -6 cycloalkyl
  • AryA, AryB and AryC are each independently phenyl which is optionally substituted with 1 or 2 substituents each of which is independently bromo, chloro, fluoro, C 1.4 alkyl, CF3, C(O)NH2, C(O)NH(Ci_4 alkyl), C(O)N(CM alkyl)2, S-C1.4 alkyl, SO2-C1.4 alkyl, or S ⁇ 2N(Ci_4 alkyl)2; and
  • HetA, HetB, and HetC are each independently a 5- or 6-membered heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, isooxazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridinyl, pyridinyl N-oxide, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein the heteroaromatic ring is optionally substituted with from 1 or 2 substituents each of which is independently a Cl .4 alkyl;
  • Embodiment E 18 is a compound of
  • A, B, C and D as set forth in Embodiment El 1 are applied.
  • X is N(RK).
  • a nineteenth embodiment of the present invention (Embodiment E 19) is a compound of
  • a twentieth embodiment of the present invention is a compound of
  • X is N(RK).
  • RK the definitions of variables in the provisos set forth in Embodiments El 1, El 2 and El 3 can be customized in the provisos in Embodiments El 8, El 9 and E20 so that the definitions therein match (i.e., are consistent with) the definitions of the variables in Embodiment E17.
  • part (3) of the definition of RK in Embodiment E17 recites "(CH2)l-2-T".
  • the reference to "C1.4 alkyl substituted with T" in part (3) of the definition of RK in proviso C of Embodiment El 1 can be rewritten here to refer to "(CH2)l-2-T".
  • a twenty-first embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
  • X is N(RK) or O
  • RK is:
  • T is CO2H, CO2CH3, CO2CH2CH3, CN, N(CH3>2, N(CH 2 CH 3 )2, C(O)NH2, C(O)NH(CH3), C(O)N(CH 3 )2, C(O)NH(CH 2 CH 3 ),
  • (CH2)l-2-U wherein U is cyclopropyl, cyclopentyl, cyclohexyl, phenyl, or a heteroaromatic ring selected from the group consisting of pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, and pyrazinyl, wherein the heteroaromatic ring is optionally substituted with methyl, (15) (CH2)l-2C(O)N(H)-(CH 2 )l-2-pyridinyl,
  • Ci_ 4 alkyl (3) (CH2)l-2-V, wherein V is OH, OCH 3 , SCH3, SO2CH3, N(CH 3 )2, C(0)NH2,
  • R2 is H or C 1-4 alkyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form cyclopropyl, cyclopentyl, cyclohexyl, or tetrahydropyran-4-yl;
  • each R3 is H, and each R4 is H; or alternatively R3 and R4 attached to the same carbon atom together form oxo;
  • each R5 is H, and each R6 is H; or alternatively R5 and R6 attached to the same carbon atom together form oxo;
  • R7 is H
  • R8 is H; or alternatively R7 and R& together form oxo;
  • R9 is H
  • RlO is CH2-phenyl, wherein the phenyl is optionally substituted with 1 or 2 substituents each of which is independently bromo, chloro, fluoro, CH3, CF3, C(O)NH 2 , C(0)NH(CH3), C(O)N(CH3)2, SCH3, SO 2 CH 3 , or SO 2 N(CH3)2;
  • RC is CH2-cyclohexyl or CH2-phenyl where the phenyl is optionally substituted with 1 or 2 substituents each of which is independently bromo, chloro, fluoro, methyl, ethyl, CF3, C(O)NH 2 , C(0)NH(CH3), C(O)NH(CH 2 CH 3 ), C(O)N(CH3)2, SCH3, SO2CH3, or S ⁇ 2N(CH3)2; or alternatively:
  • HetA is a heteroaromatic ring selected from the group consisting of pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridinyl N-oxide, and pyrazinyl, wherein the heteroaromatic ring is optionally substituted with methyl;
  • X is N(RK).
  • a twenty-second embodiment of the present invention is a compound of Formula-I as defined in Embodiment E21, or a pharmaceutically acceptable salt thereof, wherein provisos A, B, C and D as set forth in Embodiment El 1 are applied.
  • X is N(RK).
  • a twenty-third embodiment of the present invention is a compound of Formula I as defined in Embodiment E21, or a pharmaceutically acceptable salt thereof, wherein provisos A, B and C as set forth in Embodiment E12 are applied.
  • X is N(RK).
  • a twenty-fourth embodiment of the present invention is a compound of Formula I as defined in Embodiment E21, or a pharmaceutically acceptable salt thereof, wherein provisos A, B and C as set forth in Embodiment E13 are applied.
  • X is
  • a first class of the present invention includes compounds of Formula VIII and pharmaceutically acceptable salts thereof:
  • RK is:
  • Rl is:
  • RC is CH2-cyclohexyl, CH2-phenyl, or CH2-phenyl where the phenyl is para-substituted with fluoro;
  • Yl and Y2 are each independently H, Br, Cl, F, CH3, C(0)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2.
  • a sub-class of the first class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment El 1 is applied.
  • Another sub-class of the first class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment E12 is applied.
  • Another sub-class of the first class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment El 3 is applied.
  • a second class of the present invention includes compounds of Formula IX and pharmaceutically acceptable salts thereof:
  • RK is H or C 1-3 alkyl, CH2-phenyl, or CH2-pyridinyl
  • Yl and Y2 are each independently H, Br, Cl, F, CH3, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2.
  • a sub-class of the second class includes compounds of Formula IX, and pharmaceutically acceptable salts thereof, wherein R.K is H or Cl _3 alkyl; and all other variables are as originally defined in the second class.
  • Another sub-class of the second class includes compounds of Formula DC, and pharmaceutically acceptable salts thereof, wherein R.K is C 1.3 alkyl, CH2-phenyl, or CH2-pyridinyl; and all other variables are as originally defined in the second class.
  • a third class of the present invention includes compounds of Formula X and pharmaceutically acceptable salts thereof:
  • Rl is:
  • Yl and Y2 are each independently H, Br, Cl, F, CH3, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2.
  • a sub-class of the third class includes the compounds of Formula X, and pharmaceutically acceptable salts thereof, wherein Rl is other than H; i.e., Rl is any one of the groups (2) to (25) as originally defined in the third class; and all other variables are as originally defined in the third class.
  • a fourth class of the present invention includes compounds of Formula XI and pharmaceutically acceptable salts thereof:
  • R2 is H or methyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form cyclopropyl or tetrahydropyran-4-yl; and
  • Yl and Y2 are each independently H, Br, Cl, F, CH3, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2.
  • a sub-class of the fourth class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein provisos C and D as set forth in Embodiment El 1 is applied.
  • Another sub-class of the fourth class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment E12 is applied.
  • Another sub-class of the fourth class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment El 3 is applied.
  • a fifth class of the present invention includes compounds of Formula XII and pharmaceutically acceptable salts thereof:
  • RK is Ci-3 alkyl, CH2-phenyl, CH2-pyridinyl, or (CO)CHa;
  • Yl and ⁇ 2 are each independently H, Br, Cl, F, CH3, C(O)NH(CHa), C(O)N(CH3)2, SCH3, SO2CH3, or SO 2 N(CH 3 )2.
  • a sixth class of the present invention includes compounds of Formula XIH, XTV, and XV, and pharmaceutically acceptable salts thereof:
  • RK is Ci-3 alkyl, CH2-phenyl, or CH2-pyridinyl
  • Yl and ⁇ 2 are each independently H, Br, Cl, F, CH3, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or S ⁇ 2N(CH3)2-
  • a sub-class of the sixth class includes compounds of Formula XV, and pharmaceutically acceptable salts thereof.
  • Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in Table 1 below.
  • Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from Compounds 1-4, 6, 7, 9-39 and 41-185.
  • Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from Compounds 60, 61, 63, 64, 69, 71, 72, 75, 76, 82, 84, 85, 86, 87, 89, 91, 92, 110, 113-136, 138, 142-150, 153-157, 180 and 181.
  • Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from Compounds 87, 116-119, 121, 123-136, 142-150, 154-157, 180 and 181.
  • Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from Compounds 116-119, 121, 123-136, 142-150, 154-157, 180 and 181.
  • the compounds in these two embodiments have exhibited excellent potency in the integrase assay (Example 32) and in the spread assay (Example 33). It is believed that these compounds are active against clinical mutants that have been generated with approved HTV reverse transcriptase inhibitors and protease inhibitors.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as originally defined or as defined in any of the foregoing embodiments, classes, or sub-classes, wherein the compound or its salt is in a substantially pure form.
  • substantially pure means suitably at least about 60 wt.%, typically at least about 70 wt.%, preferably at least about 80 wt.%, more preferably at least about 90 wt.% (e.g., from about 90 wt.% to about 99 wt.%), even more preferably at least about 95 wt.% (e.g., from about 95 wt.% to about 99 wt.%, or from about 98 wt.% to 100 wt.%), and most preferably at least about 99 wt.% (e.g., 100 wt.%) of a product containing a compound Formula I or its salt (e.g., the product isolated from a reaction mixture affording the compound
  • the level of purity of the compounds and salts can be determined using a standard method of analysis such as thin layer chromatography, gel electrophoresis, high performance liquid chromatography, and/or mass spectrometry.
  • a compound or salt of 100% purity is one which is free of detectable impurities as determined by one or more standard methods of analysis.
  • a substantially pure compound can be either a substantially pure mixture of the stereoisomers or a substantially pure individual diastereomer or enantiomer.
  • compositions comprising an effective amount of a compound of Formula I and a pharmaceutically acceptable carrier.
  • pharmaceutical composition which comprises the product prepared by combining (e.g., mixing) an effective amount of a compound of Formula I and a pharmaceutically acceptable carrier.
  • an anti-HTV agent selected from the group consisting of HTV antiviral agents, immunomodulators, and anti-infective agents.
  • composition of (c), wherein the anti-FflV agent is an antiviral selected from the group consisting of FHV protease inhibitors, non-nucleoside HTV reverse transcriptase inhibitors, and nucleoside HTV reverse transcriptase inhibitors.
  • a pharmaceutical combination which is (i) a compound of Formula I and (ii) an anti-HTV agent selected from the group consisting of FlIV antiviral agents, immunomodulators, and anti- infective agents; wherein the compound of Formula I and the anti-FHV agent are each employed in an amount that renders the combination effective for the inhibition of FHV integrase, for the treatment or prophylaxis of infection by FUV, or for the treatment, prophylaxis or delay in the onset of ADDS.
  • anti-HTV agent is an antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HTV reverse transcriptase inhibitors and nucleoside HTV reverse transcriptase inhibitors.
  • (k) The method of (j), wherein the compound is administered in combination with an effective amount of at least one antiviral selected from the group consisting of HTV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HTV reverse transcriptase inhibitors.
  • a method of inhibiting HTV integrase in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • (m) A method for the treatment or prophylaxis of infection by HTV in a subj ect in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • a method for the treatment, prophylaxis, or delay in the onset of AIDS in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • the present invention also includes a compound of the present invention (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) the inhibition of HTV integrase, (b) treatment or prophylaxis of infection by HTV, or (c) treatment, prophylaxis, or delay in the onset of AIDS, hi these uses, the compounds of the present invention can optionally be employed in combination with one or more anti-HTV agents selected from HTV antiviral agents, anti-infective agents, and immunomodulators.
  • Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub-classes, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt.
  • the present invention also includes prodrugs of the compounds of Formula I.
  • prodrug refers to a derivative of a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is converted in vivo into Compound I.
  • Prodrugs of compounds of Formula I can exhibit enhanced solubility, absorption, and/or lipophilicity compared to the compounds per se, thereby resulting in increased bioavailability and efficacy.
  • the in vivo conversion of the prodrug can be the result of an enzyme-catalyzed chemical reaction, a metabolic chemical reaction, and/or a spontaneous chemical reaction (e.g., solvolysis).
  • the prodrug can be an ester or an amide
  • the prodrug can be an amide, carbamate, imine, or a Mannich base.
  • One or more functional groups in Compound I can be derivatized to provide a prodrug thereof.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, edited by H. Bundgaard, Elsevier, 1985; C. S. Larsen and J. Ostergaard, "Design and application of prodrugs" in: Textbook of Drug Design and Discovery, 3 rd edition, edited by C. S.
  • Cj-6 alkyl refers to all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-buryl, n- and isopropyl, ethyl and methyl.
  • Ci -4 alkyl refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • alkylene refers to any divalent linear or branched chain aliphatic hydrocarbon radical (or alternatively an “alkanediyl”) having a number of carbon atoms in the specified range.
  • -Ci_6 alkylene- refers to any of the Ci to C ⁇ linear or branched alkylenes.
  • a class of alkylenes of particular interest with respect to the invention is -(CH2)l-6-j and sub-classes of particular interest include -(CH2)l-4-, -(CH2)l-3-, -(CH2)l-2- > and -CH2-.
  • alkylene -CH(CH3)- is also of interest.
  • cycloalkyl refers to any cyclic ring of an alkane having a number of carbon atoms in the specified range.
  • C3-8 cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopenryl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • halogen refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
  • haloalkyl refers to an alkyl group as defined above in which one or more of the hydrogen atoms has been replaced with a halogen (i.e., F, Cl, Br and/or I).
  • a halogen i.e., F, Cl, Br and/or I.
  • Ci -6 haloalkyl or “Ci-Cg haloalkyl” refers to a Ci to Cg linear or branched alkyl group as defined above with one or more halogen substituents.
  • fluoroalkyl has an analogous meaning except that the halogen substituents are restricted to fluoro. Suitable fluoroalkyls include the series (CH2) ⁇ -4CF3 (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
  • diazacycloalkyl means a saturated cyclic ring consisting of two nitrogens and one or more carbon atoms (e.g., imidazolidinyl, pyrazolidinyl, or piperazinyl).
  • oxyazacycloalkyl means a saturated cyclic ring consisting of an oxygen atom, a nitrogen atom, and one or more carbon atoms.
  • thioazacycloalkyl means a saturated cyclic ring consisting of a sulfur atom, a nitrogen atom, and one or more carbon atoms.
  • 1 - to 4-membered methylene chain means a divalent radical of formula
  • a heterocyclic ring described as containing from “1 to 4 heteroatoms” means the ring can contain 1, 2, 3 or 4 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. Thus, for example, a heterocyclic ring described as containing from “1 to 4 heteroatoms” is intended to include as aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, and so forth.
  • any variable e.g., RA J RB 3 O r AryD
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • substituted e.g., as in “is optionally substituted with from 1 to 5 substituents "
  • substitution by a named substituent is permitted on any atom in a ring (e.g., aryl, a heteroaromatic ring, or a saturated heterocyclic ring) provided such ring substitution is chemically allowed and results in a stable compound.
  • a ring e.g., aryl, a heteroaromatic ring, or a saturated heterocyclic ring
  • Any of the various carbocyclic and heterocyclic rings and ring systems defined herein may be attached to the rest of the compound at any ring atom (i.e., any carbon atom or any heteroatom) provided that a stable compound results.
  • Suitable aryls include phenyl, 9- and 10-membered bicyclic, fused carbocyclic ring systems, and 11- to 14-membered tricyclic fused carbocyclic ring systems, wherein in the fused carbocyclic ring systems at least one ring is aromatic.
  • Suitable aryls include, for example, phenyl, naphthyl, tetrahydronaphthyl (tetralinyl), indenyl, anthracenyl, and fluorenyl.
  • Suitable heteroaryls include 5- and 6-membered heteroaromatic rings and 9- and 10-membered bicyclic, fused ring systems, wherein the heteroaromatic ring or the bicyclic, fused ring system contains from 1 to 4 heteroatoms selected from N, O and S.
  • Suitable 5- or 6-membered heteroaromatic rings include, for example, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
  • Suitable heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromenyl, quinolinyl, isoquinolinyl, cinnolinyl, and quinazolinyl.
  • Suitable saturated heterocyclics include 4- to 7- membered saturated heterocyclic rings containing 1 or 2 heteroatoms selected from N, O and S.
  • Suitable 4- to 7-membered saturated heterocyclics include, for example, azetidinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, and dioxanyl.
  • saturated heterocyclics that may be formed by the joining of Rl and R.2 together with the ring carbon to which they are both attached.
  • Saturated heterocyclics that may be formed by the joining of RP and R.E together with the nitrogen to which they are both attached include, for example, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepanyl, diazepanyl, and thiazinanyl.
  • a “stable” compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
  • substituents and substituent patterns certain of the compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers or enantiomers. All isomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention.
  • certain of the compounds of the present invention can exist as tautomers. All tautomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention.
  • Compounds of the present invention having a hydroxy substituent on a carbon atom of a heteroaromatic ring are understood to include compounds in which only the hydroxy is present, compounds in which only the tautomeric keto form (i.e., an oxo substitutent) is present, and compounds in which the keto and enol forms are both present.
  • the compounds of the present inventions are useful in the inhibition of HTV integrase (e.g., HTV-I integrase), the prophylaxis or treatment of infection by HTV and the prophylaxis, treatment or the delay in the onset of consequent pathological conditions such as AIDS.
  • HTV integrase e.g., HTV-I integrase
  • the prophylaxis of ADDS, treating AIDS, delaying the onset of AIDS, the prophylaxis of infection by HTV, or treating infection by HTV is defined as including, but not limited to, treatment of a wide range of states of HTV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HTV.
  • the compounds of this invention are useful in treating infection by HTV after suspected past exposure to HTV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HTV integrase, e.g., by competitive inhibition.
  • the compounds of this invention can be commercial products to be sold for these purposes.
  • the compounds of the present invention can be administered in the form of pharmaceutically acceptable salts.
  • salt refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
  • Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
  • suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
  • alkali metal salts e.g., sodium or potassium salts
  • alkaline earth metal salts e.g., calcium or magnesium salts
  • suitable organic ligands such as quaternary ammonium salts.
  • pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
  • administration and variants thereof (e.g., “administered” or “administering") in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment or prophylaxis.
  • a compound of the invention or a prodrug thereof is provided in combination with one or more other active agents (e.g., antiviral agents useful for the prophylaxis or treatment of HIV infection or ADDS)
  • “administration” and its variants are each understood to include provision of the compound or prodrug and other agents at the same time or at different times.
  • the agents of a combination are administered at the same time, they can be administered together in a single composition or they can be administered separately.
  • composition is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
  • pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • the term "effective amount” as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • the effective amount is a "therapeutically effective amount” for the alleviation of the symptoms of the disease or condition being treated.
  • the effective amount is a "prophylactically effective amount” for prophylaxis of the symptoms of the disease or condition being prevented.
  • the term also includes herein the amount of active compound sufficient to inhibit HIV integrase and thereby elicit the response being sought (i.e., an "inhibition effective amount").
  • references to the amount of active ingredient are to the free acid or free base form of the compound.
  • the compounds of the present invention can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the compounds of the invention can, for example, be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
  • Liquid preparations suitable for oral administration e.g., suspensions, syrups, elixirs and the like
  • Solid preparations suitable for oral administration can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like.
  • Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as a solubility aid.
  • injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose.
  • compositions can be provided in the form of tablets or capsules containing about 1.0 to about 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
  • an anti-HIV agent is any agent which is directly or indirectly effective in the inhibition of HTV integrase or another enzyme required for HTV replication or infection, the treatment or prophylaxis of HIV infection, and/or the treatment, prophylaxis or delay in the onset of AIDS. It is understood that an anti-HIV agent is effective in treating, preventing, or delaying the onset of HTV infection or AIDS and/or diseases or conditions arising therefrom or associated therewith.
  • the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more HTV antivirals, imunomodulators, antiinfectives, or vaccines useful for treating HTV infection or AIDS, such as those disclosed in Table 1 of WO 01/38332 or in the Table in WO 02/30930.
  • HTV antivirals for use in combination with the compounds of the present invention include, for example, HTV protease inhibitors (e.g., indinavir, atazanavir, lopinavir optionally with ritonavir, saquinavir, or nelfinavir), nucleoside HTV reverse transcriptase inhibitors (e.g., abacavir, lamivudine (3TC), zidovudine (AZT), or tenofovir), and non-nucleoside HTV reverse transcriptase inhibitors (e.g., efavirenz or nevirapine).
  • HTV protease inhibitors e.g., indinavir, atazanavir, lopinavir optionally with ritonavir, saquinavir, or nelfinavir
  • nucleoside HTV reverse transcriptase inhibitors e.g., abacavir, lamivudine
  • HTV antivirals and other agents will typically be employed in these combinations in then- conventional dosage ranges and regimens as reported in the art, including, for example, the dosages described in the Physicians' Desk Reference, 57 th edition, Thomson PDR, 2003, or the 59 th edition thereof, 2005.
  • the dosage ranges for a compound of the invention in these combinations are the same as those set forth above.
  • Scheme B depicts the synthesis of 3-hydroxy-7,8,8-substituted-4-oxo-4,6,7,8- tetrahydroimidazo[l ,5- ⁇ ]pyrimidine-2-caxboxamides.
  • the 2-substituted-5,6-dihydroxypyrimidine-4- carboxamide 1-1 can be treated with trimethyl orthofbrmate and an aldehyde or ketone to obtain the compound 1-5.
  • Substrate 1-1 can alternatively be treated with trimethyl orthoformate and phosgene to provide compound 1-5 in which R? and R.8 together form oxo.
  • Scheme C depicts the synthesis of 3-hydroxy-9,10 5 10-substituted-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2- ⁇ ][l,4]diazepine-2-carboxamides.
  • the 2-substituted-5,6-dihydroxypyrimidine-4- carboxamide 1-7 can be obtained by reductive alkylation of the amino derivative 1-1 with a ben2yl protected hydroxyalkyl aldehyde (exemplified in Scheme C with 3-(benzyloxy)propanal) followed by removal of the benzyl protective group by, e.g., hydrogenolysis.
  • Intramolecular cyclization under Mitsunobu conditions e.g., treatment with DEAD in the presence of PPI13
  • Acylation, sulfonylation, or alkylation of the nitrogen at the 9 position of 1-8 can then provide the desired compound 1-9.
  • reductive amination can provide desired compound l-9a.
  • Scheme D depicts the synthesis of 10-substituted-3-hydroxy-8-substituted-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2- ⁇ [l,4]diazepine-2-carboxamides.
  • Amide 1-10 can be prepared in accordance with WO 2001/090082.
  • the amidoxime 1-11 can be obtained by thioamidation of the amide 1-10 with P4S10 followed by treatment with hydroxylamine.
  • Reaction of the amidoxime 1-11 with dimethylacetylenedicarboxylate, followed by cylization at high temperature in a suitable solvent e.g., toluene, xylenes (individually or mixtures), chlorobenzene, or an alkyl alcohol such as MeOH
  • a suitable solvent e.g., toluene, xylenes (individually or mixtures), chlorobenzene, or an alkyl alcohol such as MeOH
  • a suitable solvent e.g., toluene, xylenes (individually or mixtures), chlorobenzene, or an alkyl alcohol such as MeOH
  • the methyl ester 1-12 can then be treated with DDQ, followed by treatment with with with benzylamine or a N-benzyl-N-alkylamine to obtain compound 1-13.
  • the benzyl group of 1-13 can be removed by hydrogenolysis, after which the methyl ester can be converted to amide 1-14 by
  • Scheme E shows an alternative approach to Scheme D for the preparation of compound 1-16.
  • the intermediate compound 1-13 is first deprotected, followed by acylation, sulfonylation or reductive amination using standard chemistry to give 1-17.
  • Hydrogenolysis of 1-17 followed by acylation, sulfonylation or reductive amination using standard chemistry provides compound 1-18, and then coupling 1-18 with the appropriate amine affords the desired compound 1-16 or l-16a.
  • Scheme G depicts the synthesis of 10-substituted-3-hydroxy-8-substituted-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2- ⁇ [l,4]diazepme-2-carboxamides.
  • Nitrile 1-21 prepared in the manner described in Eur. J. Org. Chem.
  • amidoxime 1-22 is treated with dimethylacetylenedicarboxylate, and then cyclized at high temperature in a suitable solvent (e.g., toluene, xylenes (individually or in mixtures), chlorobenzene, or an alkyl alcohol such as MeOH) to obtain the pyrimidine methyl ester.
  • a suitable solvent e.g., toluene, xylenes (individually or in mixtures), chlorobenzene, or an alkyl alcohol such as MeOH
  • the 5-hydroxy in the pyrimidine methyl ester intermediate is then protected using, e.g., benzoic anhydride to afford methyl ester 1-23.
  • Ester 1-23 can be converted into an amide by coupling with an appropriate amine followed by the Boc deprotection with a suitable acid (e.g., TFA) to generate the free amino compound 1-24.
  • a suitable acid e.g., TFA
  • Reductive amination of amine 1-24 with chloroacetaldehyde followed by ring closure with KO-t-Bu can provide the cyclized compound 1-25.
  • Boc protection of the nitrogen in the 8 position of 1-25 and removal of the benzyl group by hydrogenolysis produces alcohol 1-26, which can be activated with MsCl (e.g., at room temperature in the presence of TEA and a suitable solvent such as CHCI3) and then displaced with an appropriate benzylamine (e.g., coupling with the amine in a suitable solvent such as acetonitrile at elevated temperature and then ageing the reaction mixture until completion of the reaction) to afford amine compound 1-27.
  • MsCl e.g., at room temperature in the presence of TEA and a suitable solvent such as CHCI3
  • an appropriate benzylamine e.g., coupling with the amine in a suitable solvent such as acetonitrile at elevated temperature and then ageing the reaction mixture until completion of the reaction
  • R* R 8 SO 2 -, R 6 CO-, or R 6 CH 2 -
  • Scheme H depicts the synthesis of 8-substituted-3-hydroxy-4-oxo-4 ; 6,7,8,9,10- hexahydropyrimido[l,2-c(][l,4]diazepine-2-carboxamides.
  • the intermediate compound 1-12 is first deprotected (e.g., by treating with an acid such as TFA), followed by acylation, sulfonylation or reductive amination using standard chemistry to give 1-30. Coupling with the appropriate amine produces the compound 1-31.
  • Scheme I depicts the synthesis of 10-substituted-3-hydroxy-4-oxo-6,7,9,10-tetrahydro- 4H-pyrimido[l,2- ⁇ [l,4]oxazepine-2-carboxamides.
  • Thioamidation of 4-oxacaprolactam 1-32 with P4S10 followed by treatment with hydroxylamine affords amidoxime 1-33.
  • Scheme J depicts a method for preparing 3-hydroxy-4,7-dioxo-6,7,8,9-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2-carboxamides and 3-hydroxy-4,7,7-trioxo-8,9-dihydro-4H-pyrimido[2,l- d][l,2,5]thiadiazine-2-carboxamides.
  • the amino group at the 2-position of pyrimidine carboxamide 1-1 is sulfonylated/acylated with halomethylsufonyl halide/haloacetyl halide to afford sulfonylated/acylated intermediate 1-40, which can then undergo internal alkylation via treatment with cesium carbonate to afford the desired bicyclic 1-41.
  • Scheme K depicts a method for preparing 3-hydroxy-4,6-dioxo-6,7,8,9-tetrahydro-4H- pyrimido[l,6-a]pyrimidine-2-carboxamides.
  • the Boc-protected aminonitrile 1-42 (which can be prepared from commercially available starting materials using known chemistry) is first treated with hydroxylamine to obtain the corresponding amidoxime, which is then reacted with DMAD and the resulting adduct cyclized to a dihydroxypyrimdine methyl ester at elevated temperature in a suitable solvent.
  • the 3 -hydroxy group on the pyrimidine ring can then be protected by treating with benzoyl anhydride to afford 1-43.
  • Scheme L depicts an alternative synthesis for the preparation of 3-hydroxy-8,9,9- substituted-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- ⁇ ]pyrimidine-2-carboxamides.
  • the core hydroxyl group can readily be protected, for instance using a benzyl protection group, and then the nitrogen alkylated with bromoacetonitrile to give the required nitrile 1-46.
  • Nitrile 1-46 can then undergo a [3+2]- cycloaddition, typically with concurrent deprotection of the hydroxyl group, to provide tetrazole 1-47 using sodium azide in the presence of catalytic triethylamine hydrochloride in a high boiling solvent like NMP.
  • the tetrazole can be alkylated which after deprotection of the hydroxyl group provides isomeric tetrazoles 1-48 and 1-49.
  • nitrile 1-46 can be reacted with hydroxylamine to yield an amide oxime, which in turn can be reacted with various anhydrides to provide, following deprotection, the 1,2,4-oxadiazoles 1-50.
  • Scheme M depicts additional routes for the preparation of 3-hydroxy-8,9,9-substituted-4- oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- ⁇ ]pyrimidine-2-carboxamides.
  • substrate 1-3 is alkylated with propargyl bromide to give the alkynee 1-51.
  • Alkyne 1-51 can then undergo a [3+2]-cycloaddition with a nitrile oxide generated in situ from a nitro-compound in the presence of an isocyanate and a base, to yield isoxazole 1-52 after deprotection of the hydroxyl group.
  • R alkyl
  • R 1 R" H, alkyl, aryl, arylalkyl, heteroarylalkyl, or together form a heterocycle
  • R* H, alkyl, aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, etc.
  • protection can be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973 and in T. W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3 rd edition, 1999, and 2 nd edition, 1991.
  • the protecting groups may be removed at a convenient subsequent stage using methods known in the art.
  • the interfering group can be introduced into the molecule subsequent to the reaction step of concern.
  • Step 1 2- ⁇ l-[(2-Chloroethyl)amino]-l-methylethyl ⁇ -N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide.
  • Step 2 N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- ⁇ ]pyrimidine-2-carboxamide
  • Step 1 3-(Benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[ 1 ,2- ⁇ ]pyrimidine-2-carboxamide.
  • Step 2 N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methylisoxazol-3-yl)methyl]-4-oxo-
  • Step 1 3-(Benzyloxy)-8-(cyanomethyl)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2- ⁇ ]pyrimidine-2-carboxamide.
  • Step 2 N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(2H-tetrazol-5-ylmethyl)-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2- ⁇ ]pyrimidine-2-carboxamide.
  • Step 1 2- ⁇ [(4-Fluorobenzyl)amino]carbonyl ⁇ -9,9-dimethyl-4-oxo-8-(lH-tetrazol-5-ylmethyl)-
  • Step 2 N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-tetrazol-5-yl)methyl]-4- oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- ⁇ ]pyriini(iine-2-carboxamide; N-(4- Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(2-methyl-2H-tetrazol-5-yl)methyl]-4-oxo- 6, 7, 8,9-tetrahydro-4H-pyrazino [ 1 ,2- ⁇ ]pyrimidine-2-carboxamide
  • N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-tetrazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2- ⁇ ]pyrimidine-2-carboxamide shows: l ⁇ MR (600 MHz, d ⁇ -DMSO) ⁇
  • N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(2-methyl-2H-tetrazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2- ⁇ ]pyrimidine-2-carboxamide shows: l ⁇ ⁇ MR (600 MHz, d6-DMSO) ⁇
  • Step 1 N-(4-fluorobenzyl)-5,6-dihydroxy-2- ⁇ l-[(3-hydroxypropyl)amino]-l- methylethyl ⁇ pyrimidine-4-carboxamide
  • Step 2 N-(4-fluorobenzyl)-3 -hydroxy- 10, 10-dimethyl-4-oxo-4,6,7,8,9, 10- hexahydropyrimido [ 1 ,2- ⁇ ] [ 1 ,4] diazepine-2-carboxamide
  • N-(4-fluorobenzyl)-5,6-dihydroxy-2- ⁇ l-[(3-hydroxypropyl)amino]-l- methylethyl ⁇ pyrimidine-4-carboxamide prepared as described in Step 1 was dissolved in THF, and treated with triphenylphosphine (1.5 eq.) and DEAD (1.5 eq.).
  • Step 1 tert-Butyl 5-thioxo-l,4-diazepane-l-carboxylate tert-Butyl 5-oxo-l,4-diazepane-l-carboxylate, P4S10 (0.2 eq.), HMDO (2 eq.) and dichloromethane were combined and stirred magnetically at room temperature for 1 hour. The reaction mixture was then cooled to 0 0 C and aqueous K2CO3 solution (1.26 mL of 5.3 M/mmol P4S10 taken) was added. A volume of acetone equal to one half of the reaction solvent was added to obtain a stirrable mixture, and the reaction mixture was stirred vigorously for 30 minutes at O 0 C.
  • Step 2 tert-Butyl 5-(hydroxyimino)-l,4-diazepane-l-carboxylate A solution of hydroxylamine hydrochloride (2 eq.) in methanol was added to an equimolar methanolic solution of potassium hydroxide. Potassium chloride was filtered off and the filtrate was added to a solution of the above ter/-butyl 5-thioxo-l,4-diazepane-l-carboxylate (1 eq.) in methanol. The mixture was stirred at 55 0 C overnight, then cooled to room temperature and the solvent was removed under reduced pressure.
  • Step 3 8-rert-buryl-2-methyl-3-hydroxy-4-oxo-6,7,9,10-tetrahydropyrimido[l,2- d] [ 1 ,4] diazepine-2, 8(4H)-dicarboxylate.
  • Step 4 S-tert-butyl 2-methyl 10-[benzyl(methyl)amino]-3 -hydroxy-4-oxo-6,7,9, 10- tetrahydropyrimidof 1 ,2-d] [ 1 ,4]diazepine-2,8(4H)-dicarboxylate
  • Step 5 tot-butyl 2- ⁇ [(4-fluoro-3-methylbenzyl)amino]carbonyl ⁇ -3-hydroxy- 10-(methylamino)-
  • Step 6 tert-b ⁇ tyl 10-[[(dimethylamino)(oxo)acetyl](methyl)amino]-2- ⁇ [(4-fluoro-3- methylbenzyl)amino]carbonyl ⁇ -3-hydroxy-4-oxo-6,7,9, 10-tetrahydropyrimido[ 1 ,2- fi[][l,4]diazepine-8(4H)-carboxylate.
  • Step 7 N-(2- ⁇ [(4-fluoro-3-methylbenzyl)amino]carbonyl ⁇ -3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-N ⁇ V ⁇ V-trimethylethanediamide.
  • the compound of Step 6 was stirred in dichloromethane/trifluoroacetic acid (8/2 v/v) for 1 hour, then concentrated under reduced pressure and purified by RP HPLC (Ci 8, 5 ⁇ M, H2 ⁇ /MeC ⁇ with 1% of TFA as eluant) affording desired compound as trifluoroacetic salt.
  • N-(8-cyclopropyl-2- ⁇ [(4-fluoro-3 -methylbenzyl)amino] carbonyl ⁇ -3 -hydroxy-4-oxo- 4 5 6 5 7 5 8,9,10-hexahydropyrimido[l,2- ⁇ [l,4]diazepin-10-yl)-N 5 N 5 N-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral SFC using the following conditions: Solvents: CO2, modifier: MeOH 30%, TFA 0.2 %. Column: Chiracel OD-H 250x10 mm at 9.99 mL/min,
  • Step 1 tert-butyl 2- ⁇ [(3 -chloro-4-methylbenzyl)amino] carbonyl ⁇ -3 -hydroxy- 10-(methylamino)-
  • Step 2 tert-butyl 2- ⁇ [(3-chloro-4-methylbenzyl)amino]carbonyl ⁇ -10- [[(dimethylamino)(oxo)acetyl](methyl)amino]-3-hydroxy-4-oxo-6,7,9, 10- tetrahydropyrimido[ 1 ,2-d ⁇ [1 ,4]diazepine-8(4H)-carboxylate.
  • Step 3 N-(2- ⁇ [(3-chloro-4-methylbenzyl)amino]carbonyl ⁇ -8-cyclopropyl-3-hydroxy-4-oxo-
  • N-(2- ⁇ [(3-chloro-4-methylbenzyl)amino]carbonyl ⁇ -8-cyclopropyl-3-hydroxy-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-tf][l,4]diazepm-10-yl)-N ⁇ V,N l -trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral HPLC using the following conditions: Solvents: a mixture 35:65 0.2%TFA in Hexanes:EtOH. Column: Chiralpack AD column, 250x46 mm at 10.0 mL/min, detected by absorption at 300 run.
  • Step 1 Methyl 10-[benzyl(methyl)amino]-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d ⁇ [ 1 ,4]diazepine-2-carboxylate.
  • Step 2 Methyl 10-[[(dimethylamino)(oxo)acetyl](methyl)ammo]-3-hydroxy-8-methyl-4-oxo-
  • reaction mixture was refluxed overnight, then cooled to room temperature and purified by RP HPLC (CiS, 5 ⁇ M, H2 ⁇ /MeC ⁇ with 1% of TFA as eluant) affording desired compound (trifluoroacetic salt) as a white solid.
  • Step 1 Methyl 10-[benzyl(methyl)amino]-8-ethyl-3-hydroxy-4-oxo-4,6,7,8,9, 10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4] diazepine-2-carboxylate.
  • Step 2 Methyl 10-[[(dimethylamino)(oxo)acetyl](methyl)amino]-8-ethyl-3-hydroxy-4-oxo-
  • Step 3 N-(8-ethyl-2- ⁇ [(4-fluoro-3-methylbenzyl)amino]carbonyl ⁇ -3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-c(][l,4]diazepin-10-yl)-N ⁇ V,N-trimethylethanediamide.
  • Step 1 tert-butyl [(2£)-2-amino-l-[(benzyloxy)methyl]-2-(hydroxyimino)etliyl]carbamate.
  • Step 2 Methyl 5-(benzoyloxy)-2- ⁇ 2-(benzyloxy)-l-[(re ⁇ -butoxycarbonyl)amino]ethyl ⁇ -6- hydroxypyrimidine-4-carboxylate.
  • tert-Butyl [(2 J E)-2-amino-l-[(benzyloxy)methyl]-2-(hydroxyimino)ethyl]carbamate prepared as described in Step 1 was dissolved in chloroform and treated with 1.2 eq. of dimethylacetylenedicarboxylate and the reaction was refluxed for 2.5 hours. After cooling at room temperature, the reaction mixture was concentrated and the solvent switched to xylene. The mixture was heated at 145 0 C for 24 hours.
  • Step 3 2-[ 1 -amino-2-(benzyloxy)ethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4- carboxamide.
  • Step 4 2- ⁇ 2-(benzyloxy)-l-[(2-chloroethyl)amino]ethyl ⁇ -N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide.
  • Step 5 9-[(benzyloxy)methyl]-2- ⁇ [(4-fluorobenzyl)amino]carbonyl ⁇ -3-hydroxy-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2- ⁇ ]pyrimidin-8-ium trifluoroacetate.
  • Step 6 tert-b ⁇ tyl 2- ⁇ [(4-fluorobenzyl)amino]carbonyl ⁇ -3 -hydroxy-9-(hydroxymethyl)-4-oxo-
  • Step 7 tert-butyl 9- ⁇ [benzyl(methyl)amino]methyl ⁇ -2- ⁇ [(4-fluorobenzyl)amino]carbonyl ⁇ -3 - hydroxy-4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[l,2- ⁇ ]pyrimidine-8-carboxylate.
  • the reaction mixture was concentrated under vacuum at 30 0 C and the solvent switched to dry acetonitrile.
  • the insoluble material was filtered off and to the filtrated 5 equivalents of N- benzylmethylamine were added.
  • the mixture was warmed at 110°C upon microwave irradiation for 30 minutes then stirred at room temperature for further 36 hours.
  • the mixture was concentrated by rotary evaporation and the resulting residue, dissolved in the minimum amount of MeOH, was carefully acidified with some drops of glacial acetic acid applied on cation-exchange resin.
  • the resin was washed with MeOH and the crude product was eluted with IM ammonia in methanol.
  • Step 8 N-(4-fluorobenzyl)-3-hydroxy-9-[(methylamino)methyl]-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[l ,2- ⁇ ]pyrimidine-2-carboxamide.
  • Step 9 N-(4-fluorobenzyl)-3-hydroxy-8-methyl-9- ⁇ [methyl(methylsulfonyl)amino]methyl ⁇ -4- oxo-6,7 5 8,9-tetrahydro-4H-pyrazmo[l,2-a]pyrimidine-2-carboxamide.
  • N-(4-fluorobenzyl)-3-hydroxy-9-[(methylamino)methyl]-4-oxo-6,7,8,9-tetrahydro-4H- pyraz ⁇ io[l,2- ⁇ ]pyrimidine-2-carboxamide was suspended in dry C ⁇ 2CI2 and triethylamine (2.5 eq.), methane sulphonylchloride (1.3 eq.) was slowly added to the solution under nitrogen atmosphere and the reaction mixture was stirred at room temperature overnight. Volatiles were removed under reduced pressure and title product was purified RP HPLC (Ci8, 5 ⁇ M, H2 ⁇ /MeC ⁇ with 1% of TFA as eluant).
  • Step 1 Methyl 8-acetyl-3-(acetyloxy)-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2-
  • Step 2 8-Acetyl-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2- d ⁇ [ 1 ,4]diazepine-2-carboxamide.
  • the mixture of products obtained in Step 1 was taken in methanol and treated with 2.5 equivalents of p-fluorobenzylamine. The resulting mixture was refluxed for 24 hours, then cooled to room temperature and concentrated under reduced pressure.
  • the crude material was purified by RP HPLC (C 18, 5 ⁇ M, H2 ⁇ /MeCN with 1% of TFA as eluant). Lyophilization of appropriate fractions gave title compound as a white solid.
  • Step 1 l,4-Oxazepane-5-thione l,4-Oxazepan-5-one, P4S10 (0.2 eq.), ⁇ MDO (2 eq.) and dichloromethane were combined and stirred magnetically at room temperature for 1 hour. The reaction mixture was then cooled to 0 0 C and aqueous K2CO3 solution (1.26 mL of 5.3 M/mmol P4S10 taken) was added. A volume of acetone equal to one half of the reaction solvent was added to obtain a stirrable mixture, and the reaction mixture was stirred vigorously for 30 minutes at 0 0 C.
  • Step 2 l,4-oxazepan-5-one oxime
  • Step 4 Methyl 10-[ben2yl(methyl)amino]-3-hydroxy-4-oxo-6,7,9, 10-tetrahydro-4H- pyrimido[l,2-uTj[l,4]oxazepine-2-carboxylate.
  • Step 5 N-(4-fluorobenzyl)-3-hydroxy-10-(methylamino)-4-oxo-6,7,9,10-tetrahydro-4H- pyrimido[l ,2-d] [ 1 ,4]oxazepine-2-carboxamide.
  • Step 6 N-(2- ⁇ [(4-fluorobenzyl)amino]carbonyl ⁇ -3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4H- pyrimido [ 1 ,2-d] [ 1 ,4]oxazepin- 10-yl)-N ⁇ V JV-trimethylethanediamide.
  • N-(2- ⁇ [(4-fluorobenzyl)amino]carbonyl ⁇ -3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4H- pyrimido [ 1 ,2-d] [ 1 ,4] oxazepin- 10-yl)-NN,N-trimethylethanediarnide has been resolved into its enantiomers by semipreparative chiral ⁇ PLC using the following conditions: Solvents: a mixture 40:60
  • Step 1 2-(l- ⁇ [(chloromethyl)sulfonyl]amino ⁇ -l-methylethyl)-4- ⁇ [(4- fluorobenzyl)amino]carbonyl ⁇ -6-hydroxypyrimidin-5-yl chloromethanesulfonate.
  • 2-(l -amino- l-methylethyl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide hydrochloride prepared as described in WO2003035076 Al
  • triethylamine (4 eq.
  • Step 2 N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8,9-dihydro-4H-pyrimido[2,l- d] [ 1 ,2,5]thiadiazine-2-carboxamide 7,7-dioxide.
  • Step 1 tert-Butyl [3-amino-3-(hydroxyimino)propyl]benzylcarbamate
  • Step 3 / 1 ert-Butyl ben2yl[2-(4- ⁇ [(4-fluoroben2yl)amino]carbonyl ⁇ -5,6-dihydroxypyrimidin-2- yl)ethyl]carbamate.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compounds of Formula I are inhibitors of FHV integrase and inhibitors of FHV replication (I), wherein m, n, X, Rl, R2, R3, R4, R5, R6 R7; R8 R9 and R10 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HTV and the prophylaxis, treatment , or delay in the onset of AIDS. The compounds are employed against HTV infection and ADDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Description

TITLE OF THE INVENTION HIV INTEGRASE INHIBITORS
This application claims the benefit of U.S. Provisional Application No. 60/666,897, filed March 31, 2005, the disclosure of which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
The present invention is directed tetrahydropyrazinopyrimidine carboxamides and related compounds and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of the HTV integrase enzyme. The compounds and pharmaceutically acceptable salts thereof of the present invention are useful for the prophylaxis or treatment of infection by HTV and for the prophylaxis, treatment, or delay in the onset of AIDS.
BACKGROUND OF THE INVENTION A retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HTV type-1 (HIV-I) virus and type-2 (HIV-2) virus, is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. A common feature of retrovirus replication is the insertion by virally-encoded integrase of +proviral DNA into the host cell genome, a required step in FHV replication in human T-lymphoid and monocytoid cells. Integration is believed to be mediated by integrase in three steps: assembly of a stable nucleoprotein complex with viral DNA sequences; cleavage of two nucleotides from the 3' termini of the linear proviral DNA; covalent joining of the recessed 3' OH termini of the proviral DNA at a staggered cut made at the host target site. The fourth step in the process, repair synthesis of the resultant gap, may be accomplished by cellular enzymes.
Nucleotide sequencing of HIV shows the presence of a pol gene in one open reading frame [Ratner, L. et al., Nature, 313, 277(1985)]. Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, integrase and an HTV protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M.D. et al., Science, 231, 1567 (1986); Pearl, L.H. et al., Nature, 329, 351 (1987)]. All three enzymes have been shown to be essential for the replication of BQV.
It is known that some antiviral compounds which act as inhibitors of HIV replication are effective agents in the treatment of AIDS and similar diseases, including reverse transcriptase inhibitors such as azidothymidine (AZT) and efavirenz and protease inhbitors such as indinavir and nelfmavir. The compounds of this invention are inhibitors of HIV integrase and inhibitors of HIV replication. The inhibition of integrase in vitro and HtV replication in cells is a direct result of inhibiting the strand transfer reaction catalyzed by the recombinant integrase in vitro in HTV infected cells. The particular advantage of the present invention is highly specific inhibition of HTV integrase and HTV replication.
The following references are of interest as background: US 6380249, US 6306891, and US 6262055 disclose 2,4-dioxoburyric acids and acid esters useful as HTV integrase inhibitors.
US 2003/0229079 (corresponding to WO 01/00578) discloses l-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)- 1, 3 -propanediones useful as BDV integrase inhibitors. US 2003/0055071 (corresponding to WO 02/30930), US 2004/0034221 (corresponding to WO 02/30426), and US 2004/0044207 (corresponding to WO 02/55079) each disclose certain 8-hydroxy-l,6-naphthyridine-7-carboxamides as HTV integrase inhibitors.
US 2005/010048 (corresponding to WO 02/036734) discloses certain aza- and polyaza- naphthalenyl ketones to be HIV integrase inhibitors. US2004/229909 (corresponding to WO 2003/016275) discloses certain compounds having integrase inhibitory activity.
WO 03/35076 discloses certain 5,6-dihydroxypyrimidine-4-carboxamides as HTV integrase inhibitors, and US 2005/025774 (corresponding to WO 03/35077) discloses certain N- substituted 5-hydroxy-6-oxo-l,6-dihydropyrimidine-4-carboxamides as HTV integrase inhibitors. WO 03/062204 discloses certain hydroxynaphthyridinone carboxamides that are useful as HTV integrase inhibitors.
US 2004/204498 (corresonding to WO 2004/062613) and US 2004/229892
(corresponding to WO 2004/096128) disclose certain pyrimidine carboxamides that are useful as HTV integrase inhibitors. WO 2005/016927 discloses certain nitrogenous condensed ring compounds that are HIV integrase inhibitors.
WO 2005/061490 discloses certain hydroxypyrimidinone derivatives having HTV integrase inhibitory activity. Various pyrimidinone compounds useful as HTV integrase inhibitors are also disclosed in WO 2005/115398, WO 2005/118589, WO 2005/118590, WO 2005/118593, and US 2005/0256109.
SUMMARY OF THE INVENTION
The present invention is directed to tetrahydropyrazinopyrimidine carboxamides and related compounds. These compounds are useful in the inhibition of HTV integrase, the prophylaxis or treatment of infection by HIV, and the prophylaxis, treatment, or delay in the onset of AIDS and/or ARC, either as compounds or their pharmaceutically acceptable salts or hydrates (when appropriate), or as pharmaceutical composition ingredients, whether or not in combination with other HIV antivirals, anti- infectives, immunomodulators, antibiotics or vaccines. More particularly, the present invention includes compounds of Formula I, and pharmaceutically acceptable salts thereof:
Figure imgf000004_0001
wherein:
X is N(RK)5 O, S, S(O), S(0)2,
Figure imgf000004_0002
where each * denotes the point of attachment to the rest of the molecule;
RK is:
(1) H,
(2) Ci_6 alkyl,
(3) Ci_6 alkyl substituted with T, wherein T is Cθ2RA, CN, Sθ2RA, N(RD)RE,
C(O)N(RD)RE, N(RA)-C(O)C(O)-N(RD)RE, N(RA)-C(O)RB5 N(RA)-SO2RB,
N(RA)-SO2N(RD)RE or N(RA)-CO2RB,
(4) C 1-6 haloalkyl,
(5) C(O)RA5
(6) C(O)-Ci_6 haloalkyl,
Figure imgf000004_0003
(8) C(O)-U,
(9) C(O)-Ci-6 alkylene-U,
(10) C(O)N(RD)RE
(H) C(O)-Ci_6 alkylene-N(RD)RE
(12) C(O)C(O)-U,
(13) C(0)C(0)-Ci-6 alkylene-U, (14) C(O)C(O)-N(RD)RE,
(15) C(O)C(O)-Ci-6 alkylene-N(RD)RE
(16) SO2RA,
(17) SO2-U, (18) SO2-C1.6 alkylene-U,
Figure imgf000005_0001
(20) CycB,
(21) Ci_6 alkyl substituted with U, or
(22) Ci-6 alkyl substituted with C(O)N(RA)-C i_6 alkylene-U, wherein U is CycB, AryB, or HetB;
m and n are each independently integers equal to zero, 1, or 2, with the proviso that m + n is zero, 1, or 2;
Rl is: (1) H,
(2) Ci-6 alkyl,
(3) Ci-6 haloalkyl,
(4) Ci-6 alkyl substituted with V, wherein V is OH, O-Ci-6 alkyl, O-Ci-6 haloalkyl, SRA, S(O)RA, SO2RA, N(RD)RE, C(0)N(RD)RE N(RA)-C(O)C(O)-N(RD)RE, N(RA)-C(O)RB, N(RA)-SO2RB, N(RA)-C1-6 alkylene-SO2RB, N(RA)C(O)-C i_6 alkylene-SO2RB, N(RA)-SO2N(RD)RE, N(RA)_CO2RB, or N(RA)-C(0)N(RD)RE,
(5) C 1 _6 alkyl substituted with W, wherein W is CycA, AryA, HetA, O-C 1 -6 alkylene-CycA, O-Ci-6 alkylene-AryA, O-Ci-6 alkylene-HetA, S(O)j-Ci-6 alkylene-CycA, S(0)j-Ci_6 alkylene-AryA, S(0)j-Ci-6 alkylene-HetA, N(RA)-C(O)-AryA, or N(RA)-C(O)-HetA,
(6) N(RA)-SO2RB,
(7) N(RA)-SO2N(RD)RE,
(8) N(RA)-CO2RB,
(9) N(RD)RE (10) N(RC)RA,
(11) N(RA)-C(O)RB,
(12) N(RC)-C(O)RA,
(13) S(O)jRF
(14) ORF, (16) CycA,
(17) AryA,
(18) HetA,
(19) N(RA)-C(O)-CycA,
(20) N(RA)-C(O)-AryA,
(21) N(RA)-C(O)-HetA,
(22) N(RA)-C(O)-N(RD)RE,
(23) N(RC)-C(O)-CycA,
(24) N(RC)-C(O)-AryA,
(25) N(RC)-C(O)-HeIA,
(26) N(RC)-C(O)-N(RD)RE,
(27) N(RA)-C(O)C(O)-CycA,
(28) N(RA)-C(O)C(O)-AryA,
(29) N(RA)-C(O)C(O)-HetA,
(30) N(RA)-C(O)C(O)-N(RD)RE,
(31) N(RC)-C(O)C(O)-CycA,
(32) N(RC)-C(O)C(O)-AiyA,
(33) N(RC)-C(O)C(O)-HetA, or
(34) N(RC)-C(O)C(O)-N(RD)RE;
each j is independently an integer equal to zero, 1, or 2;
R2 is H or Cl _6 alkyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form (i) a 3- to 7-membered saturated carbocyclic ring or (ii) a 4- to 7-membered saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from N, O and S, where independently each N is optionally substituted with C\.β alkyl and each S is optionally oxidized to S(O) or S(O)2; ( note: the ring formed by the joining of Rl and R2 provides a spiro ring system)
each R.3 is independently H or Ci -6 alkyl, and each R4 is independently H or Cl -6 alkyl; or alternatively R3 and R4 attached to the same carbon atom together form oxo or thioxo;
each R5 is independently H or Ci_6 alkyl, and each R6 is independently H or Ci -6 alkyl; or alternatively R5 and R6 attached to the same carbon atom together form oxo or thioxo; R7 is H or C 1-6 alkyl;
R.8 is H or C\.β alkyl; or alternatively R? and R^ together form oxo or thioxo;
R9 is H or alkyl;
RlO is Cχ-6 alkyl substituted with CycC, AryC or HetC;
each RA is independently H or Ci_β alkyl;
each RB is independently H or C\.β alkyl;
RC is C l_6 alkyl substituted with CycA, AryA, or HetA; or alternatively, when X is N(RK) and Rl includes the N(RC) moiety, RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- to 7-membered diazacycloalkyl ring, wherein the portion of the fused ring obtained from RC and RK is a 1- to 4- membered methylene chain optionally substituted with oxo or C\.β alkyl;
each RD and RE are each independently H or C\.β alkyl, or together with the nitrogen to which they are both attached form a 4- to 7-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to RD and RE selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently C\.β alkyl or S(O)2-Ci_6 alkyl;
RF is C 1-6 alkyl, or alternatively, when X is N(RK) and Rl is 8RF or ORF, RF and RK together with (i) the N atom to which RK is attached, (ii) the S or O atom to which RF is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused S- to 7-membered oxyazacycloalkyl or thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is a 1- to 4-membered methylene chain;
each CycA is independently C3.8 cycloalkyl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
(i) from zero to 6 substituents are each independently: (1) halogen,
(2) CN
(3) Ci-6 alkyl,
(4) OH, (5) O-Ci-6 alkyl,
(6) C 1-6 haloalkyl, or
(7) O-C i _6 haloalkyl, and
(ii) from zero to 2 substituents are each independently:
(1) CycD, (2) AryD,
(3) HetD, or
(4) Ci_6 alkyl substituted with CycD, AryD, or HetD;
CycB and CycC each independently have the same definition as CycA;
each AryA is independently aryl which is optionally substituted with a total of from 1 to 5 substituents, wherein:
(i) from zero to 5 substituents are each independently:
(I) Ci-6 alkyl, (2) Ci_6 alkyl substituted with OH, O-Ci-6 alkyl, O-Cl-6 haloalkyl, CN, NO2,
N(RA)RB5 C(O)N(RA)RB5 C(O)RA, CO2RA SRA5 S(O)RA S(0)2RA, S(O)2N(RA)RB5 N(RA)C(O)RB5 N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB; OC(O)N(RA)RB5 N(RA)C(O)N(RA)RB5 or
N(RA)C(O)C(O)N(RA)RB5 (3) O-Ci-6 alkyl,
(4) C 1-6 haloalkyl,
(5) O-C 1-6 haloalkyl,
(6) OH,
(7) halogen, (8) CN,
(9) NO2,
(10) N(RA)RB5
(I I) C(O)N(RA)RB5 (12) C(O)RA, (13) C(0)-Ci_6 haloalkyl,
(14) C(O)ORA5
(15) OC(O)N(RA)RB9
(16) SRA5
(17) S(O)RA,
(18) S(O)2RA,
(19) S(O)2N(RA)RB5
(20) N(RA)S(O)2RB5
(21) N(RA)S(O)2N(RA)RB5
(22) N(RA)C(O)RB5
(23) N(RA)C(O)N(RA)RB5
(24) N(RA)C(O)-C(O)N(RA)RB5 Or
(25) N(RA)CO2RB5 and
(ϋ) from zero to 2 substituents are each independently:
(1) CycD,
(2) AryD,
(3) HetD, or
(4) C i_6 alkyl substituted with CycD, AryD, or HetD;
AryB and AryC each independently have the same definition as AryA;
each HetA is independently a heteroaryl which is optionally substituted with a total of from 1 to 5 substituents, wherein:
(i) from zero to 5 substituents are each independently: (1) Ci_6 alkyl,
(2) Ci_6 alkyl substituted with OH, O-Ci-6 alkyl, O-Ci_6 haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB5 C(O)RA5 CO2RA5 SRA, S(O)RA S(O)2RA5 S(O)2N(RA)RB5 N(RA)C(O)RB5 N(RA)CO2RB5 N(RA)S(O)2RB5 N(RA)S(O)2N(RA)RB5 OC(O)N(RA)RB5 N(RA)C(O)N(RA)RB5 or N(RA)C(O)C(O)N(RA)RB5
(3) O-Ci-6 alkyl,
(4) Ci-6 haloalkyl,
(5) O-Ci-6 haloalkyl,
(6) OH, (7) oxo,
(8) halogen,
(9) CN,
(10) NO2, (H) N(RA)RB5
(12) C(O)N(RA)RB3
(13) C(O)RA,
(14) C(O)-Ci-6 haloalkyl,
(15) C(O)ORA (16) OC(O)N(RA)RB5
(17) SRA
(18) S(O)RA
(19) S(O)2RA
(20) S(O)2N(RA)RB5 (21) N(RA)S(O)2RB,
(22) N(RA)S(O)2N(RA)RB5
(23) N(RA)C(O)RB5
(24) N(RA)C(O)N(RA)RB5
(25) N(RA)C(O)-C(O)N(RA)RB5 or (26) N(RA)CO2RB, and
(ii) from zero to 2 substituents are each independently:
(1) CycD,
(2) AryD,
(3) HetD, or (4) C i _6 alkyl substituted with CycD, AryD, or HetD;
HetB and HetC each independently have the same definition as HetA;
each CycD is independently a C3_8 cycloalkyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, Ci_6 alkyl, OH, O-Ci-6 alkyl, or Ci_6 haloalkyl;
each AryD is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 5 substituents each of which is independently any one of the substituents (1) to (25) as set forth above in part (i) of the definition of AryA; each HetD is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, Ci _6 alkyl, C\s haloalkyl, O-Ci_β alkyl, O-Ci_6 haloalkyl, or hydroxy;
each aryl is independently (i) phenyl, (ii) a 9- or 10-membered bicyclic, fused carbocyclic ring system in which at least one ring is aromatic, or (iii) an 11- to 14-membered tricyclic, fused carbocyclic ring system in which at least one ring is aromatic;
each heteroaryl is independently (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, or (ii) a 9- or 10-membered bicyclic, fused ring system containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein either one or both of the rings contain one or more of the heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2;
The present invention also includes pharmaceutical compositions containing a compound of Formula I or a pharmaceutically acceptable salt thereof. The present invention further includes methods for the treatment of AIDS, the delay in the onset of AIDS, the prophylaxis of ADDS, the prophylaxis of infection by HIV, and the treatment of infection by HTV.
Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.
DETAILED DESCRIPTION OF THE INVENTION The present invention includes compounds of Formula I above, and pharmaceutically acceptable salts thereof. These compounds and their pharmaceutically acceptable salts are HTV integrase inhibitors (e.g., HIV-I integrase inhibitors).
A first embodiment of the present invention (i.e., Embodiment El) is a compound of
Formula I, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as originally defined (i.e., as defined for Formula I in the Summary of the Invention), and provided that:
(A) when m is zero and X is O, then Rl is not H or Ci-6 alkyl;
(B) when m is zero, X is O, and the -X[-C(R5R6)nC(R7R8)]_ moiety is -OCH2- or -OCH2CH2- or -OCH2CH2CH2-, then Rl and R2 do not together form a ring (C) when X is N(RK) and RK is: (1) H,
(2) Ci-6 alkyl,
(3) Ci_6 alkyl substituted with T, wherein T is CO2RA, CN, Sθ2RA, N(RD)RE5 C(O)N(RD)RE5 or N(RA)-C(O)RB, (4) Ci_6 haloalkyl,
(5) C(O)RA5
(6) C(O)-C 1-6 haloalkyl,
(8) C(O)-U and U is AryB or HetB,
(9) C(O)-Ci_6 alkylene-U (10) C(O)N(RD)RE
(11) C(O)-Ci-6 alkylene-N(RD)RE
(14) C(O)C(O)-N(RD)RE (except when RD and RE together with the N to which they are both attached form a saturated heterocyclic ring), (16) SO2RA, (18) SO2-CI-6 alkylene-U, or
(21) C 1-6 alkyl substituted with U (except when Cl -6 alkyl substituted with U is CH2-HetB, and HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group, and m is zero and the -C(R5R6)nC(R7R8). moiety is -CH2CH2-), then Rl is:
(4) C 1 _6 alkyl substituted with V, wherein V is S(O)RA5 N(RA)-C(O)C(O)-N(RD)RE5 N(RA)-SO2RB, N(RA)-CI_6 alkylene-S02RB, N(RA)C(O)-C i_6 alkylene-SO2RB, N(RA)-S02N(RD)RES N(RA)-Cθ2RB, or N(RA)-C(O)N(RD)RE when N(RA)-C(O)N(RD)RE is other than NH-C(0)NH2,
(5) C 1-6 alkyl substituted with W, wherein W is O-Ci-6 alkylene-CycA, O-Ci-6 alkylene-AryA, O-Cμ6 alkylene-HetA, S(0)j-Ci_6 alkylene-CycA, S(0)j-Ci-6 alkylene-AryA, S(0)j-Ci_6 alkylene-HetA, N(RA)-C(O)-AryA, or N(RA)_c(O)-HetA, (7) N(RA)-SO2N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring,
(10) N(RC)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(12) N(RC)-C(O)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(13) S(O)jRF when RF and R.K are involved in the formation of a fused thioazacycloalkyl ring, (14) ORF when RF and RK are involved in the formation of a fused oxyazacycloalkyl ring, (16) CycA,
(21) N(RA)-C(O)-HetA,
(22) N(RA)-C(O)-N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring,
(23) N(RC)-C(O)-CycA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(24) N(RC)-C(O)-AryA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(25) N(RC)-C(O)-HetA,
(26) N(RC)-C(O)-N(RD)RE when (i) RD and RE together with the N to which they are both attached form a optionally substituted saturated heterocyclic ring or (ii) RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring),
(27) N(RA)-C(O)C(O)-CycA,
(28) N(RA)-C(O)C(O)-AryA,
(29) N(RA)-C(O)C(O)-HetA,
(30) N(RA)-C(O)C(O)-N(RD)RE, (31) N(RC)-C(O)C(O)-CycA,
(32) N(RC)-C(O)C(O)-AryA,
(33) N(RC)-C(O)C(O)-HetA, or
(34) N(RC)-C(O)C(O)-N(RD)RE; or (D) when m is zero, the -C(R5R6)nC(R7R8). moiety is -CH2CH2-, X is N(RK), RK is CH2-HetB, and HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group, then either:
(dl) Rl is as defined in proviso C, or
(d2) Rl and R2 are both methyl, R9 is H, and RlO is 4-fluorobenzyl. A second embodiment of the present invention (Embodiment E2) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as originally defined, and provided that:
(A) when m is zero and X is O, then Rl is not H or Ci_6 alkyl;
(B) when m is zero, X is O, and the -X[-C(R5R6)QC(R7R8)]_ moiety is -OCH2- or -OCH2CH2- or -OCH2CH2CH2-, then Rl and R2 do not together form a ring;
(C) when X is N(RK) and RK is:
(1) H,
(2) Ci-6 alkyl,
(3) C 1-6 alkyl substituted with T, wherein T is Cθ2RA, CN5 Sθ2RA,
N(RD)RE, C(O)N(RD)RE5
(4) Cχ_6 haloalkyl,
(5) C(O)RA,
(6) C(O)-Ci-6 haloalkyl,
(8) C(O)-U and U is AryB or HetB,
(9) C(O)-Ci-6 alkylene-U
(10) C(O)N(RD)RE
(H) C(O)-Ci-6 alkylene-N(RD)RE
(14) C(O)C(O)-N(RD)RE (except when RD and RE together with the N to which they are both attached form a saturated heterocyclic ring),
(16) SO2RA,
(18) SO2-C1-6 alkylene-U, or
(21) C 1-6 alkyl substituted with U, then Rl is:
(4) Ci-6 alkyl substituted with V, wherein V is S(O)RA,
N(RA)-C(O)C(O)-N(RD)RE5 N(RA)-C1^ alkylene-S02RB, N(RA)C(O)-CI_6 alkylene-SO2RB, N(RA)-SO2N(RD)RE5 N(RA)-Cθ2RB, or N(RA)-C(O)N(RP)RE when N(RA)-C(O)N(RD)RE is other than NH-C(0)NH2, (5) C 1-6 alkyl substituted with W, wherein W is O-Ci_6 alkylene-CycA,
O-Ci-6 alkylene-AryA, O-Ci-6 alkylene-HetA, S(0)j-Ci-6 alkylene-CycA, S(0)j-Ci_6 alkylene-AryA, S(O)j-Ci_6 alkylene-HetA,
N(RA)-C(O)-AryA, or N(RA)-C(O)-HetA, (7) N(RA)-SO2N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring, (10) N(RC)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
( 12) N(RC)-C(O)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(13) S(O)JRF when RF and RK are involved in the formation of a fused thioazacycloalkyl ring,
(14) ORF when RF and RK are involved in the formation of a fused oxyazacycloalkyl ring,
(16) CycA, (21) N(RA)-C(O)-HetA, (22) N(RA)-C(O)-N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring, (23) N(RC)-C(O)-CycA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring, (24) N(RC)-C(O)-AryA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(25) N(RC)-C(O)-HetA,
(26) N(RC)-C(O)-N(RD)RE when (i) RD and RE together with the N to which they are both attached form a optionally substituted saturated heterocyclic ring or (ii) RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring),
(27) N(RA)-C(O)C(O)-CycA,
(28) N(RA)-C(O)C(O)-AryA,
(29) N(RA)-C(O)C(O)-HetA, (30) N(RA)-C(O)C(O)-N(RD)RE5
(31) N(RC)-C(O)C(O)-CycA,
(32) N(RC)-C(O)C(O)-AryA,
(33) N(RC)-C(O)C(O)-HetA, or (34) N(RC)-C(O)C(O)-N(RD)RE.
A third embodiment of the present invention (Embodiment E3) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as originally defined, and provided that:
(A) when X is O, then Rl is not H or C].6 alkyl; (B) when X is O3 and the -X[-C(R5R6)nC(R7R8)]_ moiety is -OCH2- or
-OCH2CH2- or -OCH2CH2CH2-, then Rl and R2 do not together form a ring; or (C) when X is N(RK)5 then Rl is:
(27) N(RA)-C(O)C(O)-CycA,
(28) N(RA)-C(O)C(O)-AryA, (29) N(RA)-C(O)C(O)-HetA,
(30) N(RA)-C(O)C(O)-N(RD)RE5
(31) N(RC)-C(O)C(O)-CycA,
(32) N(RC)-C(O)C(O)-AryA,
(33) N(RC)-C(O)C(O)-HetA, or (34) N(RC)-C(O)C(O)-N(RD)RE.
A fourth embodiment of the present invention (Embodiment E4) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the integer m is equal to 1 and the integer n is equal to 1, or m is zero and n is 2, or m is zero and n is 1, or m is 1 and n is zero, or m is zero and n is zero; and all other variables are as originally defined (i.e., as defined for Formula I in the Summary of the Invention) or as defined in any of the preceding embodiments. Li an aspect of this embodiment, m = n = 1. In another aspect of this embodiment, m = 0 and n = 2. In another aspect, m = 0 and n = 1. In another aspect, m = 1 and n = 0. In another aspect m = n = 0.
It is understood that when m = 0 the ring carbon substituted with Rl and R2 is directly attached to X by a single bond, and when n = 0 the ring carbon substituted with R7 and R^ is directly attached to X by a single bond. Accordingly, the compounds represented by values of m and n set forth in Embodiment E4 are compounds of Formula I-A (i.e., m = n = 0), I-B (m = 1; n = 0), I-C (m = 0; n = 1), I-D (m = n = 1), or I-E (m = 0; n = 2):
Figure imgf000017_0001
A fifth embodiment of the present invention (Embodiment E5) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein X is N(RK) or O; and all other variables are as originally defined or as defined in any of the preceding embodiments. In an aspect of this embodiment, X is N(RK).
A sixth embodiment of the present invention (Embodiment E6) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R9 is H or Cl -.4 alkyl; RlO is:
(1) CH2-phenyl or CH2-HetC, wherein the phenyl is optionally substituted with a total of from 1 to 3 substituents, wherein (i) from zero to 3 substituents are each independently bromo, chloro, fluoro, C1-4 alkyl, CF3, C(O)NH2, C(O)NH(CM alkyl), C(O)N(Ci_4 alkyl)2, S-C1-4 alkyl, SO2-C1-4 alkyl, or Sθ2N(Ci_4 alkyl)2, and (ii) from zero to 1 substituent is a heteroaromatic selected from the group consisting of imidazolyl, triazolyl, oxadiazolyl, pyrrolyl, and pyrazolyl, wherein the heteroaomatic ring is optionally substituted with 1 or 2 substituents each of which is independently Cl, Br, F,
Ci-4 alkyl, CF3, O-C1.4 alkyl, OCF3, or OH,
(2) CH2-HetC, wherein HetC is a heteroaryl which is (i) a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero to 1 O atom, and zero to 1 S atom, or (ii) a 9 or 10-membered bicyclic, fused ring system in which one ring is a benzene ring and the other ring is a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from zero to 3 N atoms, zero to 1 O atom, and zero to 1 S atom, wherein the heteroaryl is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, or Ci_4 alkyl; and all other variables are as originally defined or as defined in any one of the preceding embodiments. In an aspect of this embodiment, R.9 is H and the definition of RlO js unchanged.
A seventh embodiment of the present invention (Embodiment E7) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R? is H or C 1.4 alkyl; RlO is: (1) CH2-phenyl wherein the phenyl is optionally substituted with a total of from 1 to 2 substituents wherein (i) from zero to 2 substituents are each independently bromo, chloro, fluoro, CH3, CF3, C(O)NH2, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or Sθ2N(CH3)2, and (ii) from zero to 1 substituent is oxadiazolyl optionally substituted with CH3, or (2) CH2-HetC, wherein HetC is a heteroaryl which is quinolinyl, indazolyl, benzoxazolyl, isoquinolinyl, cinnolinyl, quinazolinyl, benzopyranyl, wherein the heteroaryl is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, or C 1.4 alkyl; and all other variables are as originally defined or as defined in any one of the preceding embodiments. In an aspect of this embodiment, R9 is H and the definition of RlO is unchanged.
An eighth embodiment of the present invention (Embodiment E8) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R9 is H; RlO is 4-fluorobenzyl, 3- chloro-4-fluorobenzyl, 3-chloro-4-methylbenzyl, 4-fluoro-3-methylbenzyl, 3-chlorobenzyl, 4-fluoro-2- methylsulfonylbenzyl, 3-bromo-4-fluorobenzyl, 4-fluoro-2-[(methylamino)carbonyl]benzyl, 2- methylthiobenzyl, 4-fluoro-2-[(3-methyl)-l,2,4-oxadiazol-5-yl]benzyl, or [(5-fluoro)quinolin-8- yljmethyl; and all other variables are as originally defined or as defined in any one of the preceding embodiments.
A ninth embodiment of the present invention (Embodiment E9) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R9 is H; RlO is 4-fluorobenzyl; and all other variables are as originally defined or as defined in any one of the preceding embodiments.
A tenth embodiment of the present invention (Embodiment ElO) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
X is N(RK) or O;
RK is:
(1) H,
(2) Ci-4 alkyl,
(3) Ci-4 alkyl substituted with T, wherein T is Cθ2RA, CN, N(RD)RE, or C(O)N(RD)RE, (4) C(O)RA,
(5) C(O)-Ci-4 fluoroalkyl,
(6) CO2RA
(7) SO2RA
(8) SO2-AiyB,
(9) SO2N(RD)RE
(10) C(O)N(RD)RE5
(H) C(O)C(O)-N(RD)RE .
(12) C(O)-Ci_4 alkylene-N(RD)REs
(13) CycB,
(14) Ci_4 alkyl substituted with U, wherein U is CycB, AryB, or HetB, or
(15) Ci-4 alkyl substituted with C(O)N(RA)-C 1.4 alkylene-HetB;
(1) H5
(2) C 1.4 alkyl,
(3) C 1-4 alkyl substituted with V, wherein V is OH, O-C1.4 alkyl, SRA, S(O)RA, SO2RA,
N(RD)RE5 C(O)N(RD)RE, N(RA)-C(O)C(O)-N(RD)RE, N(RA)-C(O)RB,
N(RA)-SO2RB, N(RA)-Ci-4 alkylene-SO2RB, N(RA)C(O)-Ci .4 alkylene-SO2RB,
N(RA)-SO2N(RD)RE, or N(RA)-CO2RB,
(4) C 1-4 alkyl substituted with W, wherein W is CycA, AryA, HetA, O-Ci-4 alkylene-AryA, O-Ci_4 alkylene-HetA, or N(RA)-C(O)-HetA,
(5) N(RA)-SO2RB,
(6) N(RA)-SO2N(RD)RE,
(7) N(RA)-CO2RB,
(8) N(RD)RE,
(9) N(RC)RA
(10) N(RA)-C(O)RB,
(H) N(RC)-C(O)RA,
(12) SRF, S(O)RF, or S(O)2RF,
(13) N(RA)-C(O)-HetA,
(14) N(RC)-C(O)-N(RD)RE5 or
(15) N(RA)-C(O)C(O)-N(RD)RE5 or
(16) N(RC)-C(O)C(O)-N(RD)RE; R2 is H or C 1-4 alkyl; or alternatively Rl and R^ together with the ring carbon atom to which they are both attached form (i) a 3- to 6-membered saturated carbocyclic ring or (ii) a 6-membered saturated heterocyclic ring containing 1 heteroatom selected from N, O and S, where the N is optionally substituted with C 1-4 alkyl and the S is optionally oxidized to S(O) or S(O)2;
each R3 is independently H or C 1.4 alkyl, and each R4 is independently H or C 1.4 alkyl; or alternatively R3 and R4 attached to the same carbon atom together form oxo;
each R5 is independently H or Ci_4 alkyl, and each Rfi is independently H or Ci_4 alkyl; or alternatively R5 and R^ attached to the same carbon atom together form oxo;
R? is H or C 1-4 alkyl;
R8 is H or C 1-4 alkyl; or alternatively R7 and R^ together form oxo;
R9 is H or Ci-4 alkyl;
RlO is C 1-4 alkyl substituted with CycC, AryC or HetC;
each RA is independently H or Ci .4 alkyl;
each RB is independently H or Ci .4 alkyl;
RC is C I_4 alkyl substituted with CycA, AryA, or HetA; or alternatively, when X is N(RK) and Rl includes the N(RC) moiety, RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered diazacycloalkyl ring; wherein the portion of the fused ring obtained from RC and RK is a 1- to 3- membered methylene chain optionally substituted with oxo or C 1.4 alkyl;
each RD and RE are independently H or C 1.4 alkyl, or together with the nitrogen to which they are both attached form a 5- or 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently Ci .4 alkyl or S(O)2-Ci_4 alkyl;
RF is Ci-4 alkyl, or alternatively, when X is N(RK) and Rl is SRF, RF and RK together with (i) the N atom to which RK is attached, (ii) the S atom to which RF is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is a 1- to 3-membered methylene chain;
each CycA is independently a C3.6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl, OH, or O-C1.4 alkyl;
CycB is a C3.6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl, OH, or O-C1.4 alkyl;
CycC is a C3-6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl, OH, or O-C1.4 alkyl;
each AryA is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 3 substituents each of which is independently:
(1) C i-4 alkyl, which is optionally substituted with OH, O-C1.4 alkyl, O-C1.4 haloalkyl, CN5 N(RA)RB3 C(O)N(RA)RB5 C(O)RA, CO2RA, SRA S(O)RA, SO2RA, or
Figure imgf000021_0001
(2) O-C1.4 alkyl, (3) Ci-4 haloalkyl,
(4) O-Ci-4 haloalkyl,
(5) OH,
(6) halogen,
(7) CN, (8) NO2,
(9) N(RA)RB,
(10) C(O)N(RA)RB5
(11) C(O)RA
(12) C(O)-Ci_4 haloalkyl, (13) CO2RA,
(14) SRA,
(15) S(O)RA
(16) SO2RA or
Figure imgf000022_0001
AryB independently has the same definition as AryA;
AryC is phenyl or naphthyl, wherein the phenyl or naphthyl is: (i) optionally substituted with from 1 to 3 substituents each of which is independently any one of the substituents (1) to (17) as set forth above in the definition of AryA, and (ii) optionally substituted with:
(1) AryD,
(2) HetD, (3) CycD, or
(4) C 1 _4 alkyl substituted with CycD, AryD or HetD;
each HetA is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, C 1.4 alkyl, or OH;
HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, C 1.4 alkyl, or OH;
HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is:
(i) optionally substituted with from 1 to 3 substituents each of which is independently halogen, Ci .4 alkyl, or OH; and
(ii) optionally substituted with AryD, HetD, CycD, or C 1.4 alkyl substituted with AryD, HetD or CycD; each CycD is independently a C3.6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently Ci .4 alkyl, OH, or O-C1.4 alkyl;
each AryD is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 3 substituents each of which is independently any one of the substituents (1) to (17) as set forth above in the definition of AryA; and
each HetD is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, C 1.4 alkyl, or OH.
An eleventh embodiment of the present invention (Embodiment El 1) is a compound of Formula I wherein the variables are as defined in Embodiment ElO, and provided that: (A) when m is zero and X is O, then Rl is not H or C 1.4 alkyl;
(B) when m is zero, X is O, and the -X[-C(R5R6)ΠC(R7R8)]. moiety is -OCH2- or -OCH2CH2- or -OCH2CH2CH2-, then Rl and R2 do not together form a ring;
(C) when X is N(RK) and RK is:
(I) H, (2) Ci_4 alkyl,
(3) Ci-4 alkyl substituted with T, wherein T is Cθ2RA, CN, N(RD)RE5 or C(O)N(RD)RE,
(4) C(O)RA
(5) C(O)-Ci_4 fluoroalkyl,
Figure imgf000023_0001
(10) C(O)N(RD)RE,
(II) C(O)C(O)-N(RD)RE (exCept when RD and RE together with the N to which they are both attached form a saturated heterocyclic ring), (12) C(O)-Ci-4 alkylene-N(RD)RE or ( 14) C 1.4 alkyl substituted with U (except when C 1.4 alkyl substituted with
U is CH2-HetB, and HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group, and m is zero and the -C(R5R6)nC(R7R8). moiety is -CH2CH2-), then Rl is:
(3) Ci-4 alkyl substituted with V, wherein V is S(O)RA, N(RA)-C(O)C(O)-N(RD)RE3 N(RA)-SO2RB, N(RA)-CI_4 alkylene-S02RB, N(RA)C(O)-Ci -4 alkylene-SO2RB, N(RA)-SO2N(RD)RE, OΓ N(RA)-CO2RB,
(4) C 1.4 alkyl substituted with W, wherein W is 0-C 1.4 alkylene-AryA, O-Ci-4 alkylene-HetA, or N(RA)-C(O)-HetA, (6) N(RA)-SO2N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring, (9) N(RC)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring, (11) N(RC)-C(O)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(12) SRF, S(O)RF, or S(0)2RF when RF and RK are involved in the formation of a fused thioazacycloalkyl ring,
(13) N(RA)-C(O)-HetA, (14) N(RC)-C(O)-N(RD)RE when (i) RD and RE together with the N to which they are both attached form a optionally substituted saturated heterocyclic ring or (ii) RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring), (15) N(RA)-C(O)C(O)-N(RD)RE or (16) N(RC)-C(O)C(O)-N(RD)RE; or
(D) when m is zero, the -C(R5R6)ΠC(R7R8)- moiety is -CH2CH2-, X is N(RK), RK is CH2-HetB, and HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group, then either:
(dl) Rl is as defined in proviso C, or
(d2) Rl and R2 are both methyl, R9 is H, and RlO is 4-fluorobenzyl. A twelfth embodiment of the present invention (Embodiment E 12) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined in Embodiment ElO, and provided that:
(A) when m is zero and X is O, then Rl is not H or C 1.4 alkyl; (B) when m is zero, X is O, and the -X[-C(R5R6)nC(R7R8)]. moiety is -OCH2- or
-OCH2CH2- or -OCH2CH2CH2-, then Rl and R2 do not together form a ring;
(C) when X is N(RK) and RK is:
(1) H,
(2) Ci_4 alkyl, (3) Ci-4 alkyl substituted with T, wherein T is Cθ2RA, CN, N(RD)RE, or
C(O)N(RD)RE, (4). C(O)RA
(5) C(O)-Ci_4 fluoroalkyl, (7) SO2RA (10) C(O)N(RD)RE
(11) C(O)C(O)-N(RD)RE (except when RD and RE together with the N to which they are both attached form a saturated heterocyclic ring),
(12) C(O)-Ci-4 alkylene-N(RD)REs Or
(14) Ci-4 alkyl substituted with U, then Rl is:
(3) Ci_4 alkyl substituted with V, wherein V is S(O)RA, N(RA)-C(O)C(O)-N(RD)RE5 N(RA)-SO2RB, N(RA)-Ci_4 alkylene-SO2RB, N(RA)C(O)-Ci -4 alkylene-SO2RB, N(RA)-SO2N(RD)RE5 orN(RA)-CO2RB, (4) C 1-4 alkyl substituted with W, wherein W is O-C i_4 alkylene-AryA,
O-Ci-4 alkylene-HetA, or N(RA)-C(O)-HetA,
(6) N(RA)-Sθ2N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring, (9) N(RC)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(11) N(RC)-C(O)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring, (12) S(O)JRF when RF and RK are involved in the formation of a fused thioazacycloalkyl ring,
(13) N(RA)-C(O)-HeIA,
(14) N(RC)-C(O)-N(RD)RE when (i) RD and RE together with the N to which they are both attached form a optionally substituted saturated heterocyclic ring or (ii) RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring),
(15) N(RA)-C(O)C(O)-N(RD)RE, or
(16) N(RC)-C(O)C(O)-N(RD)RE. A thirteenth embodiment of the present invention (Embodiment E13) is a compound of
Formula I, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined in Embodiment ElO, and provided that:
(A) when X is O, then Rl is not H or C 1.4 alkyl;
(B) when X is O, and the -X[-C(R5R6)nC(R7R8)]. moiety is -OCH2- or -OCH2CH2- or -OCH2CH2CH2-, then Rl and R2 do not together form a ring; or
(C) when X is N(RK)5 then Rl is:
(15) N(RA)-C(O)C(O)-N(RD)RE or
(16) N(RC)-C(O)C(O)-N(RD)RE.
A fourteenth embodiment of the present invention (Embodiment E 14) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is a compound of Formula II, HI, IV, V, VI, orVπ:
Figure imgf000026_0001
and all other variables are as defined in any one of Embodiments ElO, E11, E12 and E 13. A fifteenth embodiment of the present invention (Embodiment E15) is a compound of any one of Formulas π, DI, IV, V and VI, or a pharmaceutically acceptable salt thereof, wherein: Rl and R2 are both methyl (except in Formula IV where Rl and R2 are both H); R5, R6, RV and R^ are each H; RlO is 4-fluorobenzyl; RK is CH2-HetB; and HetB is a 5-membered heteroaromatic ring containing from
2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group. In an aspect of this embodiment, the compound is a compound of Formula π, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, the compound is a compound of Formula DI, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, the compound is a compound of Formula IV, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, the compound is a compound of Formula V, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, the compound is a compound of Formula VI, or a pharmaceutically acceptable salt thereof.
A sixteenth embodiment of the present invention (Embodiment E 16) is a compound of any one of Formulas II, IH, V, VI and VD, or a pharmaceutically acceptable salt thereof, wherein: Rl is N(RA)-C(O)C(O)-N(RD)RE or N(RC)-C(O)C(O)-N(RD)RE; R2 is H; and all other variables are as defined in Embodiment ElO. In an aspect of this embodiment, the compound is a compound of Formula H, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, the compound is a compound of Formula DI, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, the compound is a compound of Formula V, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, the compound is a compound of Formula VI, or a pharmaceutically acceptable salt thereof. In another aspect of this embodiment, the compound is a compound of Formula Vπ, or a pharmaceutically acceptable salt thereof.
A seventeenth embodiment of the present invention (Embodiment El 7) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
X is N(RK) or O;
RK is:
(1) H,
(2) Ci_4 alkyl, (3) (CH2)l-2-T, wherein T is Cθ2RA, CN, N(RD)RE, Or C(O)N(RD)RE,
(4) C(O)RA,
(5) C(O)-(CH2)0-2-CF3,
(6) CO2RA,
(7) SO2RA, (8) Sθ2-AryB,
(9) SO2N(RD)RE5
(10) C(O)N(RD)RE5
(H) C(O)C(O)-N(RD)RE5
(12) C(O)-(CH2)1-2-N(RD)RE
(13) CycB,
(14) (CH2)l-2-U, wherein U is CycB, AryB, or HetB, or
(15) (CH2)l-2C(O)N(RA)-(CH2)l-2-HetB;
Rl iis: (D H,
(2) Ci_4 alkyl5
(3) (CH2)l-2-V, wherein V is OH, O-C1.4 alkyl, SRA, S(O)RA, SO2RA, N(RD)RES
C(O)N(RD)RE5 N(RA)-C(O)C(O)-N(RD)RE5 N(RA)-C(O)RB, N(RA)-SO2RB,
N(RA)-CI_4 alkylene-SO2RB, N(RA)C(O)-C 1.4 alkylene-SO2RB,
N(RA)-SO2N(RD)RE5 or N(RA)-CO2RB5
(4) (CH2)l-2-W, wherein W is CycA, AryA, HetA, O-(CH2)l-2-AryA, O-(CH2)l-2-HetA, or N(RA)-C(O)-HetA,
Figure imgf000028_0001
(6) N(RA)-SO2N(RD)RE5
(7) N(RA)-CO2RB5
(8) N(RD)RE5
(9) N(RC)RA5
(10) N(RA)-C(O)RB5
(H) N(RC)-C(O)RA5
(12) SRF
(13) N(RA)-C(O)-HetA,
(14) N(RC)-C(O)-N(RD)RE5
(15) N(RA)-C(O)C(O)-N(RD)RE or
(16) N(RC)-C(O)C(O)-N(RD)RE;
R2 is H or C I_4 alkyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form cyclopropyl, cyclobutyl, cyclopenryl, cyclohexyl, or oxacyclohexyl (alternatively known in the art as tetrahydropyranyl); each Rβ is H, and each R.4 is H; or alternatively Rβ and R.4 attached to the same carbon atom together form oxo;
each Rβ is H, and each R6 is H; or alternatively Rβ and Rβ attached to the same carbon atom together form oxo;
R7 is H;
R8 is H; or alternatively R7 and Rβ together form oxo;
R9 is H;
RlO is CH2-CycC, CH2-AryC or Clfe-HetC;
each RA is independently H or C 1-4 alkyl;
each RB is independently H or C 1.4 alkyl;
RC is (CH2) l -2-CycA, (CH2) 1 -2-AryA, or (CH2) 1 -2-HetA; or alternatively, when X is N(RK), RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered diazacycloalkyl ring; wherein the portion of the fused ring obtained from RC and RK is a 1- to 3-membered methylene chain optionally substituted with oxo;
each RD and RE are independently H or C 1.4 alkyl, or together with the nitrogen to which they are both attached form a 5- or 6-membered saturated heterocyclic ring selected from the group consisting of *— N^ I *-N ) *-N p *-N S *-N S(O) *-N S(O)2
*— N N-C1-4 alkyl *-N N-S(O)2-C1-4 alkyl \ — / , and \ — / , wherein * denotes the point of attachment to the rest of the molecule; RF is C 1-4 alkyl, or alternatively, when X is N(RK) and Rl is SRF, RF and RK together with (i) the N atom to which RK is attached, (ii) the S atom to which RF is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is a 1- to 3-membered methylene chain;
each CycA is independently a C3_6 cycloalkyl;
CycB is a C3.6 cycloalkyl;
CycC is a C^-6 cycloalkyl;
AryA, AryB and AryC are each independently phenyl which is optionally substituted with 1 or 2 substituents each of which is independently bromo, chloro, fluoro, C 1.4 alkyl, CF3, C(O)NH2, C(O)NH(Ci_4 alkyl), C(O)N(CM alkyl)2, S-C1.4 alkyl, SO2-C1.4 alkyl, or Sθ2N(Ci_4 alkyl)2; and
HetA, HetB, and HetC are each independently a 5- or 6-membered heteroaromatic ring selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, isooxazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridinyl, pyridinyl N-oxide, pyrimidinyl, pyridazinyl, and pyrazinyl, wherein the heteroaromatic ring is optionally substituted with from 1 or 2 substituents each of which is independently a Cl .4 alkyl;
and the integers m and n are as originally defined or as defined in Embodiment E4. In an aspect of this embodiment, X is N(RK). An eighteenth embodiment of the present invention (Embodiment E 18) is a compound of
Formula I as defined in Embodiment E 17, or a pharmaceutically acceptable salt thereof, wherein provisos
A, B, C and D as set forth in Embodiment El 1 are applied. In an aspect of this embodiment, X is N(RK). A nineteenth embodiment of the present invention (Embodiment E 19) is a compound of
Formula I as defined in Embodiment El 7, or a pharmaceutically acceptable salt thereof, wherein provisos A, B and C as set forth in Embodiment E12 are applied. In an aspect of this embodiment, X is N(RK). A twentieth embodiment of the present invention (Embodiment E20) is a compound of
Formula I as defined in Embodiment El 7, or a pharmaceutically acceptable salt thereof, wherein provisos
A, B and C as set forth in Embodiment E13 are applied. In an aspect of this embodiment, X is N(RK). It is understood that the definitions of variables in the provisos set forth in Embodiments El 1, El 2 and El 3 can be customized in the provisos in Embodiments El 8, El 9 and E20 so that the definitions therein match (i.e., are consistent with) the definitions of the variables in Embodiment E17. For example, part (3) of the definition of RK in Embodiment E17 recites "(CH2)l-2-T". Accordingly, the reference to "C1.4 alkyl substituted with T" in part (3) of the definition of RK in proviso C of Embodiment El 1 can be rewritten here to refer to "(CH2)l-2-T".
A twenty-first embodiment of the present invention (Embodiment E21) is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:
X is N(RK) or O;
RK is:
(1) H, (2) Ci-4 alkyl,
(3) (CH2)l-2-T, wherein T is CO2H, CO2CH3, CO2CH2CH3, CN, N(CH3>2, N(CH2CH3)2, C(O)NH2, C(O)NH(CH3), C(O)N(CH3)2, C(O)NH(CH2CH3),
Figure imgf000031_0001
*-N S(O)2 *-N N-CH3 *-N N-S(O)2CH3 C(O)-N I
C(O)-N > C(O)-N O C(O)-N S C(O)-N S(O)
\ / \ / 9 9 \ / 5
C(O)-N S(O)2 C(O)-N N-CH3 C(O)-N N-S(O)2CH3
\ — / > ^- _/ , or \ /
(4) C(O)CH3,
(5) C(O)CF3,
(6) CO2CH3,
(7) SO2CH3,
(S) SO2-phenyl, wherein the phenyl is optionally substituted with methyl,
(9) SO2N(CH3)2,
C(O)-N
(10) C(O)NH(CH3), C(O)NH(CH2CH3), C(O)N(CH3)2, C(O)N(CH2CH3 )2,
Figure imgf000031_0002
C(O)C(O)-N^ J C(O)C(O))--NN^. y C(O)C(O)-NN
(11) C(O)C(O)-N(CH3)2,
C(O)C(O)-N " S C(O)C(O)-N S(O) C(O)C(O)-N S(O)2
C(O)C(O)-N N-CH3 C(O)C(O)-N N-S(O)2CH3 \ — / , or \ — /
(12) C(O)-(CH2)l-2-N(CH3)2, (13) cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl,
(14) (CH2)l-2-U, wherein U is cyclopropyl, cyclopentyl, cyclohexyl, phenyl, or a heteroaromatic ring selected from the group consisting of pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, and pyrazinyl, wherein the heteroaromatic ring is optionally substituted with methyl, (15) (CH2)l-2C(O)N(H)-(CH2)l-2-pyridinyl,
(16) (CH2)l-2C(O)N(H)-(CH2)l-2-pyrimidinyl,
(17) (CH2)l-2C(O)N(H)-(CH2)l-2-pyrazinyl,
(18) (CH2)l-2C(O)N(CH3)-(CH2)l.2-pyridinyl,
(19) (CH2)l-2C(O)N(CH3)-(CH2)l.2-pyrimidinyl, or (20) (CH2)l-2C(O)N(CH3)-(CH2)l-2-pyrazinyl;
(1) H,
(2) Ci_4 alkyl, (3) (CH2)l-2-V, wherein V is OH, OCH3, SCH3, SO2CH3, N(CH3)2, C(0)NH2,
C(O)NH(CH3), C(O)N(CH3)2, C(O)NH(CH2CH3), C(O)N(O^CH3 )2, *-N \ *-N O *-N S *-N S(O) *-N S(O)2
*-N N-CH3 *-N N-S(O)2CH3 C(O)-N I C(O)-N )
C(O)-N O C(O)-N S C(O)-N S(O) C(O)-N S(O)2
C(O)-N N-CH3 C(O)-N N-S(O)2CH3 \ — / , or \ — / , N(CH3)-C(O)C(O)-N(CH3)2,
N(CH3)-C(O)CH3, N(CH3)-Sθ2CH3, N(CH3)CH2Sθ2CH3, N(CH3)C(O)CH2Sθ2CH3, N(CH3)-SO2N(CH3)2, or N(CH3)-CO2CH3, (4) (CH2) 1-2-W, wherein W is 0CH2-phenyl or N(CH3 )-C(O)-HetA, (5) N(H)-SO2CH3,
(6) N(CH3)-SO2CH3,
(O)2
Figure imgf000033_0001
(9) N(CH3)-CO2CH3,
(10) NH(CH2CH(CH3)2),
(11) NH(CH3), (12) NH(CH2CH3),
(13) N(CH3)2,
(14) N(CH2CH3)2,
(15) N(RC)CH3,
(16) NH(RC), (17) NH-C(O)CH3,
(18) N(CH3 )-C(O)CH3,
(19) N(CH2CH3)-C(O)CH3,
(20) N(CH2CH(CH3)2)-C(O)CH3,
(21) N(RC)-C(O)CH3, (22) SRF, S(O)RF, or S(O)2RF,
(23) N(CH3)-C(0)-HetA,
(24) N(RC)-C(O)-N(RD)RE,
(25) N(H)-C(O)C(O)-N(CH3)2,
(26) N(CH3)-C(O)C(O)-N(CH3)2, (27) N(CH2CH3)-C(O)C(O)-N(CH3)2,
(28) N[CH(CH3)2]-C(O)C(O)-N(CH3)2,
(29) N[CH2CH(CH3)2)]C(O)C(O)-N(CH3)2,
N(CHs)-C(O)C(O)-N7^] N(CH3)-C(0)C(0)-N \ N(CH3)-C(O)C(O)-N O
(JU) — , ^ —> , ^ ' ;
/ \ / \
N(CH3J-C(O)C(O)-N S N(CH3J-C(O)C(O)-N S(O) N(CH3)-C(O)C(O)-N S(O)2 N(CH3)-C(O)C(O)-N N-CH3
\ / , \ — / , or
N(CH3)-C(O)C(O)-N N-S(O)2CH3
\ — / , or
(31) N(RC)-C(O)C(O)-N(CH3)2;
R2 is H or C 1-4 alkyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form cyclopropyl, cyclopentyl, cyclohexyl, or tetrahydropyran-4-yl;
each R3 is H, and each R4 is H; or alternatively R3 and R4 attached to the same carbon atom together form oxo;
each R5 is H, and each R6 is H; or alternatively R5 and R6 attached to the same carbon atom together form oxo;
R7 is H;
R8 is H; or alternatively R7 and R& together form oxo;
R9 is H;
RlO is CH2-phenyl, wherein the phenyl is optionally substituted with 1 or 2 substituents each of which is independently bromo, chloro, fluoro, CH3, CF3, C(O)NH2, C(0)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2;
RC is CH2-cyclohexyl or CH2-phenyl where the phenyl is optionally substituted with 1 or 2 substituents each of which is independently bromo, chloro, fluoro, methyl, ethyl, CF3, C(O)NH2, C(0)NH(CH3), C(O)NH(CH2CH3), C(O)N(CH3)2, SCH3, SO2CH3, or Sθ2N(CH3)2; or alternatively:
(a) when X is N(RK), Rl is N(RC)-C(O)C(O)-N(CH3)2, and m=n=l , then RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) and the ring carbon between X and the ring carbon to which Rl is attached, form a fused 6-membered diazacycloalkyl ring; wherein the portion of the fused ring obtained from RC and RK is -CH2CH2-, (b) when X is N(RK), Rl is N(RC)-C(O)CH3, m=0, and n=l , then RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, and (iii) the ring carbon to which Rl is attached, form a fused 5-membered diazacycloalkyl ring; wherein the portion of the fused ring obtained from RC and RK is -C(O)CH2- or -CH2C(O)-, or
(c) when X is N(RK), Rl is N(RC)CH3, and m=n=l, then RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) and the ring carbon between X and the ring carbon to which Rl is attached, form a fused 6-membered diazacycloalkyl ring; wherein the portion of the fused ring obtained from RC and RK is -C(O)CH2- or -CH2C(O)-; and
RF is CH3, or alternatively, when X is N(RK)5 Rl is SRF, and m=n=0, RF and RK together with (i) the N atom to which RK is attached, (ii) the S atom to which RF is attached, and (iii) the ring carbon to which Rl is attached, form a fused 5-membered thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is -CH2CH2-;
HetA is a heteroaromatic ring selected from the group consisting of pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, pyridinyl, pyridinyl N-oxide, and pyrazinyl, wherein the heteroaromatic ring is optionally substituted with methyl;
and the integers m and n are as originally defined or as defined in Embodiment E4. In an aspect of this embodiment, X is N(RK).
A twenty-second embodiment of the present invention (Embodiment E22) is a compound of Formula-I as defined in Embodiment E21, or a pharmaceutically acceptable salt thereof, wherein provisos A, B, C and D as set forth in Embodiment El 1 are applied. In an aspect of this embodiment, X is N(RK).
A twenty-third embodiment of the present invention (Embodiment E23) is a compound of Formula I as defined in Embodiment E21, or a pharmaceutically acceptable salt thereof, wherein provisos A, B and C as set forth in Embodiment E12 are applied. In an aspect of this embodiment, X is N(RK).
A twenty-fourth embodiment of the present invention (Embodiment E24) is a compound of Formula I as defined in Embodiment E21, or a pharmaceutically acceptable salt thereof, wherein provisos A, B and C as set forth in Embodiment E13 are applied. In an aspect of this embodiment, X is
N(RK). It is understood that the definitions of variables in the provisos set forth in Embodiments El 1, E12 and E13 can be customized in the provisos in Embodiments E22, E23 and E24 so that the definitions therein match the definitions in Embodiment E21.
A first class of the present invention includes compounds of Formula VIII and pharmaceutically acceptable salts thereof:
Figure imgf000036_0001
wherein:
RK is:
(D H,
(2) methyl,
(3) ethyl,
(4) isopropyl,
(5) C(O)CH3,
(6) SO2CH3,
(7) C(O)C(O)-N(CH3)2,
(8) cyclopropyl
(9) cyclopentyl,
(10) CH2-cyclopropyl,
(H) CH2-phenyl, or
(12) CH2CH2-phenyl;
Rl is:
(1) H,
(2) methyl,
(3) ethyl,
(4) isopropyl,
(5) N(H)-SO2CH3,
(6) N(CH3)-SO2CH3, (7) N(CH3)-SO2N(CH3)2,
(8) N(CH3)-CO2CH3,
(9) NH(CH2CH(CH3)2),
(10) NH(CH3),
(H) NH(CH2CH3),
(12) N(CH3)2,
(13) N(CH2CH3)2,
(14) N(H)RC,
(15) N(RC)CH3,
(16) NH-C(O)CH3,
(17) N(CH3)-C(O)CH3,
(18) N(CH2CH3)-C(O)CH3,
(19) N(CH2CH(CH3)2)-C(O)CH3,
Figure imgf000037_0001
(22) N(H)-C(O)C(O)-N(CH3)2,
(23) N(CH3)-C(O)C(O)-N(CH3)2,
(24) N(CH2CH3)-C(O)C(O)-N(CH3)2,
(25) N[CH2CH(CH3)2]-C(O)C(O)-N(CH3)2,
N(CHs)-C(O)C(O)-N J
(26)
/ \
N(CH3)-C(O)C(O)-N )
(27)
N(CH3)-C(O)C(O)— N O
(28)
N(CH3J-C(O)C(O)-N S
(29)
N(CH3)-C(O)C(O)-N N-CH3
(30)
/ — ^
N(CH3)SO2-N J
(31)
I N.
N(CH3)SO2-N J
(32)
N(CH3)SO2-N O
(33) N(CH3)SO2-N S
(34) ^^ ,
N(CH3)SO2-N N-CH3
(35) ^-V , or
(36) N(RC)-C(O)C(O)-N(CH3)2;
RC is CH2-cyclohexyl, CH2-phenyl, or CH2-phenyl where the phenyl is para-substituted with fluoro; and
Yl and Y2 are each independently H, Br, Cl, F, CH3, C(0)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2. A sub-class of the first class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment El 1 is applied. Another sub-class of the first class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment E12 is applied. Another sub-class of the first class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment El 3 is applied. It is understood that the definitions of variables in the proviso C set forth in Embodiments El 1, E 12, and El 3 can be customized in the provisos included in these sub-classes so that the definitions therein match the definitions set forth in the first class.
A second class of the present invention includes compounds of Formula IX and pharmaceutically acceptable salts thereof:
Figure imgf000038_0001
wherein:
RK is H or C 1-3 alkyl, CH2-phenyl, or CH2-pyridinyl; and
Yl and Y2 are each independently H, Br, Cl, F, CH3, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2. A sub-class of the second class includes compounds of Formula IX, and pharmaceutically acceptable salts thereof, wherein R.K is H or Cl _3 alkyl; and all other variables are as originally defined in the second class.
Another sub-class of the second class includes compounds of Formula DC, and pharmaceutically acceptable salts thereof, wherein R.K is C 1.3 alkyl, CH2-phenyl, or CH2-pyridinyl; and all other variables are as originally defined in the second class.
A third class of the present invention includes compounds of Formula X and pharmaceutically acceptable salts thereof:
Figure imgf000039_0001
wherein:
Rl is:
(1) H,
(2) N(CH3)-SO2N(CH3)2, (3) NH(CH3),
(4) NH(CH2CH3),
(5) NH(CH2CH(CH3)2),
(6) N(CH3)2,
(7) N(CH2CH3)2, (8) N(CH3)-C(O)CH3,
(9) N(CH2CH3)-C(O)CH3,
(10) N(CH2CH(CH3)2)-C(O)CH3,
Figure imgf000039_0002
(12) N(H)-C(O)C(O)-N(CH3)2, (13) N(CH3)-C(O)C(O)-N(CH3)2,
(14) N(CH2CH3)-C(O)C(O)-N(CH3)2,
(15) N(CH(CH3)2)-C(O)C(O)-N(CH3)2,
Figure imgf000040_0001
Yl and Y2 are each independently H, Br, Cl, F, CH3, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2.
A sub-class of the third class includes the compounds of Formula X, and pharmaceutically acceptable salts thereof, wherein Rl is other than H; i.e., Rl is any one of the groups (2) to (25) as originally defined in the third class; and all other variables are as originally defined in the third class.
A fourth class of the present invention includes compounds of Formula XI and pharmaceutically acceptable salts thereof:
Figure imgf000040_0002
wherein: (1) H,
(2) methyl,
(3) ethyl,
(4) isopropyl,
(5) CH2CO2H,
(6) CH2CN,
(7) CH2CH2NH(CH3), CH2CH2NH(CH2CHB), CH2CH2N(CHS)2 or
CH2CH2N(CH2CH3)2,
(8) CH2C(O)NH2,
(9) CH2C(O)NH(CH3),
(10) CH2C(O)N(CH3)2,
Figure imgf000041_0001
(12) C(O)CH3,
(13) C(O)CF3,
(14) CO2CH3,
Figure imgf000041_0002
(17) SO2N(CH3)2,
(18) C(O)NH(CH3), C(O)NH(CH2CH3), C(O)N(CH3 )2, or C(O)N(CH2C
Figure imgf000041_0003
(20) C(O)C(O)-N(CH3)2,
(21) C(O)CH2N(CH3)2,
(22) CH2-phenyl,
(23) CH2-pyridinyl,
(24) CH2CH2-pyridinyl,
Figure imgf000042_0001
(24)
CH2CH2-N CH2CH2-N ) CH2CH2-N O CH2CH2-N S
V> , \ / , \ — / , \ / , or
CH2CH2-N N-CH3 \ /
(25) CH2C(O)N(H)CH2-pyridinyl, or
(26) CH2C(O)N(CH3)CH2-pyridinyl;
(1) H,
(2) methyl,
(3) CH2OH,
(4) CH2N(CH3)2,
(5) CH2N(CH3)-C(O)C(O)-N(CH3)2,
(6) CH2N(CH3)-SO2CH3,
(7) CH2N(CH3)C(O)CH2-SO2CH3,
(8) CH2N(CH3)-SO2N(CH3)2,
(9) CH2SCH3,
(10) CH2SO2CH3,
Figure imgf000043_0001
R2 is H or methyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form cyclopropyl or tetrahydropyran-4-yl; and
Yl and Y2 are each independently H, Br, Cl, F, CH3, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2. A sub-class of the fourth class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein provisos C and D as set forth in Embodiment El 1 is applied. Another sub-class of the fourth class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment E12 is applied. Another sub-class of the fourth class includes the compounds as defined therein, and pharmaceutically acceptable salts thereof, wherein proviso C as set forth in Embodiment El 3 is applied. It is understood that the definitions of variables in the provisos C and D set forth in Embodiments El 1, E12, and E13 can be customized in the provisos included in these sub-classes so that the definitions therein match the definitions set forth in the fourth class.
A fifth class of the present invention includes compounds of Formula XII and pharmaceutically acceptable salts thereof:
Figure imgf000043_0002
wherein:
RK is Ci-3 alkyl, CH2-phenyl, CH2-pyridinyl, or (CO)CHa; and
Yl and γ2 are each independently H, Br, Cl, F, CH3, C(O)NH(CHa), C(O)N(CH3)2, SCH3, SO2CH3, or SO2N(CH3)2. A sixth class of the present invention includes compounds of Formula XIH, XTV, and XV, and pharmaceutically acceptable salts thereof:
Figure imgf000044_0001
wherein:
RK is Ci-3 alkyl, CH2-phenyl, or CH2-pyridinyl; and
Yl and γ2 are each independently H, Br, Cl, F, CH3, C(O)NH(CH3), C(O)N(CH3)2, SCH3, SO2CH3, or Sθ2N(CH3)2- A sub-class of the sixth class includes compounds of Formula XV, and pharmaceutically acceptable salts thereof.
Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in Table 1 below.
Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from Compounds 1-4, 6, 7, 9-39 and 41-185.
Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from Compounds 60, 61, 63, 64, 69, 71, 72, 75, 76, 82, 84, 85, 86, 87, 89, 91, 92, 110, 113-136, 138, 142-150, 153-157, 180 and 181.
Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from Compounds 87, 116-119, 121, 123-136, 142-150, 154-157, 180 and 181. Another embodiment of the present invention is a compound, or a pharmaceutically acceptable salt thereof, selected from Compounds 116-119, 121, 123-136, 142-150, 154-157, 180 and 181. The compounds in these two embodiments have exhibited excellent potency in the integrase assay (Example 32) and in the spread assay (Example 33). It is believed that these compounds are active against clinical mutants that have been generated with approved HTV reverse transcriptase inhibitors and protease inhibitors. Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as originally defined or as defined in any of the foregoing embodiments, classes, or sub-classes, wherein the compound or its salt is in a substantially pure form. As used herein "substantially pure" means suitably at least about 60 wt.%, typically at least about 70 wt.%, preferably at least about 80 wt.%, more preferably at least about 90 wt.% (e.g., from about 90 wt.% to about 99 wt.%), even more preferably at least about 95 wt.% (e.g., from about 95 wt.% to about 99 wt.%, or from about 98 wt.% to 100 wt.%), and most preferably at least about 99 wt.% (e.g., 100 wt.%) of a product containing a compound Formula I or its salt (e.g., the product isolated from a reaction mixture affording the compound or salt) consists of the compound or salt. The level of purity of the compounds and salts can be determined using a standard method of analysis such as thin layer chromatography, gel electrophoresis, high performance liquid chromatography, and/or mass spectrometry. A compound or salt of 100% purity is one which is free of detectable impurities as determined by one or more standard methods of analysis. With respect to a compound of the invention which has one or more asymmetric centers and can occur as mixtures of stereoisomers, a substantially pure compound can be either a substantially pure mixture of the stereoisomers or a substantially pure individual diastereomer or enantiomer.
Other embodiments of the present invention include the following: (a) A pharmaceutical composition comprising an effective amount of a compound of Formula I and a pharmaceutically acceptable carrier. (b) A pharmaceutical composition which comprises the product prepared by combining (e.g., mixing) an effective amount of a compound of Formula I and a pharmaceutically acceptable carrier.
(c) The pharmaceutical composition of (a) or (b), further comprising an effective amount of an anti-HTV agent selected from the group consisting of HTV antiviral agents, immunomodulators, and anti-infective agents.
(d) The pharmaceutical composition of (c), wherein the anti-FflV agent is an antiviral selected from the group consisting of FHV protease inhibitors, non-nucleoside HTV reverse transcriptase inhibitors, and nucleoside HTV reverse transcriptase inhibitors.
(e) A pharmaceutical combination which is (i) a compound of Formula I and (ii) an anti-HTV agent selected from the group consisting of FlIV antiviral agents, immunomodulators, and anti- infective agents; wherein the compound of Formula I and the anti-FHV agent are each employed in an amount that renders the combination effective for the inhibition of FHV integrase, for the treatment or prophylaxis of infection by FUV, or for the treatment, prophylaxis or delay in the onset of ADDS. (f) The combination of (e), wherein the anti-HTV agent is an antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HTV reverse transcriptase inhibitors and nucleoside HTV reverse transcriptase inhibitors.
(g) A method of inhibiting HTV integrase in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I.
(h) A method for the treatment or prophylaxis of infection by HTV in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I.
(i) The method of (h), wherein the compound of Formula I is administered in combination with an effective amount of at least one antiviral selected from the group consisting of HTV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HTV reverse transcriptase inhibitors.
(j) A method for the treatment, prophylaxis, or delay in the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of a compound of Formula I.
(k) The method of (j), wherein the compound is administered in combination with an effective amount of at least one antiviral selected from the group consisting of HTV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside HTV reverse transcriptase inhibitors. (1) A method of inhibiting HTV integrase in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
(m) A method for the treatment or prophylaxis of infection by HTV in a subj ect in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
(n) A method for the treatment, prophylaxis, or delay in the onset of AIDS in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
The present invention also includes a compound of the present invention (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) the inhibition of HTV integrase, (b) treatment or prophylaxis of infection by HTV, or (c) treatment, prophylaxis, or delay in the onset of AIDS, hi these uses, the compounds of the present invention can optionally be employed in combination with one or more anti-HTV agents selected from HTV antiviral agents, anti-infective agents, and immunomodulators. Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub-classes, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt.
The present invention also includes prodrugs of the compounds of Formula I. The term "prodrug" refers to a derivative of a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is converted in vivo into Compound I. Prodrugs of compounds of Formula I can exhibit enhanced solubility, absorption, and/or lipophilicity compared to the compounds per se, thereby resulting in increased bioavailability and efficacy. The in vivo conversion of the prodrug can be the result of an enzyme-catalyzed chemical reaction, a metabolic chemical reaction, and/or a spontaneous chemical reaction (e.g., solvolysis). The prodrug can be, for example, a derivative of a hydroxy group such as an ester (-OC(O)R), a carbonate ester (-OC(O)OR), a phosphate ester (-O-P(=O)(OH)2), or an ether (-OR).
Other examples include the following: When the compound of Formula I contains a carboxylic acid group, the prodrug can be an ester or an amide, and when the compound of Formula I contains a primary amino group, the prodrug can be an amide, carbamate, imine, or a Mannich base. One or more functional groups in Compound I can be derivatized to provide a prodrug thereof. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, edited by H. Bundgaard, Elsevier, 1985; C. S. Larsen and J. Ostergaard, "Design and application of prodrugs" in: Textbook of Drug Design and Discovery, 3rd edition, edited by C. S. Larsen, 2002, pp. 410-458; and Beaumont et al., Current Drug Metabolism 2003, vol. 4, pp. 461-458; the disclosures of each of which are incorporated herein by reference in their entireties. Prodrugs of compounds of Formula I can also be selected and prepared by application of the descriptions in WO 2005/070901 and WO 2005/117904, both herein incorporated by reference in their entireties. As used herein, the term "alkyl" refers to any linear or branched chain alkyl group having a number of carbon atoms in the specified range. Thus, for example, "Cj-6 alkyl" (or "Ci-Cβ alkyl") refers to all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-buryl, n- and isopropyl, ethyl and methyl. As another example, "Ci -4 alkyl" refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. The term "alkylene" refers to any divalent linear or branched chain aliphatic hydrocarbon radical (or alternatively an "alkanediyl") having a number of carbon atoms in the specified range. Thus, for example, "-Ci_6 alkylene-" refers to any of the Ci to Cβ linear or branched alkylenes. A class of alkylenes of particular interest with respect to the invention is -(CH2)l-6-j and sub-classes of particular interest include -(CH2)l-4-, -(CH2)l-3-, -(CH2)l-2-> and -CH2-. Also of interest is the alkylene -CH(CH3)-.
The terms "cycloalkyl" refers to any cyclic ring of an alkane having a number of carbon atoms in the specified range. Thus, for example, "C3-8 cycloalkyl" (or "C3-C8 cycloalkyl") refers to cyclopropyl, cyclobutyl, cyclopenryl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
The term "haloalkyl" refers to an alkyl group as defined above in which one or more of the hydrogen atoms has been replaced with a halogen (i.e., F, Cl, Br and/or I). Thus, for example, "Ci -6 haloalkyl" (or "Ci-Cg haloalkyl") refers to a Ci to Cg linear or branched alkyl group as defined above with one or more halogen substituents. The term "fluoroalkyl" has an analogous meaning except that the halogen substituents are restricted to fluoro. Suitable fluoroalkyls include the series (CH2)θ-4CF3 (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
The term "diazacycloalkyl" means a saturated cyclic ring consisting of two nitrogens and one or more carbon atoms (e.g., imidazolidinyl, pyrazolidinyl, or piperazinyl).
The term "oxyazacycloalkyl" means a saturated cyclic ring consisting of an oxygen atom, a nitrogen atom, and one or more carbon atoms.
The term "thioazacycloalkyl" means a saturated cyclic ring consisting of a sulfur atom, a nitrogen atom, and one or more carbon atoms. The term " 1 - to 4-membered methylene chain" means a divalent radical of formula
-(CH2)M-.
Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heterocyclic ring described as containing from "1 to 4 heteroatoms" means the ring can contain 1, 2, 3 or 4 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. Thus, for example, a heterocyclic ring described as containing from "1 to 4 heteroatoms" is intended to include as aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, and so forth.
When any variable (e.g., RAJ RB3 Or AryD) occurs more than one time in any constituent or in Formula I or in any other formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. The term "substituted" (e.g., as in "is optionally substituted with from 1 to 5 substituents ...") includes mono- and poly-substitution by a named substituent to the extent such single and multiple substitution (including multiple substitution at the same site) is chemically allowed. Unless expressly stated to the contrary, substitution by a named substituent is permitted on any atom in a ring (e.g., aryl, a heteroaromatic ring, or a saturated heterocyclic ring) provided such ring substitution is chemically allowed and results in a stable compound.
Any of the various carbocyclic and heterocyclic rings and ring systems defined herein may be attached to the rest of the compound at any ring atom (i.e., any carbon atom or any heteroatom) provided that a stable compound results. Suitable aryls include phenyl, 9- and 10-membered bicyclic, fused carbocyclic ring systems, and 11- to 14-membered tricyclic fused carbocyclic ring systems, wherein in the fused carbocyclic ring systems at least one ring is aromatic. Suitable aryls include, for example, phenyl, naphthyl, tetrahydronaphthyl (tetralinyl), indenyl, anthracenyl, and fluorenyl. Suitable heteroaryls include 5- and 6-membered heteroaromatic rings and 9- and 10-membered bicyclic, fused ring systems, wherein the heteroaromatic ring or the bicyclic, fused ring system contains from 1 to 4 heteroatoms selected from N, O and S. Suitable 5- or 6-membered heteroaromatic rings include, for example, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Suitable heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromenyl, quinolinyl, isoquinolinyl, cinnolinyl, and quinazolinyl. Suitable saturated heterocyclics include 4- to 7- membered saturated heterocyclic rings containing 1 or 2 heteroatoms selected from N, O and S. Suitable 4- to 7-membered saturated heterocyclics include, for example, azetidinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, and dioxanyl. The foregoing are representative of saturated heterocyclics that may be formed by the joining of Rl and R.2 together with the ring carbon to which they are both attached. Saturated heterocyclics that may be formed by the joining of RP and R.E together with the nitrogen to which they are both attached include, for example, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepanyl, diazepanyl, and thiazinanyl.
A "stable" compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject). As a result of the selection of substituents and substituent patterns, certain of the compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers or enantiomers. All isomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention. As would be recognized by one of ordinary skill in the art, certain of the compounds of the present invention can exist as tautomers. All tautomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention.
In instances where a hydroxy (-OH) substituent(s) is(are) permitted on a heteroaromatic ring and keto-enol tautomerism is possible, it is understood that the substituent might in fact be present, in whole or in part, in the keto form, as exemplified here for a hydroxypyridinyl substituent:
Figure imgf000050_0001
Compounds of the present invention having a hydroxy substituent on a carbon atom of a heteroaromatic ring are understood to include compounds in which only the hydroxy is present, compounds in which only the tautomeric keto form (i.e., an oxo substitutent) is present, and compounds in which the keto and enol forms are both present.
The compounds of the present inventions are useful in the inhibition of HTV integrase (e.g., HTV-I integrase), the prophylaxis or treatment of infection by HTV and the prophylaxis, treatment or the delay in the onset of consequent pathological conditions such as AIDS. The prophylaxis of ADDS, treating AIDS, delaying the onset of AIDS, the prophylaxis of infection by HTV, or treating infection by HTV is defined as including, but not limited to, treatment of a wide range of states of HTV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HTV. For example, the compounds of this invention are useful in treating infection by HTV after suspected past exposure to HTV by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery. The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HTV integrase, e.g., by competitive inhibition. Thus the compounds of this invention can be commercial products to be sold for these purposes. The compounds of the present invention can be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof). Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. Certain compounds of the invention carry an acidic moiety, in which case suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
The term "administration" and variants thereof (e.g., "administered" or "administering") in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment or prophylaxis. When a compound of the invention or a prodrug thereof is provided in combination with one or more other active agents (e.g., antiviral agents useful for the prophylaxis or treatment of HIV infection or ADDS), "administration" and its variants are each understood to include provision of the compound or prodrug and other agents at the same time or at different times. When the agents of a combination are administered at the same time, they can be administered together in a single composition or they can be administered separately.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
By "pharmaceutically acceptable" is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
The term "subject" (or, alternatively, "patient") as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term "effective amount" as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. In one embodiment, the effective amount is a "therapeutically effective amount" for the alleviation of the symptoms of the disease or condition being treated. In another embodiment, the effective amount is a "prophylactically effective amount" for prophylaxis of the symptoms of the disease or condition being prevented. The term also includes herein the amount of active compound sufficient to inhibit HIV integrase and thereby elicit the response being sought (i.e., an "inhibition effective amount"). When the active compound (i.e., active ingredient) is administered as the salt, references to the amount of active ingredient are to the free acid or free base form of the compound. For the purpose of the inhibition of HIV integrase, the prophylaxis or treatment of HTV infection, or the prophylaxis or treatment or delay in the onset of AIDS, the compounds of the present invention, optionally in the form of a salt, can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The compounds of the invention can, for example, be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. Liquid preparations suitable for oral administration (e.g., suspensions, syrups, elixirs and the like) can be prepared according to techniques known in the art and can employ any of the usual media such as water, glycols, oils, alcohols and the like. Solid preparations suitable for oral administration (e.g., powders, pills, capsules and tablets) can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like. Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as a solubility aid. Injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further description of methods suitable for use in preparing pharmaceutical compositions of the present invention and of ingredients suitable for use in said compositions is provided in Remington's Pharmaceutical Sciences. 18th edition, edited by A. R. Gennaro, Mack Publishing Co., 1990 and in Remington - The Science and Practice of Pharmacy. 21st edtion, Lippincott Williams & Wilkins, 2005. The compounds of this invention can be administered orally in a dosage range of about
0.001 to about 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses. One preferred dosage range is about 0.01 to about 500 mg/kg body weight per day orally in a single dose or in divided doses. Another preferred dosage range is about 0.1 to about 100 mg/kg body weight per day orally in single or divided doses. For oral administration, the compositions can be provided in the form of tablets or capsules containing about 1.0 to about 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
As noted above, the present invention is also directed to use of the HIV integrase inhibitor compounds of the present invention with one or more anti-HIV agents useful in the treatment of HIV infection or AIDS. An "anti-HIV agent" is any agent which is directly or indirectly effective in the inhibition of HTV integrase or another enzyme required for HTV replication or infection, the treatment or prophylaxis of HIV infection, and/or the treatment, prophylaxis or delay in the onset of AIDS. It is understood that an anti-HIV agent is effective in treating, preventing, or delaying the onset of HTV infection or AIDS and/or diseases or conditions arising therefrom or associated therewith. For example, the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more HTV antivirals, imunomodulators, antiinfectives, or vaccines useful for treating HTV infection or AIDS, such as those disclosed in Table 1 of WO 01/38332 or in the Table in WO 02/30930. Suitable HTV antivirals for use in combination with the compounds of the present invention include, for example, HTV protease inhibitors (e.g., indinavir, atazanavir, lopinavir optionally with ritonavir, saquinavir, or nelfinavir), nucleoside HTV reverse transcriptase inhibitors (e.g., abacavir, lamivudine (3TC), zidovudine (AZT), or tenofovir), and non-nucleoside HTV reverse transcriptase inhibitors (e.g., efavirenz or nevirapine). It will be understood that the scope of combinations of the compounds of this invention with HTV antivirals, immunomodulators, anti-infectives or vaccines is not limited to the foreogoing substances or to the list in the above-referenced Tables in WO 01/38332 and WO 02/30930, but includes in principle any combination with any pharmaceutical composition useful for the treatment of HTV infection or AIDS. The HTV antivirals and other agents will typically be employed in these combinations in then- conventional dosage ranges and regimens as reported in the art, including, for example, the dosages described in the Physicians' Desk Reference, 57th edition, Thomson PDR, 2003, or the 59th edition thereof, 2005. The dosage ranges for a compound of the invention in these combinations are the same as those set forth above. It is understood that pharmaceutically acceptable salts of the compounds of the invention and/or the other agents (e.g., indinavir sulfate) can be used as well. Abbreviations employed herein include the following: AcOH = acetic acid; Bn = benzyl; BOC or Boc = t-butyloxycarbonyl; Bz = benzoyl; CBZ = carbobenzoxy (alternatively, benzyloxycarbonyl); CDI = carbonyldiimidazole; DCM = dichloromethane; DDQ = 2,3-dichloro-5,6- dicyano-l,4-benzoquinone; DEAD = diethylazodicarboxylate; DMAD = dimethylacetylenedicarboxylate; DMF = N,N-dimethylformamide; EDC = l-ethyl-3-(3-dimethylaminopropyl) carbodiimide; ES MS = electrospray mass spectroscopy; Et = ethyl; EtOAc = ethyl acetate; EtOH = ethanol; HMDO = hexamethyl disiloxane; HOBT or HOBt = 1 -hydroxy benzotriazole hydrate; Me = methyl; MeOH = methanol; MsCl = methanesulfonyl chloride; NMP = N-methyl pyrrolidinone; NMR = nuclear magnetic resonance; Ph = phenyl; Py = pyridine; RP HPLC = reverse phase high performance liquid chromatography; t-Bu = tert-butyl; SFC = supercritical fluid chromatography; TBAF = tetraburylammonium fluoride; TFA = trifluoroacetic acid; THF = tetrahydrofuran; TsOH = toluenesulfonic acid.
The compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above. Scheme A depicts the synthesis of 3-hydroxy-8,9,9-substituted-4-oxo-6,7,8,9-tetrahydro-
4H-pyrazino[l,2-α]pyrimidine-2-carboxamides. Reductive alkylation of the amino derivative 1-1 with chloroacetaldeyde using standard chemistry (such as that described in Jerry March, Advanced Organic Chemistry. 3rd edition, John Wiley & Sons, 1985, pp. 798-800) can afford 2-substituted-5,6- dihydroxypyrimidine-4-carboxamide 1-2. Intramolecular alkylation of 1-2 with cesium carbonate provides tetrahydropyrazinopyrimidine carboxamide 1-3. Acylation or sulfonylation [see, e.g., the description in Jerry March, Advanced Organic Chemistry. 3rd edition, John Wiley & Sons, 1985, pp. 370- 371 (acylation) and p. 445 (sulfonylation)] of the nitrogen at the 8 position of 1-3 followed by hydrolysis (e.g., with a base such as NaOH) provides the desired compound 1-4. Alternatively, protection of the 3-hydroxy with a suitable protective group (e.g., benzyl chloride or benyzl bromide; further description on suitable protective groups is in T. W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis. 3rd edition, John Wiley & Sons, 1999, pp. 249-287) followed by alkylation of the nitrogen [see, e.g., the description in Jerry March, Advanced Organic Chemistry. 3rd edition, John Wiley & Sons, 1985, pp. 377- 379] provides the desired 1-4. Another alternative is alkylation of 1-3 to l-4a by reductive amination using standard chemistry. Scheme A:
Figure imgf000055_0001
1 a) reaction with RA-Q,
or
Figure imgf000055_0002
hydrogenation
Alternative:
Figure imgf000055_0003
Scheme B depicts the synthesis of 3-hydroxy-7,8,8-substituted-4-oxo-4,6,7,8- tetrahydroimidazo[l ,5-α]pyrimidine-2-caxboxamides. The 2-substituted-5,6-dihydroxypyrimidine-4- carboxamide 1-1 can be treated with trimethyl orthofbrmate and an aldehyde or ketone to obtain the compound 1-5. Substrate 1-1 can alternatively be treated with trimethyl orthoformate and phosgene to provide compound 1-5 in which R? and R.8 together form oxo. Acylation, sulfonylation or alkylation of the nitrogen at the 7 position of 1-5 using the procedures described in Scheme A can provide the desired compound 1-6. Alternatively, nitrogen alkylation of 1-5 to desired l-6a can be achieved by reductive amination. Scheme B:
Figure imgf000056_0001
Scheme C depicts the synthesis of 3-hydroxy-9,10510-substituted-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-σ][l,4]diazepine-2-carboxamides. The 2-substituted-5,6-dihydroxypyrimidine-4- carboxamide 1-7 can be obtained by reductive alkylation of the amino derivative 1-1 with a ben2yl protected hydroxyalkyl aldehyde (exemplified in Scheme C with 3-(benzyloxy)propanal) followed by removal of the benzyl protective group by, e.g., hydrogenolysis. Intramolecular cyclization under Mitsunobu conditions (e.g., treatment with DEAD in the presence of PPI13) provides 3-hydroxy-10,10- substituted-4-oxo-456,7,8,9,10-hexahydropyrimido[l,2-α][l,4]diazepine-2-carboxamide 1-8. Acylation, sulfonylation, or alkylation of the nitrogen at the 9 position of 1-8 can then provide the desired compound 1-9. Alternatively, reductive amination can provide desired compound l-9a.
Scheme C:
Figure imgf000057_0001
Scheme D depicts the synthesis of 10-substituted-3-hydroxy-8-substituted-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-^[l,4]diazepine-2-carboxamides. Amide 1-10 can be prepared in accordance with WO 2001/090082. The amidoxime 1-11 can be obtained by thioamidation of the amide 1-10 with P4S10 followed by treatment with hydroxylamine. Reaction of the amidoxime 1-11 with dimethylacetylenedicarboxylate, followed by cylization at high temperature in a suitable solvent (e.g., toluene, xylenes (individually or mixtures), chlorobenzene, or an alkyl alcohol such as MeOH) can provide the methyl ester 1-12. The methyl ester 1-12 can then be treated with DDQ, followed by treatment with with benzylamine or a N-benzyl-N-alkylamine to obtain compound 1-13. The benzyl group of 1-13 can be removed by hydrogenolysis, after which the methyl ester can be converted to amide 1-14 by treatment with a suitable amine. Acylation, sulfonylation or reductive amination of the secondary amine at the 10 position of 1-14 using standard chemistry can provide compound 1-15. Removal of the Boc protective group (e.g., by treatment with an acid such as TFA) from 1-15 followed by acylation or sulfonylation and then hydrolysis (e.g., with NaOH) can provide the desired 1-16. Alternatively, removal of the Boc protective group form 1-15 followed by reductive amination can provide the desired l-16a. Scheme D
Figure imgf000058_0001
Alternative:
Figure imgf000058_0002
Figure imgf000058_0003
Scheme E shows an alternative approach to Scheme D for the preparation of compound 1-16. The intermediate compound 1-13 is first deprotected, followed by acylation, sulfonylation or reductive amination using standard chemistry to give 1-17. Hydrogenolysis of 1-17 followed by acylation, sulfonylation or reductive amination using standard chemistry provides compound 1-18, and then coupling 1-18 with the appropriate amine affords the desired compound 1-16 or l-16a.
Scheme E
1) Boc deprotection
Figure imgf000059_0001
1-16 when Rκ = RASO2- or RAC0- 1-16a when Rκ = RACH2-
The first two steps of Scheme E can be conducted in the reverse order as shown in Scheme F, wherein the intermediate compound 1-13 is first subject to hydrogenolysis and then the methyl ester is converted to the desired amide by coupling with the appropriate amine to obtain the compound 1-19. Acylation, sulfonylation or reductive amination using standard chemistry followed by Boc deprotection step gives 1-20. Scheme F
Figure imgf000060_0001
[R* = R6SO2-, R6CO-, R6CH2-]
Scheme G depicts the synthesis of 10-substituted-3-hydroxy-8-substituted-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-^[l,4]diazepme-2-carboxamides. Nitrile 1-21 (prepared in the manner described in Eur. J. Org. Chem. 1999, 9: 2127-2135) is treated with hydroxylamine to obtain amidoxime 1-22, which is then treated with dimethylacetylenedicarboxylate, and then cyclized at high temperature in a suitable solvent (e.g., toluene, xylenes (individually or in mixtures), chlorobenzene, or an alkyl alcohol such as MeOH) to obtain the pyrimidine methyl ester. The 5-hydroxy in the pyrimidine methyl ester intermediate is then protected using, e.g., benzoic anhydride to afford methyl ester 1-23. Ester 1-23 can be converted into an amide by coupling with an appropriate amine followed by the Boc deprotection with a suitable acid (e.g., TFA) to generate the free amino compound 1-24. Reductive amination of amine 1-24 with chloroacetaldehyde followed by ring closure with KO-t-Bu can provide the cyclized compound 1-25. Boc protection of the nitrogen in the 8 position of 1-25 and removal of the benzyl group by hydrogenolysis produces alcohol 1-26, which can be activated with MsCl (e.g., at room temperature in the presence of TEA and a suitable solvent such as CHCI3) and then displaced with an appropriate benzylamine (e.g., coupling with the amine in a suitable solvent such as acetonitrile at elevated temperature and then ageing the reaction mixture until completion of the reaction) to afford amine compound 1-27. Removal of the Boc (e.g., with TFA), followed by sulfonyiation, acylation or reductive amination of the secondary amine in the 8-position of the bicyclic system, and then removal of the benzyl group by hydrogenolysis affords amino compound 1-28. Sulfonyiation, acylation or reductive amination of the secondary amine can then afford the desired compound 1-29. Alternatively, alcohol 1-26, after activation with MsCl, can be displaced with sodium thiomethoxide to afford after Boc deprotection compound l-27a. Reductive animation of the secondary amine in the 8-position of the bicyclic system and oxidation of the thioether affords compound 1-28.
Scheme G:
Figure imgf000061_0001
or RB-Q or
Figure imgf000061_0002
R* = R8SO2-, R6CO-, or R6CH2-
Figure imgf000062_0001
reductive amination with RB-CHO oxidation with H2O2
Figure imgf000062_0002
Scheme H depicts the synthesis of 8-substituted-3-hydroxy-4-oxo-4;6,7,8,9,10- hexahydropyrimido[l,2-c(][l,4]diazepine-2-carboxamides. The intermediate compound 1-12 is first deprotected (e.g., by treating with an acid such as TFA), followed by acylation, sulfonylation or reductive amination using standard chemistry to give 1-30. Coupling with the appropriate amine produces the compound 1-31.
Scheme H:
1) Boc deprotection
Figure imgf000062_0003
Figure imgf000062_0004
1-12 2b) reductive amination 1-30 with RA-CHO [ Rκ = RA802. RA00^ or RACH2.j
Figure imgf000062_0005
Scheme I depicts the synthesis of 10-substituted-3-hydroxy-4-oxo-6,7,9,10-tetrahydro- 4H-pyrimido[l,2-^[l,4]oxazepine-2-carboxamides. Thioamidation of 4-oxacaprolactam 1-32 with P4S10 followed by treatment with hydroxylamine affords amidoxime 1-33. Reaction of the amidoxime
1-33 with dimethylacerylenedicarboxylate, followed by cylization at high temperature in a suitable solvent provides the methyl ester 1-34, which can be benzoylated and then brominated (e.g., with N-bromosuccinimide) to obtain compound 1-35. The bromoderivative can then be treated with benzyl amine or the appropriate N-benzyl-N-alkylamine to obtain, after hydrogenative removal of the benzyl group, compound 1-36. Acylation, sulfonylation or reductive amination of the secondary amine at the 10 position of 1-36 using standard chemistry provides compound 1-37. Coupling of the appropriate amine to 1-37 produces the compound 1-38.
Scheme I:
Figure imgf000063_0001
1-35 1-36
Figure imgf000063_0002
Scheme J depicts a method for preparing 3-hydroxy-4,7-dioxo-6,7,8,9-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2-carboxamides and 3-hydroxy-4,7,7-trioxo-8,9-dihydro-4H-pyrimido[2,l- d][l,2,5]thiadiazine-2-carboxamides. The amino group at the 2-position of pyrimidine carboxamide 1-1 is sulfonylated/acylated with halomethylsufonyl halide/haloacetyl halide to afford sulfonylated/acylated intermediate 1-40, which can then undergo internal alkylation via treatment with cesium carbonate to afford the desired bicyclic 1-41.
Scheme J
Figure imgf000064_0001
1-41
Scheme K depicts a method for preparing 3-hydroxy-4,6-dioxo-6,7,8,9-tetrahydro-4H- pyrimido[l,6-a]pyrimidine-2-carboxamides. The Boc-protected aminonitrile 1-42 (which can be prepared from commercially available starting materials using known chemistry) is first treated with hydroxylamine to obtain the corresponding amidoxime, which is then reacted with DMAD and the resulting adduct cyclized to a dihydroxypyrimdine methyl ester at elevated temperature in a suitable solvent. The 3 -hydroxy group on the pyrimidine ring can then be protected by treating with benzoyl anhydride to afford 1-43. Coupling 1-43 with a suitable amine with concomitant removal of Bz followed by acid treatment to remove the Boc protective group provides 1-44, which can be cyclized to form the desired compound 1-45 by (i) acylation with CDI (to give the 7-benzyl derivative) or (ii) reductive amination with a suitable aldehyde, hydrogenolysis to remove the benzyl group, and then acylation and cyclization with CDI. Scheme K
Figure imgf000065_0001
Scheme L depicts an alternative synthesis for the preparation of 3-hydroxy-8,9,9- substituted-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamides. The core hydroxyl group can readily be protected, for instance using a benzyl protection group, and then the nitrogen alkylated with bromoacetonitrile to give the required nitrile 1-46. Nitrile 1-46 can then undergo a [3+2]- cycloaddition, typically with concurrent deprotection of the hydroxyl group, to provide tetrazole 1-47 using sodium azide in the presence of catalytic triethylamine hydrochloride in a high boiling solvent like NMP. After transient protection of the phenolic hydroxyl group, the tetrazole can be alkylated which after deprotection of the hydroxyl group provides isomeric tetrazoles 1-48 and 1-49. Alternatively, nitrile 1-46 can be reacted with hydroxylamine to yield an amide oxime, which in turn can be reacted with various anhydrides to provide, following deprotection, the 1,2,4-oxadiazoles 1-50. Scheme L:
Figure imgf000066_0001
1) protection of OH e.g. with Bz2O
[R = optionally substituted alkyl] 2) Alkyiation with R-X
3) Deprotection e.g. NaOH
Figure imgf000066_0002
Scheme M depicts additional routes for the preparation of 3-hydroxy-8,9,9-substituted-4- oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamides. After protection of the core hydroxyl group, substrate 1-3 is alkylated with propargyl bromide to give the alkynee 1-51. Alkyne 1-51 can then undergo a [3+2]-cycloaddition with a nitrile oxide generated in situ from a nitro-compound in the presence of an isocyanate and a base, to yield isoxazole 1-52 after deprotection of the hydroxyl group. Alternatively, the [3+2]-cycloaddition can be performed with trimethylsilyldiazomethane to give, after removal of the silicon group using reagents such as TBAF, the isomeric [l,2,3]-triazoles 1-52 and 1- 53. Scheme M:
Figure imgf000067_0001
Additional methods for preparing 3-hydroxy-8,9,9-substituted-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-α]pyrimidine-2-carboxamides are shown in Scheme N, wherein, after protection of the hydroxyl group, alkylation with an alkyl bromoacetate gives the intermediate 1-54, which can either be: reacted with an amide oxime to yield the corresponding 1,2,4-oxadiazole 1-55; or alternatively hydrolyzed to the corresponding carboxylic acid and coupled to various amines, giving after deprotection of the hydroxyl group, amides such as 1-56. A specific example of the latter would be coupling to propargyl amine which would yield compound 1-57. In this case, a further reaction is possible upon treatment with a mercury (II) salt, such as mercuric acetate, in acetic acid at 1000C which after removal of the protecting group provides the oxazole derivatives 1-58. Alternatively, the ester intermediate 1-54 can be reacted with hydrazine hydrate and then cyclized with various ortho esters to give after deprotection 1,3,4-oxadiazoles such as 1-59. Scheme N:
Figure imgf000068_0001
R = alkyl
R1R" = H, alkyl, aryl, arylalkyl, heteroarylalkyl, or together form a heterocycle R* = H, alkyl, aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, etc. En the methods for preparing compounds of the present invention set forth in the foregoing schemes, functional groups in various moieties and substituents (in addition to those already explicitly noted in the foregoing schemes) may be sensitive or reactive under the reaction conditions employed and/or in the presence of the reagents employed. Such sensitivity/reactivity can interfere with the progress of the desired reaction to reduce the yield of the desired product, or possibly even preclude its formation. Accordingly, it may be necessary or desirable to protect sensitive or reactive groups on any of the molecules concerned. Protection can be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973 and in T. W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd edition, 1999, and 2nd edition, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known in the art. Alternatively the interfering group can be introduced into the molecule subsequent to the reaction step of concern.
The following examples serve only to illustrate the invention and its practice. The examples are not to be construed as limitations on the scope or spirit of the invention.
EXAMPLE l
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2- carboxamide (Entry No. 41 in Table 1)
Step 1: 2-{ l-[(2-Chloroethyl)amino]-l-methylethyl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide.
To a methanolic solution of 2-(l-amino-l-methylethyl)-N-(4-fiuorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide hydrochloride (prepared as described in WO2003035076 Al) Et3Ν (1 eq.), chloroacetaldehyde (2 eq.), AcOH (ca. 1.5 eq.) were added and subsequently NaBΗβCN (1.5 eq.). The reaction mixture was stirred at room temperature overnight. To drive the reaction to completion a few drops of TFA were added and stirring was prolonged for a further 1.5 hours. MeOH was removed under reduced pressure to yield the title amine as crude. MS (ES) C17Η20CIFN4O3 requires 383, found:
384 (MH-H+).
Step 2: N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- α]pyrimidine-2-carboxamide
2- { 1 -[(2-Chloroethyl)amino]- 1-methylethyl} -N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide (1 eq.) was dissolved in 1,4-dioxane and CS2CO3 (1 eq.) was added.
The reaction mixture was stirred at 1000C overnight, then cooled to room temperature and the solvent was removed under reduced pressure. The resulting brown oil was suspended in MeOH, filtered and the filtrate was evaporated to give a residue that was purified on Cation Exchange Resin (Varian Mega Bond Elute SCX). After washing with MeOH, the product was collected eluting with 2N NH3 solution in
MeOH. The fractions containing the desired material were concentrated under reduced pressure to yield, after trituration with Et2θ the title compound as a yellow solid. A small portion of this crude was purified by RP HPLC (C is, 5 μM, H2θ/MeCN with 1% of TFA as eluant) affording the pure product as TFA salt. lH NMR (400 MHz, d6-DMSO) δ 9.41 (bs, 1 H), 7.37 (dd, J= 8.6 Hz, /= 5.7 Hz, 2 H), 7.17
(t, J= 8.6 Hz, 2 H), 4.48 (d, J= 6.4 Hz5 2 H), 3.74 (t, J= 5.5 Hz, 2 H), 3.06 (t, J= 5.5 Hz, 2 H), 1.46 (s, 6 H); MS (ES) C17H19FN4O3 requires: 346, found: 347 (M+H*).
EXAMPLE 2
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-pyrazol-3-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 61 in Table 1)
To a solution of N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (prepared as described in Example 1, Step 1-2) in MeOH and AcOH (5 eq.) was added l-methyl-lH-pyrazole-3-carbaldehyde (2 eq.) and then ΝaBΗ3CΝ (1.5 eq.).
The mixture was left to stir for 48 hours at room temperature during which time further additions of the aldehyde (1.5 eq.) was necessary to drive the reaction to completion. After concentration under reduced pressure the crude residue was purified by RP HPLC (Ci 8, 5 μM, H2θ/MeCN with 1% of TFA as eluant) affording the title product as TFA salt. iH-NMR (300 MHz, d6-DMSO) δ 12.32 (bs, 1 H), 9.51 (t, J= 6.3 Hz, 1 H), 7.74 (d, J = 1.5 Hz, IH), 7.38 (dd, J= 8.6 Hz, J= 5.7 Hz, 2 H), 7.18 (t, J= 8.6 Hz, 2 H), 6.36 (d, J= 1.5 Hz, 1 H), 4.49 (d, J= 6.3 Hz, 2 H), 4.14 (br. S, 2 H), 3.86 (m, 5 H), 3.37 (bs, 2 H), 1.77 (s, 6 H); MS (ES) C22H25FN6O3 requires 440, found: 441 (M+H÷).
EXAMPLE 3
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methylisoxazol-3-yl)methyl]-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 67 in Table 1)
Step 1: 3-(Benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[ 1 ,2-α]pyrimidine-2-carboxamide.
To a stirred solution of N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (see Example 1) in DMF was added K2CO3 (2 eq.) followed by BnCl (1.1 eq.). The mixture was stirred at 65°C overnight, after which time additional BnCl (0.3 eq.) was added and the mixture was left for a further 6 hours. The solvent was removed under reduced pressure and the brown oil was taken into EtOAc5 washed with IN HCl and brine, dried (Na2SO4) and evaporated under reduced pressure. The residue was purified by flash column chromatography, eluting with 2% MeOH/DCM to afford the title product. lH NMR (300 MHz, dβ-
DMSO) δ 8.88 (t, J= 6.2 Hz, 1 H), 7.30-7.44 (m, 7 H), 7.06 (t, J= 8.8 Hz, 2 H), 5.05 (s, 2H), 4.41 (d, J= 6.2 Hz, 2 H), 3.80 (t, J= 5.4 Hz, 2 H), 3.09 (br. s, 2 H), 1.44 (s, 6 H); MS (ES) C24H25FN4O3 requires
436, found: 437 (M+H*).
Step 2: N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methylisoxazol-3-yl)methyl]-4-oxo-
6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide. To a stirred solution of 3-(benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (prepared as described in Example 3, step 1) (1 eq.) in a mixture of 2-butanone/acetone was added K2CO3 (3.5 eq.) followed by 3-(chloromethyl)-5- methylisoxazole (2.5 eq.). The mixture was stirred at 700C for 15 days during which time further chloride (20 eq.) was added. The volatiles were removed under reduced pressure and the residue was taken up in EtOAc and was washed with brine, dried (Νa2Sθ4) and concentrated under reduced pressure. MS (ES) C29Η30FN5O4 requires 531, found: 532 (M+H1"). The resulting crude was directly dissolved in MeOH and was stirred overnight under an H2 atmosphere in the presence of 10% Pd/C. The catalyst was then filtered off through celite, and the filtrate was concentrated under reduced pressure and purified by RP HPLC (C18, 5 μM, H2θ/MeCN with 1% of TFA as eluant) to afford the title product as TFA salt. lH NMR (300 MHz, dβ-DMSO) δ 12.22 (br. S, 1 H), 9.45 (br. S, 1 H), 7.38 (m, 2 H), 7.17 (t, J= 8.7 Hz, 2
H), 6.23 (s, IH), 4.49 (d, J= 6.0 Hz, 2 H), 3.8-3.65 (m, 4 H), 2.90 (br. S, 2 H), 2.39 (s, 3 H), 1.58 (s, 6 H); MS (ES) C22H24FN5O4 requires 441, found: 442 (M+H1).
EXAMPLES 4 AND 5 N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(2H-tetrazol-5-ylmethyl)-6,7,8,9-tetrahydro-4H- pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 74 in Table 1)
Step 1: 3-(Benzyloxy)-8-(cyanomethyl)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2-α]pyrimidine-2-carboxamide. A mixture of 3-(benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-
4H-pyrazino[l,2-β]pyrimidine-2-carboxamide (see Example 3, Step 1), K2CO3 (2 eq.) and bromoacetonitrile (2 eq.) in DMF was heated at 70 0C overnight and was then cooled to room temperature. The solvent was removed under reduced pressure and the residue was taken up in EtOAc, washed with brine, dried (Νa2Sθ4) and concentrated to yield the crude nitrile which was used in the next step without further purification. lH NMR (300 MHz, d6-DMSO) δ 8.9 (t, J= 6.2 Hz, 1 H), 7.26-7.41 (m, 7 H), 7.06 (t, J= 8.8 Hz, 2 H), 5.06 (s, 2H), 4.41 (d, J= 6.2 Hz, 2 H), 3.96 (s, 2H), 3.89 (t, J= 5.2 Hz, 2 H), 3.15 (t, J= 5.2 Hz, 2 H), 1.53 (s, 6 H); MS (ES) C26H26FN5O3 requires 475, found: 476(MH-H+).
Step 2: N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(2H-tetrazol-5-ylmethyl)-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-α]pyrimidine-2-carboxamide.
The crude organic product obtained above (1 eq.), Et3ΝΗCl (1.5 eq.) and NaN3 (3 eq.) were dissolved in NMP and the reaction mixture was heated at reflux under N2 overnight. The mixture was then cooled to room temperature and the resulting mixture was purified by RP ΗPLC (C 18, 5 μM, Η2θ/MeCN with 1 % of TFA as eluant) to isolate the title tetrazole as TFA salt. lHNMR (300 MHz, d6-DMSO) δ 12.18 (br. s,l H), 9.44 (br. s,l H), 7.37 (dd, J= 8.6 Hz, J= 5.5 Hz, 2
H), 7.17 (t, J= 8.6 Hz, 2 H), 4.48 (d, J= 6.4 Hz, 2 H), 4.11 (s, 2H), 3.78 (br. s, 2H), 2.92 (br. s, 2 H), 1.56 (s, 6 H); MS (ES) C19H21FN8O3 requires 428, found: 429(MH-H+).
Also obtained and isolated by RP HPLC was 8-(cyanomethyl)-N-(4-fluorobenzyl)-3- hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[ 1 ,2-α]pyrimidine-2-carboxamide (Entry No. 73 in Table 1). lΗ NMR (300 MHz, d6-DMSO) δ 12.2 (br. s,l H), 9.43 (br. s,l H), 7.37 (dd, J= 8.5 Hz,
J= 5.6 Hz, 2 H), 7.16 (t, J= 8.5 Hz, 2 H), 4.47 (d, J= 6.4 Hz, 2 H), 3.93 (s, 2H), 3.83 (t, J= 5.3 Hz, 2 H), 3.1 l(t, J= 5.3 Hz, 2 H), 1.54 (s, 6 H); MS (ES) C19H20FN5O3 requires 385, found: 386(M-I-H+).
EXAMPLES 6 AND 7
N-(4-Fluoroben2yl)-3-hydroxy-9,9-dimethyl-8-[(2-methyl-2H-tetrazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 87 in Table 1) andN-(4- Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-tetrazol-5-yl)methyl]-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 86 in Table 1)
Step 1: 2-{[(4-Fluorobenzyl)amino]carbonyl}-9,9-dimethyl-4-oxo-8-(lH-tetrazol-5-ylmethyl)-
6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidin-3-yl benzoate. To a solution N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(2H-tetrazol-5- ylmethyl)-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (see Example 4, Steps 1-2) and benzoic anhydride (0.9 eq.) in TΗF were added triethylamine (1.1 eq.) and diethylamino pyridine (3 mol%). The mixture was stirred at room temperature overnight and was then concentrated under reduced pressure. The residue was taken up in ethyl acetate and washed with brine, dried (Νa2Sθ4) and concentrated under reduced pressure to yield the benzoylated material. MS (ES) C26Η25FN8O4 requires 532, found: 533(MH-H+). Step 2: N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-tetrazol-5-yl)methyl]-4- oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-σ]pyriini(iine-2-carboxamide; N-(4- Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(2-methyl-2H-tetrazol-5-yl)methyl]-4-oxo- 6, 7, 8,9-tetrahydro-4H-pyrazino [ 1 ,2-α]pyrimidine-2-carboxamide
A solution of the crude organic product obtained above (1 eq.) in MeCN was treated with
K2CO3 (3 eq.) and MeI (3 eq.) and the reaction was stirred at 45°C overnight. The volatiles removed under reduced pressure and MeCN added followed by IN ΝaOΗ (4 eq.). The mixture was stirred overnight at 3O0C. The solvent was removed under reduced pressure and the residue was purified by RP ΗPLC (Cl 8, 5 μM, Η^O/MeCΝ with 1% of TFA as eluant) affording the title isomeric tetrazoles in approximately 1:1 ratio as TFA salts.
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-tetrazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide shows: lΗΝMR (600 MHz, dβ-DMSO) δ
12.18 (br. s,l H), 9.46 (t, J= 6.4 Hz, 1 H), 7.37 (dd, J= 8.6 Hz, J= 5.7 Hz, 2 H), 7.17 (t, J= 8.6 Hz, 2 H), 4.47 (d, J= 6.4 Hz, 2 H), 4.13 (s, 2H), 4.07 (s, 3H), 3.70 (t, J= 5.3 Hz, 2 H), 2.80 (t, J= 5.3 Hz, 2 H), 1.61 (s, 6 H); MS (ES) C20H23FN8O3 requires 442, found: 443 (MH-H+).
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(2-methyl-2H-tetrazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide shows: lΗ ΝMR (600 MHz, d6-DMSO) δ
12.18 (br. s, 1 H), 9.45 (t, J= 6.4 Hz, 1 H), 7.37 (dd, J= 8.5 Hz, J= 5.8 Hz, 2 H), 7.17 (t, J= 8.5 Hz, 2 H), 4.48 (d, J= 6.4 Hz, 2 H), 4.35 (s, 3H), 4.07 (s, 2H), 3.70 (t, J= 5.4 Hz, 2 H), 3.03 (t, J= 5.4 Hz, 2 H), 1.59 (s, 6 H); MS (ES) C20H23FΝ8O3 requires 442, found: 443 (MH-H+).
EXAMPLE 8
N-[4-fiuoro-2-(methylsulfonyl)benzyl]-3-hydroxy-7,8,8-trimethyl-4-oxo-4,6,7,8-tetrahydroimidazo[l,5- α]pyrimidine-2-carboxamide (Entry No. 2 in Table 1)
2-(l-amino-l-methylethyl)-N-[4-fluoro-2-(methylsulfonyl)benzyl]-5,6- dihydroxypyrimidine-4-carboxamide (prepared as described in WO2003035076 Al) was taken in trimethyl orthoformate and treated with 1.1 eq. of formaldehyde. The mixture was aged at room temperature for 1 hour, and then an additional equivalent of formaldehyde was added, followed by 1.5 eq. of sodium cyanoborohydride and a few drops of acetic acid. Stirring was continued for one hour more, and the mixture was purified by RP HPLC (Ci 8, 5 μM, H2θ/MeCΝ with 1% of TFA as eluant) to afford the title compound as a white solid. 1 H-NMR (400 MHz5 DMSO-dβ) δ 12.2 (bs, 1 H). 9.32 (t, J= 6.4 Hz, 1 H), 7.72 (d, J= 7.54 Hz, 1 H),
7.62-7.58 (m, 2 H), 4.87 (d, J= 6.5 Hz, 2 H), 4.68 (s, 3 H), 3.43 (s, 3 H), 2.38 (s, 3 H), 1.31 (s, 3 H). MS (ES) C18H21FN4O5S requires 424, found: 425 (M+H÷).
EXAMPLE 9
N-(4-fluorobenzyl)-3 -hydroxy- 10, 10-dimethyl-4-oxo-4,6,7,8,9, 10-hexahydro pyrimido[ 1 ,2- α][l,4]diazepine-2-carboxamide (Entry No. 175 in Table 1)
Step 1: N-(4-fluorobenzyl)-5,6-dihydroxy-2-{ l-[(3-hydroxypropyl)amino]-l- methylethyl}pyrimidine-4-carboxamide
A methanolic solution of 2-(l-amino-l-methylethyl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide (prepared as described in WO2003035076 Al) was treated with 3- (benzyloxy)propanal (1.5 eq.) and sodium cyanoborohydride (1.5 eq.). The mixture was stirred at room temperature overnight, solution was applied on a cation exchange resin. The resin was washed with methanol and desired product was eluted with 2 Ν ammonia solution in methanol. Evaporation of appropriate fractions followed by trituration with Et2θ gave intermediate 2-(l-{[3-
(benzyloxy)propyl]amino}-l-methylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide. MS (ES) C25H29FΝ4O4 requires 468, found: 469 (M+H1"). The crude organic product was taken in methanol, treated with 1 eq. of 6N HCl and stirred under hydrogen atmosphere in the presence of catalytic amount of 10% palladium on charcoal. After overnight stirring, mixture was filtered through celite, filtrate was concentrated under reduced pressure and purified by cation exchange resin. The resin was washed with methanol and desired product was eluted with 2 N ammonia solution in methanol.
Evaporation of appropriate fractions followed by trituration with Et2θ gave title compound as a pink solid. MS (ES) C18H23FN4O4 requires 378, found: 379 (M+H*).
Step 2: N-(4-fluorobenzyl)-3 -hydroxy- 10, 10-dimethyl-4-oxo-4,6,7,8,9, 10- hexahydropyrimido [ 1 ,2-α] [ 1 ,4] diazepine-2-carboxamide Crude N-(4-fluorobenzyl)-5,6-dihydroxy-2-{l-[(3-hydroxypropyl)amino]-l- methylethyl}pyrimidine-4-carboxamide prepared as described in Step 1 was dissolved in THF, and treated with triphenylphosphine (1.5 eq.) and DEAD (1.5 eq.). The mixture was stirred under nitrogen, after 14 hours additional reagents (2 eq.) were necessary to complete reaction. Solvent was evaporated under vacuo and the residue loaded on cation exchange resin. The resin was washed with methanol and desired product was eluted with 2 Ν ammonia solution in methanol. Evaporation of appropriate fractions and further purification of the residue by RP HPLC (Ci 8, 5 μM, H2θ/MeCN with 1% of TFA as eluant) gave, after lyophilization, title compound as a white solid. lH NMR (300 MHz, 330 K, d6-DMSO) δ 12.38 (IH, bs), 9.2 (IH, bs), 9.05 (IH, t, J = 5.8 Hz), 7.38 (2H, dd, J = 8.2 Hz , J = 5.6 Hz), 7.16 (2H, t, J = 8.8 Hz), 4.52 (2H, d, J = 6.6 Hz), 4.52-4.42 (2H, m), 3.40- 3.33 (2H, m), 2.05-1.95 (2H, m), 1.80 (6H, s); MS (ES) C18H21FN4O3 requires 360, found: 361
(M+H*).
EXAMPLE 10
N-(4-fluorobenzyl)-3-hydroxy-9,10,10-trimethyl-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2- α][l,4]diazepine-2-carboxamide (Entry 176 in Table 1)
A methanolic solution of 2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-10,10- dimethyl-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2-«][l,4]diazepin-9-ium trifluoroacetate (prepared as described in Example 9, Step 1-2) was treated with formaldehyde (1.5 eq.) and sodium cyanoborohydride (1.2 eq.). The mixture was stirred at room temperature 3 hours and then directly purified by RP HPLC (C 18, 5 μM, H2θ/MeCΝ with 1 % of TFA as eluant) to give the title product as TFA salt, after lyophilization of the appropriate fractions. lH NMR (300 MHz, 330K, d6-DMSO+TFA) δ 8.95 (IH, t, J = 5.8 Hz), 7.38 (2H, dd, J = 8.2 Hz , J = 5.6
Hz), 7.16 (2H, t, J = 8.8 Hz), 5.32-5.18 (2H, m), 4.52 (2H, d, J = 6.6 Hz), 3.97-3.80 (2H, m), 2.21-2.05 (2H, m), 2.8 (3H, s),1.9 (3H, s),1.85 (3H, s); MS (ES) C19H23FN4O3 requires 374, found: 375 (M+H*).
EXAMPLE I l
N-(2-{[(4-fluoro-3-methylbenzyl)ammo]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-c?][l,4]diazepin-10-yl)-NϊΛ'',N-trimethylethanediamide and the corresponding (+) and (-) enantiomers (Entry Νos. 156 and 157 in Table 1)
Step 1: tert-Butyl 5-thioxo-l,4-diazepane-l-carboxylate tert-Butyl 5-oxo-l,4-diazepane-l-carboxylate, P4S10 (0.2 eq.), HMDO (2 eq.) and dichloromethane were combined and stirred magnetically at room temperature for 1 hour. The reaction mixture was then cooled to 00C and aqueous K2CO3 solution (1.26 mL of 5.3 M/mmol P4S10 taken) was added. A volume of acetone equal to one half of the reaction solvent was added to obtain a stirrable mixture, and the reaction mixture was stirred vigorously for 30 minutes at O0C. Volatiles were evaporated, water and ethyl acetate were added, layers were separated and the organic phase was washed with water and brine. The organic extract was dried over Νa2Sθ4 and evaporated, to afford the title compound. lH NMR (300 MHz, CDCI3) δ 8.7 (bs, 1 H), 3.68-3.60 (m, 4 H), 3.42-3.38 (m, 2 H), 3.15- 3.09 (m, 2 H), 1.43 (s, 9 H); MS (ES) Ci0Hi8N2O2S requires 230, found: 231 (M+H1).
Step 2: tert-Butyl 5-(hydroxyimino)-l,4-diazepane-l-carboxylate A solution of hydroxylamine hydrochloride (2 eq.) in methanol was added to an equimolar methanolic solution of potassium hydroxide. Potassium chloride was filtered off and the filtrate was added to a solution of the above ter/-butyl 5-thioxo-l,4-diazepane-l-carboxylate (1 eq.) in methanol. The mixture was stirred at 550C overnight, then cooled to room temperature and the solvent was removed under reduced pressure. The residue was taken in chloroform, washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give, after trituration with ethyl ether, the title amidoxime. lH NMR (300 MHz, CDCI3) δ 6.4-6.1 (bs, 1 H), 5.8 (broad triplet, 1 H), 3.6-3.5 (m, 4 H), 3.35-3.22 (m, 2 H), 2.5-2.4 (m, 2 H), 1.45 (s, 9 H); MS (ES) C10H19N3O3 requires 229, found: 230 (M+H*).
Step 3: 8-rert-buryl-2-methyl-3-hydroxy-4-oxo-6,7,9,10-tetrahydropyrimido[l,2- d] [ 1 ,4] diazepine-2, 8(4H)-dicarboxylate.
To a suspension of tei't-butyl 5-thioxo-l,4-diazepane-l-carboxylate prepared in the previous step (1 eq.) in acetonitrile, dimethylacetylene dicarboxylate (1 eq.) was added in one portion and the mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure and the oily residue was taken in xylene and stirred overnight at 1450C. After cooling to room temperature, the solvent was evaporated under reduced pressure and residue was taken in ethyl acetate and treated with saturated solution of NaΗC03. The aqueous phase was separated, washed with additional ethyl acetate, then carefully acidified with 2N HCl. The product was extracted in chloroform, and the organic solution was dried over Na2SO4 and concentrated under reduced pressure to afford title compound as a brown solid. lH NMR (300 MHz, d6-DMSQ) δ 10.43 (s, 1 H), 4.58-4.50 (m, 2 H),4.03 (s, 3 H), 3.88-3.78 (m, 4 H)3.26-3.18 (m,2 H) 1.50 (s, 9 H); MS (ES) C15H21N3O6 requires 339, found: 340 (M+H*).
Step 4: S-tert-butyl 2-methyl 10-[benzyl(methyl)amino]-3 -hydroxy-4-oxo-6,7,9, 10- tetrahydropyrimidof 1 ,2-d] [ 1 ,4]diazepine-2,8(4H)-dicarboxylate
To a solution of 8-fer/-butyl 2-methyl 3-hydroxy-4-oxo-6,7,9,10-tetrahydro pyrimido [l,2-eT][l,4]diazepme-2,8(4H)-dicarboxylate in dry dioxane, DDQ (2.2 eq.) was added and the mixture was aged for 2 days at 1050C. After cooling to room temperature, N-benzylmethylamine (7 eq.) was added and the mixture was aged at 650C for 6 hours. The reaction mixture was concentrated under vacuum and the resulting residue was dissolved in the minimum amount of MeOH and carefully acidified with glacial acetic acid. The solution was charged on a cartridge of cation exchange resin eluting first with MeOH and then with IM ammonia in methanol. The eluate was concentrated under reduced pressure to get an oily residue that was taken in ethyl acetate and washed three times with saturated solution OfNaHCO3. Organic layers were concentrated to afford crude product as brown oil, which was used without further purification. MS (ES) C23H30N4O6 requires 458, found: 459 (M+H1").
Step 5: tot-butyl 2- { [(4-fluoro-3-methylbenzyl)amino]carbonyl} -3-hydroxy- 10-(methylamino)-
4-oxo-6,7,9, 10-tetrahydropyrimido[ 1 ,2-d\ [ 1 ,4]diazepine-8(4H)-carboxylate. S-tert-butyl 2-methyl 10-[benzyl(methyl)amino]-3-hydroxy-4-oxo-6,7,9,10- tetrahydropyrimido[l,2-fi?][l,4]diazepine-2,8(4H)-dicarboxylate prepared as described in Step 4, was dissolved in MeOH, treated with 1 N HCl (1 eq.) and stirred overnight under an Η2 atmosphere in the presence of 10% Pd/C. The catalyst was filtered off through celite, and the filtrate was concentrated under reduced pressure. MS (ES) C16H24N4O6 requires 368, found: 369 (M+H1"). The crude organic product was taken in methanol and treated with 1.2 eq. of 4-fluoro-3-methyl-benzylamine and resulting mixture was refluxed overnight. After cooling to room temperature, evaporation of volatiles under reduced pressure yielded title product which was directly taken in the next step. MS (ES) C23H30FN5O5 requires 475, found: 476 (M+ff ).
Step 6: tert-bυtyl 10-[[(dimethylamino)(oxo)acetyl](methyl)amino]-2-{[(4-fluoro-3- methylbenzyl)amino]carbonyl} -3-hydroxy-4-oxo-6,7,9, 10-tetrahydropyrimido[ 1 ,2- fi[][l,4]diazepine-8(4H)-carboxylate.
To a suspension tert-butyl 2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-10- (methylamino)-4-oxo-6,7,9, 10-tetrahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepine-8(4H)-carboxylate, triethylamine (2.5 eq.) and methyl chloro(oxo)acetate (2 eq.) were added and resulting mixture was stirred one hour at room temperature. Volatiles were evaporated under reduced pressure and residue was taken in methanol and treated with an excess of dimethylamine (2 M solution in methanol). The reaction mixture was stirred overnight at room temperature, yielding after evaporation of volatiles, title product which was further reacted in the next step. MS (ES) C27Η35FN6O7 requires 574, found: 575 (M+H1").
Step 7: N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-N^V^V-trimethylethanediamide. The compound of Step 6 was stirred in dichloromethane/trifluoroacetic acid (8/2 v/v) for 1 hour, then concentrated under reduced pressure and purified by RP HPLC (Ci 8, 5 μM, H2θ/MeCΝ with 1% of TFA as eluant) affording desired compound as trifluoroacetic salt. lHNMR (300 MHz, CD3CN) δ 12.68 (bs, 1 H), 9.96 (bs, 1 H), 7.50 (d, J= 7.51 Hz, 1 H), 7.45-7.41 (m, 1 H), 7.21 (t, /= 8.62
Hz, 1 H), 5.55-5.46 (m, 2 H), 4.75 (dd, J= 14.6 Hz, J= 6.8 Hz, 1 H), 4.67 (dd, J= 14.6 Hz, J= 6.3 Hz, 1 H), 4.24-4.05 (m, 3 H), 3.96-3.92 (m, 1 H)5 3.39-3.36 (m, 1 H)5 3.24 (s, 3 H), 3.19 (s, 3 H)5 3.18 (s, 3 H), 2.46 (s, 3 H); MS (ES) C22H27FN6O5 requires 474, found: 475 (M+tf).
N-(2-{ [(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,75859510- hexahydropyrimido[l52-<^[l,4]diazepm-10-yl)-N5N'5N'-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral SFC using the following conditions: Solvents: CO2, modifier:
MeOH 30%, TFA 0.2 %. Column: Chiracel OD-H 250x10 mm at 9.99 mL/mm, P=100bar, T=35°C. The first eluate is the (+) enantiomer (EtOH5 c=0.5, 25 0C) [α]D= (+) 5.3 The second eluate is the (-) enantiomer (EtOH5 c=0.5, 25 0C) [α]D= (-) 5.0
EXAMPLE 12 N-(8-cyclopropyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9510- hexahydropyrimido[l,2-cT][l,4]diazepin-10-yl)-N,N'5N'-trimethylethanediamide and the corresponding (+) and (-) enantiomers (Entry Νos. 127 and 128 in Table 1)
N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,75859510- hexahydropyrimido[l,2-rf][l,4]diazepin-10-yl)-N5N^V-trimethylethanediamide (prepared as described in. Example 11, Step 1-7) was dissolved in methanol and treated with triethylamine (2 eq.), [(1- ethoxycyclopropyl)oxy](trimethyl)silane and acetic acid pH=5.5. To the mixture was then added
ΝaCΝBH3 (4 eq.) and reaction was refluxed overnight. After cooling to room temperature, mixture was concentrated under reduced pressure and purified by prep RP HPLC (Ci 8, 5 μM, H2θ/MeCN with 1% of TFA as eluant) affording desired compound as a white solid. lH NMR (300 MHz, CD3CN) δ 12.67 (bs, 1 H)5 10.01 (bs, 1 H)5 7.49 (d, J= 7.52 Hz, 1 H), 7.45-7.40 (m, 1 H), 7.21 (t, J= 8.62 Hz, 1 H), 5.51- 5.41 (m, 2 H), 4.76 (dd, J= 14.6 Hz5 J= 6.86 Hz, 1 H), 4.66 (dd, J= 14.6 Hz5 J= 6.41 Hz, 1 H), 4.27- 4.00 (m, 4 H)5 3.51-3.36 (m, 2 H), 3.27 (s, 3 H), 3.19 (s, 3 H), 3.17 (s, 3 H)5 2.46 (s5 3 H), 1.37-1.31 (m5 2 H)5 1.19-1.10 (m5 2 H); MS (ES) C25H31FN6O5 requires 514, found: 515 (M+H+).
N-(8-cyclopropyl-2- { [(4-fluoro-3 -methylbenzyl)amino] carbonyl} -3 -hydroxy-4-oxo- 4565758,9,10-hexahydropyrimido[l,2-^[l,4]diazepin-10-yl)-N5N5N-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral SFC using the following conditions: Solvents: CO2, modifier: MeOH 30%, TFA 0.2 %. Column: Chiracel OD-H 250x10 mm at 9.99 mL/min,
P=100bar, T=35°C.
The first eluate is the (+) enantiomer (EtOH, c=0.7, 25 0C) [α]D= (+) 32.9
The second eluate is the (-) enantiomer (EtOH, c=0.7, 25 0C) [α]D= (-) 32.5 EXAMPLE 13
N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexaliydropyrimido[l,2-ιi][l,4]diazepin-10-yl)-N^^-trimethylethanediainide and the corresponding (+) and (-) enantiomers (Entry Νos. 144 and 145 in Table 1)
Step 1: tert-butyl 2- { [(3 -chloro-4-methylbenzyl)amino] carbonyl} -3 -hydroxy- 10-(methylamino)-
4-oxo-6,7,9, 10-tetrahydropyrimido [ 1 ,2-d\ [ 1 ,4] diazepine-8(4H)-carboxylate. 2,-tert-butyl 2-methyl 10-[benzyl(methyl)amino]-3-hydroxy-4-oxo-6,7,9, 1 O- tetrahydropyrimido[l,2-d][l,4]diazepine-2,8(4H)-dicarboxylate (see Example 11, Steps 1-4) was dissolved in MeOH, treated with 1 Ν HCl (1 eq.) and stirred overnight under an Η2 atmosphere in the presence of 10% Pd/C. The catalyst was then filtered off through celite, and the filtrate was concentrated under reduced pressure. MS (ES) C16H24Ν4O6 requires 368, found: 369 (M+ff1"). The crude organic product was taken in methanol and treated with 1.2 eq. of 3-chloro-4-methyl-benzylamine and resulting mixture was refluxed overnight. After cooling to room temperature, evaporation of volatiles under reduced pressure yielded title product which was directly taken in the next step. MS (ES) C23H30CIΝ5O5 requires 491, found: 492 (MH-H+).
Step 2: tert-butyl 2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-10- [[(dimethylamino)(oxo)acetyl](methyl)amino]-3-hydroxy-4-oxo-6,7,9, 10- tetrahydropyrimido[ 1 ,2-d\ [1 ,4]diazepine-8(4H)-carboxylate. To a suspension of the above prepared tert-butyl 2-{[(3-chloro-4- methylbenzyl)amino]carbonyl}-3-hydroxy-10-(methylamino)-4-oxo-6,7,9,10-tetrahydro pyrimido[l,2- <f|[l,4]diazepine-8(4H)-carboxylate was added triethylamine (2.5 eq.) and methyl chloro(oxo)acetate (2 eq.) and resulting mixture was stirred one hour at room temperature. Volatiles were evaporated under reduced pressure and residue was taken in methanol and treated with an excess of dimethylamine (2 M solution in methanol). The reaction mixture was stirred overnight at room temperature, yielding after evaporation of volatiles, crude product which was further reacted in the next step. MS (ES) C27Η35CIN6O7 requires 590, found: 591 (M+lf).
Step 3: N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-8-cyclopropyl-3-hydroxy-4-oxo-
4,6,7, 8,9, 10-hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-NJV JV- trimethylethanediamide. The compound of Step 2 was stirred in dichloromethane/trifluoroacetic acid (8/2 v/v) for 1 hour, then concentrated under reduced pressure and triturated with diethyl ether. A portion of this material was purified by prep RP HPLC (Cl 8, 5 μM, IfeO/MeCN with 1% of TFA as eluant) affording title compound as a white solid. lH NMR (400 MHz, CD3CN) δ 12.40 (bs, 1 H), 9.78 (bs, 1 H), 7.43 (s, 1 H), 7.28-7.21 (m, 2 H), 5.37-5.29 (m, 2 H), 4.58 (dd, J= 14.6 Hz, J= 6.86 Hz, 1 H), 4.47 (dd, J= 14.6 Hz5 J= 6.41 Hz, 1 H), 4.01-3.3.92 (m, 3 H), 3.78-3.69 (m, 1 H), 3.22-3.12 (m, 1 H), 3.08 (s, 3 H), 2.93 (s, 3 H), 2.91 (s, 3 H), 2.28 (s, 3 H); MS (ES) C22H27CIN6O5 requires 490, found: 491 (M+Kf).
N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-β(][l,4]diazepin-10-yl)-Nr/V^V-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral SFC using the following conditions: Solvents: CO2, modifier: MeOH 30%, TFA 0.2 %
Column: Chiracel OD-H 250x10 mm at 10 mL/min, P=100bar, T=35°C
The first eluate is the (+) enantiomer (EtOH, c=0.2, 25 0C) [α]D= (+) 5.2
The second eluate is the (-) enantiomer (EtOH, c=0.2, 25 0C) [α]D= (-) 5.3
EXAMPLE 14
N-(2- { [(3 -chloro-4-methylbenzyI)amino] carbonyl} -8-cyclopropyl-3 -hydroxy-4-oxo-4,6,7, 8,9,10- hexahydropyrimido[l,2-tf][l,4]diazepin-10-yl)-NJVJV-trimethylethanediamide and the corresponding (+) and (-) enantiomers (Entry Νos. 115 and 116 in Table 1) Crude organic product prepared as described in Example 13, Steps 1-3 was dissolved in methanol and treated with triethylamine (2 eq.), acetic acid until pH=5.5 and [(1- ethoxycyclopropyl)oxy]-(trimethyl)silane. To the mixture was then added ΝaCΝBH3 (4 eq.) and reaction was refluxed overnight. After cooling to room temperature, mixture was concentrated under reduced pressure and purified by prep RP HPLC (C ig, 5 μM, H2θ/MeCN with 1% of TFA as eluant) affording desired compound as a white solid. *H NMR (300 MHz, CD3CN) δ 12.54 (bs, 1 H), 9.98 (bs, 1 H), 7.63 (s, 1 H), 7.49-7.42 (m, 2 H), 5.49-5.40 (m, 2 H), 4.76 (dd, J= 14.6 Hz, J= 6.86 Hz, 1 H), 4.67 (dd, J= 14.6 Hz, J= 6.41 Hz, 1 H), 4.12-3.92 (m, 4 H), 3.26 (s, 3 H), 3.19 (s, 3 H), 3.16 (s, 3 H), 2.70-2.52 (m, 2 H), 1.92 (s, 3 H) 1.25-1.01 (m, 4 H); MS (ES) C25H31CIN6O5 requires 530, found: 531 (M+lfj.
N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-8-cyclopropyl-3-hydroxy-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-tf][l,4]diazepm-10-yl)-N^V,Nl-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral HPLC using the following conditions: Solvents: a mixture 35:65 0.2%TFA in Hexanes:EtOH. Column: Chiralpack AD column, 250x46 mm at 10.0 mL/min, detected by absorption at 300 run. The first eluate is the (+) enantiomer (EtOH, c=0.7, 25 0C) [α]D= (+) 22.1 The second eluate is the (-) enantiomer (EtOH, c=0.7, 25 °C) [α]D= (-) 21.8
EXAMPLE 15
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-<fl[l,4]diazepin-10-yl)-N^V1 :N'-trimethylethanediamide and the corresponding (+) and (-) enantiomers. (Entry Νos. 154 and 155 in Table 1)
Step 1: Methyl 10-[benzyl(methyl)amino]-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d\ [ 1 ,4]diazepine-2-carboxylate. 8-ført-butyl 2-methyl 10-[benzyl(methyl)amino]-3-hydroxy-4-oxo-6,7,9,10- tetrahydropyrimido[l,2-ύ(][l,4]diazepine-2,8(4H)-dicarboxylate (prepared as described in Example 11, Step 1-4) was taken in CΗ2CI2/TFA (8/2 v/v) and stirred at room temperature for 1 hour. Volatiles were evaporated and residue was triturated with diethyl ether. MS (ES) C18H22Ν4O4 requires 358, found: 359 (M+tT1"). The crude organic product was dissolved in MeOH and treated with formaldehyde (3 eq.) and triethylamine (3 eq.). Acetic acid was added until pH = 5.5, followed by NaCNBH3 (2 eq.), and resulting mixture was stirred overnight at room temperature. The reaction mixture was concentrated to a residue which was purified on Cation Exchange Resin (Varian Mega Bond Elute SCX). After washing with MeOH, the product was collected eluting with 2N NH3 solution in MeOH. The fractions containing the desired material were concentrated under reduced pressure to yield the title compound as a yellow oil. MS (ES) C 19H24N4O4 requires 372, found: 373 (M+H1").
Step 2: Methyl 10-[[(dimethylamino)(oxo)acetyl](methyl)ammo]-3-hydroxy-8-methyl-4-oxo-
4,6,7, 8,9, 10-hexahydropyrimido [ 1 ,2-d\ [1,4] diazepine-2-carboxylate. Compound of Step 1 was dissolved in MeOH and 6 N HCl (2.5 eq.) and stirred overnight under an H2 atmosphere in the presence of 10% Pd/C. The catalyst was then filtered off through celite, and the filtrate was concentrated under reduced pressure and triturated with diethyl ether to yield methyl
3-hydroxy-8-methyl- 10-(methylamino)-4-oxo-4,6,7,8,9, 10-hexahydropyrimido[l ,2-d][l,4]diazepine-2- carboxylate as a yellow solid. MS (ES) C12H18N4O4 requires 282, found: 283 (M+H4"). The crude product was taken in dichloromethane and treated with triethylamine (2.5 eq.) and methyl chloro(oxo)acetate (1.2 eq.). After stirring one hour at room temperature, solvent was removed under reduced pressure and residue was taken in methanol and treated with an excess of dimethyl amine (2 M solution in methanol) at room temperature overnight. Volatiles were evaporated under reduced pressure to the title compound. MS (ES) C16H23N5O6 requires 381, found: 382 (M+H4). Step 3: N-(2- { [(4-fluoroben2yl)amino]carbonyl} -3-hydroxy-8-methyl-4-oxo-4,6,7,8,9, 10- hexahydropyrimido [ 1 ,2-d\ [ 1 ,4] diazepin- 10-yl)-NJV,N-trimethylethanediamide. Methyl 10-[[(dimethylamino)(oxo)acetyl](methyl)amino]-3-hydroxy-8-methyl-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-£fj[l,4]diazepine-2-carboxylate prepared as described in Step 2 was dissolved in methanol and treated with 1.2 eq. of triethylamine and 1.2 eq. of 4-fluorobenzylamine. The reaction mixture was refluxed overnight, then cooled to room temperature and purified by RP HPLC (CiS, 5 μM, H2θ/MeCΝ with 1% of TFA as eluant) affording desired compound (trifluoroacetic salt) as a white solid. ^H NMR (300 MHz, CD3CN) δ 12.4 (bs, 1 H), 10.01 (bs, 1 H), 7.63 (dd, J= 8.6 Hz, J= 5.7 Hz, 2 H), 7.29 (t, J= 8.6 Hz, 2 H), 5.53-5.30 (m, 2 H), 4.82-4.68 (m, 2 H), 4.25-4.13 (m, 3 H)5 3.95 (bs, 1 H), 3.48-3.42 (m, 1 H), 3.25 (s, 3 H), 3.20 (s, 3 H), 3.19 (s, 3 H), 3.13 (s, 3 H); MS (ES) C22H27FN6O5 requires 474, found: 475 (M+H1').
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-(/][l,4]diazepin-10-yl)-N,N',N-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral SFC using the following conditions: Solvents: CO2, modifier: 1:1 MeOH:EtOH 30%, TFA 0.2 %. Column: Chiracel OD-H 250x10 mm at 9.99 mL/min, P=100bar, T=35°C.
The first eluate is the (+) enantiomer (EtOH, c=0.7, 25 0C) [α]D= (+) 18.0 The second eluate is the (-) enantiomer (EtOH, c=0.7, 25 0C) [α]D= (-) 18.0
EXAMPLE 16
N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-(i][l,4]diazepin-10-yl)-N,N^-trimethylethanediamide and the corresponding (+) and (-) enantiomers (Entry Νos. 146 and 147 in Table 1)
The title product was prepared in the manner described in Step 3 of Example 15, wherein 3-methyl-4-fluorobenzylamine was used in place of 4-fluorobenzylamine. IR ΝMR (300 MHz, CD3CΝ) δ 12.76 (bs, 1 H), 9.75 (bs, 1 H), 7.27 (d, J= 7.52 Hz, 1 H), 7.23-7.18 (m, 1 H), 6.98 (t, J=8.6 Hz, 1 H), 5.4-5.25 (m, 2 H), 4.57-4.41 (m,2 H), 4.10-3.97 (m, 3 H), 3.76-3.72 (m, 1 H), 3.19-3.11 (m, IH), 3.03 (s, 3 H), 2.97 (s, 3 H), 2.96 (s, 3 H), 2.87 (s, 3 H), 2.23 (s, 3 H); MS (ES) C23H29FN6O5 requires 488, found: 489 (M+H4). N-Q,- { [(4-fluoro-3 -methylbenzyl)amino] carbonyl} -3 -hydroxy-8-methyl-4-oxo-
4,6,7,8,9,10-hexahydropyrimido[l,2-^][l,4]diazepin-10-yl)-N,N:rΛ?'-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral HPLC using the following conditions: Solvents: a mixture 35:65 0.2%TFA in Hexanes:EtOH. Column: Chiralpack AD column, 250x46 mm at 10.0 mL/min, detected by absorption at 300 nm. The first eluate is the (+) enantiomer (EtOH, c=0.5, 25 °C) [α]D= (+) 16.0 The second eluate is the (-) enantiomer (EtOH, c=0.5, 25 0C) [α]D= (-) 16.0
EXAMPLE 17 N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-rf][l,4]diazepin-10-yl)-N,N',N-trimethylethanediamide and the corresponding (+) and (-) enantiomers (Entry Νos. 130 and 131 in Table 1)
The title product was prepared in the manner described in Step 3 of Example 15, wherein 3-chloro-4-methylbenzylamine was used in place of 4-fluorobenzylamine. lH ΝMR (300 MHz, CD3CΝ) δ 12.38 (bs, 1 H), 9.78 (bs, 1 H), 7.40 (s, 1 H), 7.26-7.20 (m, 2 H), 5.40-5.25 (m, 2 H), 4.55 (dd, J= 14.8 Hz, J= 6.7 Hz, 1 H), 4.46 (dd, J= 14.8 Hz, J= 6.2 Hz, 1 H), 4.10-3.97 (m, 3 H), 3.20-3.11 (m, 1 H), 3.03 (s, 3 H), 2.97 (s, 3 H), 2.96 (s, 3 H), 2.87 (s, 3 H), 2.33 (s, 3 H); MS (ES) C23H29CIN6O5 requires 504, found: 505 (M+H4).
N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-£f|[l,4]diazepin-10-yl)-NJVrN'-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral SFC using the following conditions: Solvents: CO2, modifier: 1:1 MeOH:EtOH 30%, TFA 0.2 %. Column: Chiracel OD-H 250x10 mm at 9.99 mL/min, P=100bar, T=35°C.
The first eluate is the (+) enantiomer (EtOH, c=0.3, 25 0C) [α]D= (+) 6.8 The second eluate is the (-) enantiomer (EtOH, c=0.3, 25 0C) [α]D= (-) 7.0
EXAMPLE 18
N-(8-ethyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-c/][l,4]diazepin-10-yl)-N,N,N-trimethylethanediamide and the corresponding (+) and (-) enantiomers (Entry Νos. 132 and 133 in Table 1)
Step 1: Methyl 10-[benzyl(methyl)amino]-8-ethyl-3-hydroxy-4-oxo-4,6,7,8,9, 10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4] diazepine-2-carboxylate. 8-terr-butyl 2-methyl 10-[benzyl(methyl)amino]-3-hydroxy-4-oxo-6,7,9, 10- tetrahydropyrimido[ 1 ,2-d} [ 1 ,4]diazepine-2,8(4H)-dicarboxylate (prepared as described in Example 11 , Step 1-4) was taken in CΗ2CI2/TFA (8/2 v/v) and stirred at room temperature for 1 hour. Volatiles were evaporated and residue was triturated with diethyl ether. MS (ES) C18H22Ν4O4 requires 358, found:
359 (M+H1"). The crude organic product was dissolved in MeOH and treated with acetaldehyde (3 eq.) and triethylamine (3 eq.). Acetic acid was added until pH = 5.5, followed by ΝaCΝBH3 (2 eq.), and resulting mixture was stirred overnight at room temperature. The reaction mixture was concentrated to a residue which was purified on Cation Exchange Resin (Varian Mega Bond Elute SCX). After washing with MeOH, the product was collected eluting with 2N NH3 solution in MeOH. The fractions containing the desired material were concentrated under reduced pressure to yield the title compound as brown oil. MS (ES) C20H26N4O4 requires 386, found: 387 (M+H1").
Step 2: Methyl 10-[[(dimethylamino)(oxo)acetyl](methyl)amino]-8-ethyl-3-hydroxy-4-oxo-
4,6,7,8,9, 10-hexahydropyrimido[l,2-(^[l,4]diazepme-2-carboxylate. The compound of Step 1 was dissolved in MeOH and 6 N HCl (2.5 eq.) and stirred overnight under an H2 atmosphere in the presence of 10% Pd/C. The catalyst was then filtered off through celite, and the filtrate was concentrated under reduced pressure and triturated with diethyl ether to yield methyl 8-ethyl-3-hydroxy-10-(methylamino)-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2- <f][l,4]diazepine-2-carboxylate. MS (ES) C13H20N4O4 requires 296, found: 297 (MH-H+). The latter compound was taken in dichloromethane and treated with triethylamine (2.5 eq.) and methyl chloro(oxo)acetate (1.2 eq.). After stirring one hour at room temperature, solvent was removed under reduced pressure and residue was taken in methanol and treated with an excess of dimethyl amine (2 M solution in methanol) at room temperature overnight. Volatiles were evaporated under reduced pressure yielding title compound which was used without purification in the next step. MS (ES) C17H25N5O6 requires 395, found: 396 (M+H1").
Step 3: N-(8-ethyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-c(][l,4]diazepin-10-yl)-N^V,N-trimethylethanediamide. Crude methyl 10-[[(dimethylamino)(oxo)acetyl](methyl)amino]-8-ethyl-3-hydroxy-4- oxo-4,6,7,8,9,10-hexahydropyrimido[l,2-ύT][l,4]diazepine-2-carboxylate was dissolved in methanol and treated with 1.2 eq. of triethylamine and 1.2 eq. of 4-fluoro-3-methylbenzylamine. The reaction mixture was refluxed overnight, then cooled to room temperature and purified by RP HPLC (C is, 5 μM, H2θ/MeCΝ with 1% of TFA as eluant) affording desired compound as a white solid. lH NMR (300 MHz, CD3CN) δ 12.4 (bs, 1 H), 9.74 (bs, 1 H), 7.26-7.16 (m, 2 H), 6.96 (t, J= 8.62 Hz, 1 H), 5.40-5.22 (m, 2 H), 4.51 (dd, J= 14.6 Hz, J= 6.86 Hz, 1 H), 4.42 (dd, J= 14.6 Hz, J= 6.41 Hz, 1 H), 4.18-3.92 (m, 3 H), 3.78-3.73 (ms, 1 H), 3.28-3.18 (m, 3 H), 3.01 (s, 3 H), 2.95 (s, 3 H), 2.93 (s, 3 H), 2.21 (s, 3 H), 1.30 (t, J= 5.97 Hz, 3 H). MS (ES) C24H31FN6O5 requires 502, found: 503 (M+H").
N-(8-ethyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyI}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-ύTI[l,4]diazepin-10-yl)-N,N';>N'-trimethylethanediamide has been resolved into its enantiomers by semipreparative chiral SFC using the following conditions: Solvents: CO2, modifier: MeOH 30%, diethylamine 0.2 %. Column: Chiracel OD-H 250x10 mm at 9.99 mL/min, P=100bar, T=35°C.
The first eluate is the (+) enantiomer (EtOH, c=0.3, 25 0C) [α]D= (+) 16.0 The second eluate is the (-) enantiomer (EtOH, c=0.3, 25 0C) [α]D= (-) 16.0
EXAMPLE 19
N-(4-fluorobenzyl)-3-hydroxy-8-methyl-9-{[methyl(methylsulfonyl)amino]methyl}-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 21 in Table 1)
Step 1: tert-butyl [(2£)-2-amino-l-[(benzyloxy)methyl]-2-(hydroxyimino)etliyl]carbamate.
Ηydroxylamine hydrochloride in methanol was added to an equimolar stirred solution of potassium hydroxide in methanol. The mixture was stirred for 15 minutes and the precipitated potassium chloride was removed by filtration. The filtrate was added to an equimolar amount of tert-butyl [2- (benzyloxy)-l-cyanoethyl]carbamate and the solution was stirred for 5 hours at 45 0C and for 12 hours at room temperature. The reaction mixture was concentrated and the solvent switched to CΗCI3. The insoluble material was filtered off and the filtrated was evaporated to afford the title product as a white solid. iH-NMR (400MHz, CDCI3) δ 7.27-7.38 (bs, 5 H), 5.48 (d, J= 7.3 Hz, 1 H), 5.26 (bs, 2 H), 4.54 (s, 2 H),
4.38 (bs, 1 H), 3.76 (dd, J= 9.5 Hz, J= 3.8 Hz, 1 H), 3.68 (dd, J= 9.5 Hz, J= 5.3 Hz, IH), 1.43(s, 9 H). MS (ES) Ci 5H23N3O4 requires 309, found: 310 (M+H1).
Step 2: Methyl 5-(benzoyloxy)-2-{2-(benzyloxy)-l-[(re^-butoxycarbonyl)amino]ethyl}-6- hydroxypyrimidine-4-carboxylate. tert-Butyl [(2JE)-2-amino-l-[(benzyloxy)methyl]-2-(hydroxyimino)ethyl]carbamate prepared as described in Step 1 was dissolved in chloroform and treated with 1.2 eq. of dimethylacetylenedicarboxylate and the reaction was refluxed for 2.5 hours. After cooling at room temperature, the reaction mixture was concentrated and the solvent switched to xylene. The mixture was heated at 145 0C for 24 hours. After cooling at room temperature, solid material was filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in dry CH2CI2 then dry pyridine was added and finally benzoic anhydride (1.1 eq.). The mixture was stirred at room temperature overnight, then the solvent was removed by rotary evaporation and the residue taken in ethyl acetate was washed with 1 N HCl, sat. NaHCO3 and brine. Organic layer was separated, dried (Na2SO4), filtered and concentrated. The resulting residue was purified by flash chromatography (Siθ2, eluting with 60/40 v/v petroleum ether/ethyl acetate), collection and evaporation of appropriate fractions afforded title product.
1 H-NMR (400 MHz, CDCI3) δ 11.05 (bs, 1 H), 8.21 (d, J= 7.9 Hz, 2 H), 7.67 (t, J= 7.2 Hz, 1 H), 7.52 (t,
J= 7.7 Hz, 2 H), 7.23-7.38 (m, 5 H), 5.64 (d, J= 6.6 Hz, 2 H), 4.84 (bs, 1 H), 4.56 (s, 2 H), 3.99 (m, 1 H), 3.84 (s, 3 H), 3.77 (dd, J= 9.7 Hz, J= 5.3Hz, 1 H), 1.46 (s, 9 H); MS (ES) C27H29N3O8 requires 523, found: 524(MfH+).
Step 3: 2-[ 1 -amino-2-(benzyloxy)ethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4- carboxamide. To a methanolic solution of methyl 5-(benzoyloxy)-2-{2-(benzyloxy)-l-[(/ert butoxycarbonyl)amino]ethyl}-6-hydroxypyrimidine-4-carboxylate prepared as described in Step 2, 4- fluorobenzylamine (2.15 eq.) was added. The resulting solution was refluxed for 24 hours (100% conversion by LC-MS). After cooling to room temperature, the crude was concentrated under reduced pressure and the solvent switched to CH2CI2. To the solution, trifluoroacetic acid was added and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated and diethyl ether (100 mL) was added. The resulting slurry was stirred for 1 hour at room temperature and the product was collected by filtration. The cake was washed with cold diethyl ether and dried under reduced pressure to afford title compound as trifluoroacetic salt. MS (ES) C21H21FΝ4O4 requires 412, found:
413.
Step 4: 2-{2-(benzyloxy)-l-[(2-chloroethyl)amino]ethyl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide.
To a stirred suspension of compound of Step 3 in dry trimethylortoformiate, triethylamine (1.3 eq.) and 1.1 eq. of α-chloroacetaldehyde (1.1 eq.) were added. The resulting solution was aged for 2 hours at room temperature, the solvent was removed by rotary evaporation to afford a residue that was dissolved in MeOH, treated with acetic acid (pH =5) and ΝaBH3CΝ (1.1 eq.). The mixture was stirred overnight at room temperature then the solvent was removed by rotary evaporation and the resulting residue was taken in dry toluene and concentrated. This material was used without any purification for the next step. MS (ES) C23H24CIFN4O4 requires 474, found: 475.
Step 5: 9-[(benzyloxy)methyl]-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2-α]pyrimidin-8-ium trifluoroacetate.
To a solution of 2-{2-(benzyloxy)-l-[(2-chloroethyl)amino]ethyl}-N-(4-fluorobenzyl)- 5,6-dihydroxypyrimidine-4-carboxamide in dry 1,4-dioxane under nitrogen atmosphere potassium tert- butoxide (3 eq.) was added in one portion. The resulting suspension was aged at 12O0C for 2 hours. The reaction mixture was cooled to about 15° C- then acidified with trifluoroacetic acid to pH = 3-4. The solvent was removed under reduced pressure and the residue, dissolved in the minimum amount of MeOH, was applied on cation-exchange resin cartridges (Varian MEGA BOND ELUTE SCX), the cartridges washed with MeOH and the crude product was eluted with IM ammonia in methanol. The pooled eluants were concentrated to dryness under reduced pressure to get 9-[(benzyloxy)methyl]-N-(4- fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[ 1 ,2-α]pyrimidine-2-carboxamide as a brown oil (85%yield). The crude product was purified by RP ΗPLC (Cl 8, 5 μM, Η2θ/MeCΝ with 1% of
TFA as eluant) and product was obtained after freeze drying of appropriate fractions. iH-NMR (400 MHz, DMSO-d6) δ 12.51 (bs, 1 H), 9.46 (t, J= 6.5 Hz, 1 H), 7.42-7.32 (m, 7 H), 7.07 (t, J
= 8.7 Hz, 2 H), 4.76 (bs, 1 H), 4.70 (d, J= 12.1 Hz5 1 H), 4.59 (d, J= 12.1 Hz, 1 H), 4.58-4.54 (m, 1 H), 4.50 (dd, J = 15.0 Hz, J = 6.3 Hz, 1 H), 4.39 (dd, J = 10.6 Hz, J= 3.4 Hz, 1 H), 4.23-4.17 (m, 2 H), 4.01 (m, 1 H), 3.68 (m, IH), 3.54 (m, 1 H); MS (ES) C23H23FN4O4 requires 438, found: 439(M+lf).
Step 6: tert-bυtyl 2- { [(4-fluorobenzyl)amino]carbonyl } -3 -hydroxy-9-(hydroxymethyl)-4-oxo-
4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidine-8-carboxylate.
To a solution of 9-[(benzyloxy)methyl]-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy- 4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidin-8-ium trifluoroacetate in MeOH, Boc2θ (1.2 eq.) was added and the mixture was aged overnight at room temperature. Activated charcoal was added and the mixture was stirred for 30 minutes at room temperature, then was filtered through celite and concentrated under reduced pressure. Required tej't-hutyl 9-[(benzyloxy)methyl]-2-{[(4- fluorobenzy^aminoJcarbonylJ-S-hydroxy^-oxo^jόJ^-tetrahydro-SH-pyrazinofl^-^pyrimidine-δ- carboxylate was obtained after trituration with ethyl ether and further reacted. MS (ES) C28Η31FN4O6 requires 538, found: 539 (M+H"1"). The crude organic product was solubilized in methanol, treated with 1.2 eq. of IN HCl and the solution was stirred overnight under a hydrogen atmosphere in the presence of catalytic 10% Pd/C. Catalyst was then filtered off through celite, and the filtrate was neutralized with NaHCO3 aad concentrated under reduced pressure. The resulting residue was taken in CHCI3, the insoluble material was filtered off and the filtrate was evaporated to afford title compound as a slightly colored solid. MS (ES) C21H25FN4O6 requires 448, found: 449(M+!!1").
Step 7: tert-butyl 9- { [benzyl(methyl)amino]methyl } -2- { [(4-fluorobenzyl)amino]carbonyl} -3 - hydroxy-4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidine-8-carboxylate. To a solution of tei-t-butyl 2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-9- (hydroxymethyl)-4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidine-8-carboxylate in dry CΗCI3, triethylamine (2 eq.) was added and mixture was stirred ten minutes at room temperature. Methanesulfonyl chloride (1.5 eq.) was slowly added and the resulting mixture was aged at room temperature for 1.5 hours to afford tert-hutyl 2-{[(4-fluoroben2yl)amino]carbonyl}-3-hydroxy-9-
{ [(methylsulfonyl)oxy]methyl} -4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[ 1 ,2-α]pyrimidine-8-carboxylate as the main product (monitored by LC-MS). MS (ES) C22Η27FN4O8S requires 526, found: 527 (M+H*).
The reaction mixture was concentrated under vacuum at 300C and the solvent switched to dry acetonitrile. The insoluble material was filtered off and to the filtrated 5 equivalents of N- benzylmethylamine were added. The mixture was warmed at 110°C upon microwave irradiation for 30 minutes then stirred at room temperature for further 36 hours. The mixture was concentrated by rotary evaporation and the resulting residue, dissolved in the minimum amount of MeOH, was carefully acidified with some drops of glacial acetic acid applied on cation-exchange resin. The resin was washed with MeOH and the crude product was eluted with IM ammonia in methanol. The pooled eluants were concentrated to dryness under reduced pressure to get tert-butyl 9-{[benzyl(methyl)amino]methyl}-2- {^-fluorobenzy^aminoJcarbonylJ-S-hydroxy^-oxo^jόJ^-tetrahydro-SH-pyrazinofl^-fllpyrimidine- 8-carboxylate as a brown oil. MS (ES) C29Η34FN5O5 requires 551, found: 552 (M+H4).
Step 8: N-(4-fluorobenzyl)-3-hydroxy-9-[(methylamino)methyl]-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[l ,2-α]pyrimidine-2-carboxamide.
A solution of compound of Step 7 in dry CΗ2Cl2/trifiuoroacetic acid (8/2 v/v) was stirred at room temperature for 1.5 hours, then evaporated under reduced pressure. MS (ES) C24H26FΝ5O3 requires 451, found: 452 (M+H*). The residue was taken in methanol and the solution was treated with 3 equivalents of triethylamine and stirred for 10 minutes. The mixture was acidified with some drops of acetic acid (pH=5) then treated with formaldehyde (3 eq.) and sodium cyanoborohydride. After over night stirring at room temperature, volatiles were removed by rotary evaporation and the resulting residue, dissolved in the minimum amount of MeOH, was applied on cation-exchange resin. The resin was washed with MeOH and the product was eluted with 1 M ammonia in methanol. The pooled fractions were concentrated to dryness under reduced pressure to get 9- {[benzyl(methyl)amino]methyl}-N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[l,2-α]pyrimidine-2-carboxamide as a brown oil. MS (ES) C25Η28FΝ5O3 requires 465, found:
466 (M+H1"). The crude compound was dissolved in methanol, treated with 2.5 eq. of 1 N HCl and the solution was stirred overnight under a hydrogen atmosphere in the presence of catalytic 10% Pd/C. Catalyst was then filtered off through celite, and the filtrate was evaporated under reduced pressure to afford title compound as hydrochloric salt. MS (ES) C18H22FN5O3 requires 375, found: 476 (MH-H+).
Step 9: N-(4-fluorobenzyl)-3-hydroxy-8-methyl-9-{[methyl(methylsulfonyl)amino]methyl}-4- oxo-6,758,9-tetrahydro-4H-pyrazmo[l,2-a]pyrimidine-2-carboxamide.
N-(4-fluorobenzyl)-3-hydroxy-9-[(methylamino)methyl]-4-oxo-6,7,8,9-tetrahydro-4H- pyrazήio[l,2-α]pyrimidine-2-carboxamide was suspended in dry CΗ2CI2 and triethylamine (2.5 eq.), methane sulphonylchloride (1.3 eq.) was slowly added to the solution under nitrogen atmosphere and the reaction mixture was stirred at room temperature overnight. Volatiles were removed under reduced pressure and title product was purified RP HPLC (Ci8, 5 μM, H2θ/MeCΝ with 1% of TFA as eluant).
Lyophilization of appropriate fractions gave title compound as trifluoroacetate salt. iH-NMR (300 MHz, CD3CN) δ 8.52 (bs, 1 H), 7.43-7.38 (m, 2 H), 7.12 (t, J= 8.8 Hz, 2 H), 4.67-4.51
(m, 3 H), 4.30-4.13 (m, 2 H), 4.05 (dd, J= 15.7 Hz, J= 7.7 Hz, 1 H), 3.96-3.68 (m, 3 H), 3.10 (s, 3 H), 2.94 (s, 3 H), 2.89 (s, 3 H); MS (ES) C19H24FN5O5S requires 453, found: 454 (MH-H+).
EXAMPLE 20
8-Acetyl-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2-t/][l,4]diazepine-2- carboxamide (Entry No. 174 in Table 1)
Step 1: Methyl 8-acetyl-3-(acetyloxy)-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2-
</|[l,4]diazepine-2~carboxylate and methyl 8-acetyl-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-_/|[l,4]diazepine-2-carboxylate.
A solution of S-fer^-butyl^-methyl-S-hydroxy^-oxo-όJ^jlO-tetrahydropyrimidofl^- d][l,4]diazepine-2,8(4H)-dicarboxylate (prepared as described in Example 11, Steps 1-3) in dichloromethane/trifluoroacetic acid (8/2 v/v) was stirred at room temperature for 2 hours. Volatiles were evaporated under reduced pressure and residue after trituration with diethyl ether was taken in dichloromethane and treated with 2.5 equivalents of triethylamine and 2 equivalents of acetic anhydride. The resulting mixture was stirred over night at room temperature. Volatiles were evaporated and residue containing mono- and di-acylated compounds in approximately 1 : 1 ratio (as evidenced by LC/MS analysis) was taken in the next step. MS (ES) C14Η17N3O6 requires 323, found: 324 (MfH+); MS (ES) C12H15N3O5 requires 281, found: 282 (M-I-H+).
Step 2: 8-Acetyl-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2- d\ [ 1 ,4]diazepine-2-carboxamide. The mixture of products obtained in Step 1 was taken in methanol and treated with 2.5 equivalents of p-fluorobenzylamine. The resulting mixture was refluxed for 24 hours, then cooled to room temperature and concentrated under reduced pressure. The crude material was purified by RP HPLC (C 18, 5 μM, H2θ/MeCN with 1% of TFA as eluant). Lyophilization of appropriate fractions gave title compound as a white solid. iH-NMR (300 MHz, CD3CN) δ 12.19 (bs, 1 H), 8.56 (bs, 1 H), 7.47-7.42 (m, 2 H), 7.17 (t, J= 5.75 Hz, 2
H), 4.60 (bd, J= 5.53, 2 H), 4.46-4.37 (m, 2 H), 3.86-3.75 (m, 4 H), 3.7-3.05 (m, 2 H), 2.17 (s, 1.5 H), 2.14 (s, 1.5 H); MS (ES) C18H19FN4O4 requires 374, found: 375 (M+H\).
EXAMPLE 21
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4H-pyrimido[l,2- ^[l,4]oxazepin-10-yl)-N,N,N-trimethylethanediamide and the corresponding (+) and (-) enantiomers (Entry Νos. 180 and 181 in Table 1)
Step 1: l,4-Oxazepane-5-thione l,4-Oxazepan-5-one, P4S10 (0.2 eq.), ΗMDO (2 eq.) and dichloromethane were combined and stirred magnetically at room temperature for 1 hour. The reaction mixture was then cooled to 00C and aqueous K2CO3 solution (1.26 mL of 5.3 M/mmol P4S10 taken) was added. A volume of acetone equal to one half of the reaction solvent was added to obtain a stirrable mixture, and the reaction mixture was stirred vigorously for 30 minutes at 00C. Volatiles were evaporated, water and ethyl acetate were added, layers were separated and the organic phase was washed with water and brine. The organic extract was dried over Νa2S04 and evaporated, to afford crude product in quantitative yield. lΗ NMR (300 MHz, CDCI3) δ 8.96 (bs, 1 H), 3.84-3.77 (m, 4 H), 3.57-3.54 (m, 2 H), 3.28-3.26 (m, 2 H).
Step 2: l,4-oxazepan-5-one oxime
A solution of NH2OH HCl (2 eq.) in methanol was added to an equimolar methanolic solution of KOH. KCl was filtered off and the filtrate was added to a solution of l,4-oxazepane-5-thione (1 eq.) in methanol. The mixture was stirred at 55°C overnight, then cooled to room temperature and the solvent was removed under reduced pressure. The residue was taken in chloroform, washed with brine, dried (Na2SO4) and concentrated under reduced pressure to give, after trituration with ethyl ether, the title compound. lH NMR (300 MHz, CDCI3) δ 8.9 (bs, 1 H), 6.15 (bs, 1 H), 3.68-3.51 (m, 4 H), 3.21- 3.19 (m, 2 H), 2.38-2.31 (m, 2 H); MS (ES) C5H10N2O2 requires 130, found: 131 (MfH+). Step 3: Methyl 3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4H-pyrimido[l,2-(5θ[l,4]oxazepine-2- carboxylate.
To a stirred suspension of l,4-oxazepan-5-one oxime in acetonitrile, dimethylacetylene dicarboxylate (1 eq.) was added in one portion and the mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure and the oily residue was taken in xylene and stirred overnight at 145°C. After cooling to room temperature, the solvent was evaporated under reduced pressure and residue was taken in ethyl acetate and treated with saturated solution of NaΗC03. The aqueous phase was separated, washed with additional ethyl acetate and carefully acidified with 2N HCl. The product was extracted in chloroform, and the organic solution was dried over Na2SO4 and concentrated under reduced pressure to afford title compound as a brown solid. ^H NMR (300 MHz, dg-
DMSQ) δ 10.58 (bs, 1 H), 4.57-4.52 (m, 2 H),4.06 (s, 3 H), 3.91-3.82 (m, 4 H), 3.26-3.18 (m,2 H); MS (ES) C10H12N2O5 requires 240, found: 241 (M+H*).
Step 4: Methyl 10-[ben2yl(methyl)amino]-3-hydroxy-4-oxo-6,7,9, 10-tetrahydro-4H- pyrimido[l,2-uTj[l,4]oxazepine-2-carboxylate.
Methyl 3-hydroxy-4-oxo-6, 7,9, 10-tetrahydro-4H-pyrimido[l,2-^][l,4]oxazepine-2- carboxylate was taken in chloroform and treated with pyridine (3 equivalents) and benzoic anhydride (1.2 eq.). The mixture was stirred overnight at room temperature, then poured in chloroform and washed with 1 N HCl and brine. The organic phase was dried (Na2SO4), filtered and concentrated under reduced pressure to a solid residue. MS (ES) C17Η16N2O6 requires 344, found: 345 (M+H*). This residue was taken in N,N-dimethylformamide and treated with 0.5 equivalents of benzoyl peroxide and 5 equivalents of N-bromosuccinimide. The mixture was stirred at 1000C for 1 hour. To allow the reaction to progress further, another aliquot of both reagents was added and stirring continued an additional hour. After cooling to room temperature, mixture was poured in EtOAc, washed w.ith brine, dried (Na2SO4), filtered and concentrated under reduced pressure to an oily residue. This residue was treated with an excess of methylbenzylamine in THF at room temperature for 1 hour. The mixture was applied on cation exchange resin and the resin was extensively washed with methanol, while title compound was eluted with a IN solution of ammonia in methanol. The pooled fractions were evaporated to dryness. MS (ES) C18H21N3O5 requires 359, found: 360 (M+lf).
Step 5: N-(4-fluorobenzyl)-3-hydroxy-10-(methylamino)-4-oxo-6,7,9,10-tetrahydro-4H- pyrimido[l ,2-d] [ 1 ,4]oxazepine-2-carboxamide.
Crude organic product prepared as described in Step 4 was taken in methanol and reacted with p-fluorobenzylamine (2 equivalents) at 8O0C for 2 hours. Volatiles were evaporated and the residue washed by trituration with diethyl ether. MS (ES) C24H25FN4O4 requires 452, found: 453 (M+H1"). A solution of this crude material in methanol and 1 N HCl was stirred under a balloon of hydrogen in the presence of 10% Pd/C. After overnight stirring, the mixture was filtered through celite and concentrated under reduced pressure. MS (ES) C17H19FN4O4 requires 362, found: 363 (M+H1").
Step 6: N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4H- pyrimido [ 1 ,2-d] [ 1 ,4]oxazepin- 10-yl)-N^V JV-trimethylethanediamide. To a suspension of N-(4-fluorobenzyl)-3 -hydroxy- 10-(methylamino)-4-oxo-6, 7,9, 10- tetrahydro-4H-ρyrimido[l,2-<^[l,4]oxazepine-2-carboxamide was added triethylamine (2.5 eq.) and methyl chloro(oxo)acetate (2 eq.) and the resulting mixture was stirred one hour at room temperature.
Volatiles were evaporated under reduced pressure and residue was taken in methanol and treated with an excess of dimethylamine (2 M solution in methanol). The reaction mixture was stirred overnight at room temperature, evaporated under reduced pressure and purified by RP ΗPLC (C\ 8, 5 μM, Η2θ/MeCΝ with
1% of TFA as eluant). Lyophilization of appropriate fractions gave the title compound as a white solid. lH NMR. (300 MHz, CD3CN) δ 12.2 (bs, 1 H), 9.78 (bs, 1 H), 7.48-7.39 (m, 2 H), 7.07 (t, J= 8.7 Hz, 2
H), 5.20-5.12 (m, 1 H), 5.1, 4.9 (bs, 1 H), 4.61-4.50 (m, 2 H), 4.30-4.22 (m, 1 H), 4.19-4.08 (m, 2 H), 3.80-3.70 (m, 1 H), 3.60-3.49 (m, 1 H), 3.06 (s, 3 H), 2.98 (s, 3 H), 2.92 (s, 3 H); MS (ES) C21H24FN5O6 requires 461, found: 462 (M+H1").
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4H- pyrimido [ 1 ,2-d] [ 1 ,4] oxazepin- 10-yl)-NN,N-trimethylethanediarnide has been resolved into its enantiomers by semipreparative chiral ΗPLC using the following conditions: Solvents: a mixture 40:60
0.2%TFA in Ηexanes: 0.2%TFA in EtOΗ+3%MeOΗ. Column: Chiralpack AD 250x46 mm at 10 mL/min, detected by absorption at 300 nm.
The first eluate is the (+) enantiomer (EtOH, c=0.1, 25 0C) [α]D= (+) 12.3 The second eluate is the (-) enantiomer (EtOH, c=0.1, 25 0C) [α]D= (-) 12.0
EXAMPLE 22
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8,9-dihydro-4H-pyrimido[2,l-(f][l,2,5]thiadiazine-2- carboxamide 7,7-dioxide (Entry No. 105 in Table 1)
Step 1: 2-(l-{[(chloromethyl)sulfonyl]amino}-l-methylethyl)-4-{[(4- fluorobenzyl)amino]carbonyl}-6-hydroxypyrimidin-5-yl chloromethanesulfonate. To a solution of 2-(l -amino- l-methylethyl)-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide hydrochloride (prepared as described in WO2003035076 Al) in dichloromethane, triethylamine (4 eq.) was added and the mixture was cooled down with an ice/salt bath. A solution of chloromethanesulfonyl chloride in dichloromethane was added dropwise to the mixture. After 2 hours further triethylamine (1 eq.) and chloromethanesulfonyl chloride (1 eq.) were added at 00C and the reaction mixture was aged at room temperature overnight. To allow complete consumption of starting material, additional Et3N (0.5 eq.) and chloromethanesulfonyl chloride (0.5 eq.) were added at 00C. After one hour, the mixture was poured in dichloromethane and washed with IN HCl and brine, dried over Na2SO4, filtered and concentrated under reduced pressure to obtain title compound as yellow oil. lH NMR (300 MHz, d6-DMSO) δ 13.32 (bs ,1 H), 9.19 (t, J= 6.0 Hz, 1 H), 8.03 (s, 1 H),
7.37 (dd, J= 8.4 Hz , J= 5.7 Hz, 2 H), 7.15 (t, J= 8.5 Hz, 2 H), 5.59 (s, 2 H), 4.86 (s, 2 H), 4.45 (d, J= 6.2 Hz, 2 H), 1.64 (s, 6 H); MS (ES) C 17H19CI2FN4O7S2 requires 545, found: 546 (M+H1).
Step 2: N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8,9-dihydro-4H-pyrimido[2,l- d] [ 1 ,2,5]thiadiazine-2-carboxamide 7,7-dioxide.
Crude chloride of Step 1 was dissolved in 1,4-dioxane and Cs2CO3 (2 eq.) was added. The reaction mixture was stirred at 1000C overnight, then cooled down to room temperature, taken up in EtOAc washed with brine, dried over Νa2S04. The solvent was removed under reduced pressure and the resulting brown oil was purified by RP ΗPLC (C18, 5μM, Η2θ/MeCN with 1% of TFA as eluant).
Lyophilization of appropriate fractions gave title compound as a white solid. lH NMR (300 MHz, d6-DMSO) δ 12.47 (bs, 1 H), 9.47 (t, J= 6.2 Hz, 1 H), 8.24 (s, 1 H), 7.38 (dd, J= 8.5 Hz , J= 5.6 Hz, 2 H), 7.17 (t, J= 8.9 Hz, 2 H), 5.28 (s, 2 H), 4.49 (d, J= 6.4 Hz, 2 H), 1.69 (s, 6 H); MS (ES) C16H17FN4O5S requires 396, found: 397 (M+H*).
EXAMPLE 23
N-(4-fluorobenzyl)-3-hydroxy-7-methyl-4,6-dioxo-6,7,8,9-tetrahydro-4H-pyrimido[l,6-α]pyrimidine-2- carboxamide (Entry No. 104 in Table 1)
Step 1: tert-Butyl [3-amino-3-(hydroxyimino)propyl]benzylcarbamate
Ηydroxylamine hydrochloride in methanol was added to an equimolar stirred solution of potassium hydroxide in methanol. The mixture was stirred for 15 minutes and the precipitated potassium chloride is removed by filtration. The filtrate was added to an equimolar amount of the tert-butyl benzyl(2-cyanoethyl)carbamate and the solution was stirred for 2 hours at 60 0C. The reaction mixture was concentrated and the solvent switched to CΗCI3. The insoluble material was filtered off and the filtrated was evaporated to afford the title product as a white solid. MS (ES) C15H23N3O3 requires 293, found: 294 (M+H*). Step 2: Methyl 2-{2-[benzyl(tert-butoxycarbonyl)amino]ethyl}-5,6-diliydroxypyrimidine-4- carboxylate
A solution of tert-butyl [3-amino-3-(hydroxyimino)propyl]benzylcarbamate (prepared as described in Step 1) in chloroform was treated with dimethylacetylene dicarboxylate (1 eq.) and the mixture was stirred at 6O0C for 2 hours. Volatiles were evaporated under reduced pressure and the residue was taken in xylene and stirred for 2 days at 150 0C. After cooling to room temperature a brown solid precipitated from xylene and was filtered off and washed with diethyl ether to give crude title compound. MS (ES) C20H25N3O6 requires 403, found: 404 (M+H1).
Step 3: /1ert-Butyl ben2yl[2-(4-{[(4-fluoroben2yl)amino]carbonyl}-5,6-dihydroxypyrimidin-2- yl)ethyl]carbamate.
Crude methyl 2- {2-[benzyl(fer^butoxycarbonyl)amino]ethyl} -5,6-dihydroxypyrimidine- 4-carboxylate (prepared as described in Step 2) was dissolved in methanol and treated with p- fluorobenzylamine (2.5 equivalents) at 8O0C for 12 hours. The mixture was then cooled to room temperature, volatiles were evaporated and the residue was poured in EtOAc and washed 0.5 N HCl and brine. The organic phase was dried (Na2SO4), filtered and concentrated to a brown solid residue. MS (ES) C26H29FN4O5 requires 496, found: 497 (M+H*).
Step 4: 2-{2-[benzyl(methyl)amino]ethyl}-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4- carboxamide.
Crude tert-butyl benzyl[2-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6- dihydroxypyrimidin-2-yl)ethyl]carbamate (prepared as described in Step 3) was taken in dichloromethane /trifluoroacetic acid (8/2 v/v) and the mixture was stirred 1 hour at room temperature. After evaporation of volatiles, the crude organic product was taken in methanol and treated with triethyl amine (1 equivalent), formaldehyde (2 equivalents), sodium cyanoborohydride (1.2 equivalents) and acetic acid (pH=5.5). The mixture was stirred at room temperature for 1 hour. Volatiles were evaporated and product was purified by RP HPLC (Ci 8, 5 μM, H2θ/MeCΝ with 1% of TFA as eluant).
Lyophilization of appropriate fractions gave the title compound (TFA salt) as a white solid. lH NMR (400 MHz, d6-DMSQ) δ 12.78 (bs, 1 H), 12.32 (bs, 1 H), 9.5-9.4 (m, 2 H), 7.48 (s, 5 H), 7.42-7.32 (m, 2
H), 7.12 (t, J= 8.7 Hz, 2 H), 4.59-4.45 (m, 3 H), 4.23 (bs, 1 H), 3.75 (bs, 1 H), 3.52 (bs, 1 H), 3.08-3.00 (m, 2 H), 2.72 (s, 3 H); MS (ES) C22H23FN4O3 requires 410, found: 411 (M+H*). Step 5: N-(4-fluorobenzyl)-3-hydroxy-7-methyl-4,6-dioxo-6,7,8,9-tetrahydro-4H-pyrimido[l,6- α]pyrimidine-2-carboxamide.
A methanolic solution of 2-{2-[benzyl(methyl)amino]ethyl}-N-(4-fluorobenzyl)-5,6- dihydroxypyrimidine-4-carboxamide prepared as described in Step 4 was stirred under Η2 atmosphere in the presence of catalytic 10% Pd/C for 2 hours. The reaction mixture was filtered through celite to remove the catalyst then concentrated under reduced pressure. MS (ES) C17H17FΝ4O3 requires 320, found: 321 (M+H*). The crude organic product was treated with carbonyl diimidazole (1.5 equivalents) and potassium tert-butoxide in refluxing dioxane for 1 hour. Title compound was purified by RP HPLC (Ci g, 5 uM, EføO/MeCN with 1% of TFA as eluant). Lyophilization of appropriate fractions gave title compound as a white solid. lHNMR (400 MHz, d6-DMSO) δ 12.43 (bs, 1 H), 9.41 (t, J= 6.3 Hz, 1 H), 7.38 (m, 2 H), 7.17 (t, J=
8.7 Hz, 2 H), 4.45 (d, J= 6.3 Hz, 2 H), 3.61 (m, 2 H), 3.14 (s, 3 H), 3.01 (m, 2 H); MS (ES) C16H15FN4O4 requires 346, found: 347 (M+H*).
EXAMPLE 24
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(3-methylisoxazol-5-yl)methyl]-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 71 in Table 1)
Step 1: 3-(Benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-8-prop-2-yn-l-yl-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide
A mixture of 3-(benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (prepared as described in Example 3, Step 1) (1 eq.), K2CO3 (2 eq.), propargyl bromide (2.5 eq.) in DMF was heated at 45 0C overnight and then cooled at room temperature. The solvent was removed under reduced pressure and the residue was taken up in EtOAc and washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to yield the titled acetylene. MS (ES) C27H27FN4O3 requires 474, found: 475 (M+H1").
Step 2: N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(3-methylisoxazol-5-yl)methyl]-4-oxo-
6,7,8,9-tetrahydro-4H-pyrazino[ 1 ,2-α]pyrimidine-2-carboxamide A solution OfEtNO2 (6.5 eq.) and Et3N (catalytic amount) in toluene was added dropwise to a solution of PhNCO (11 eq.) and 3-(benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-8-prop-2-yn- l-yl-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (1 eq.) in toluene. The reaction mixture was stirred at room temperature for 1 hour, then heated at reflux overnight. The precipitate was filtered off, the filtrate concentrated under reduced pressure and then directly dissolved in MeOH. The mixture was stirred 1 hour under an H2 atmosphere in the presence of 10% Pd/C. Catalyst was then filtered off through celite, and the filtrate was concentrated under reduced pressure and purified by RP HPLC (C 18, 5 μm, H2OMeCN with 1% of TFA as eluant) to afford the desired isoxazole as a TFA salt after lyophilisation of the desired fractions. 1H-NMR (600 MHz, d6-DMSO) δ 12.18 (br. s,l H), 9.44 (t, J = 6.2 Hz, 1 H), 7.37 (dd, J = 7.9 Hz, J = 5.9 Hz, 2 H), 7.17 (t, J = 8.8 Hz, 2 H), 6.32 (s, 1 H), 4.47 (d, J = 6.2 Hz, 2 H), 3.87 (s, 2 H), 3.77 (t, J = 5.2 Hz, 2 H), 2.95 (t, J = 5.2 Hz, 2 H), 2.21 (s, 3 H), 1.55 (s, 6 H); MS (ES) C22H24FN5O4 requires 441, found: 442 (M+H+).
EXAMPLE 25 N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(3-methyl-l,2,4-oxadiazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 72 in Table 1)
Step 1: tert-Butyl (3-(benzyloxy)-2- { [(4-fluorobenzyl)amino]carbonyl} -9,9-dimethyl-4-oxo-
4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidin-8-yl)acetate A mixture of 3-(benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-
4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (prepared as described in Example 3, Step 1) (1 eq.), K2CO3 (2 eq.) and tert-bυtyl bromoacetate (3 eq.) in DMF was heated for 24 hours at 45 0C and then cooled to room temperature. Solvent was removed under reduced pressure and the residue was taken up in EtOAc and washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to yield the ester. MS (ES) C30H35FN4O5 requires 550, found: 551 (M+tf).
Step 2: N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(3-methyl-l,2,4-oxadiazol-5-yl)methyl]-
4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide A mixture of tert-butyl (3-(benzyloxy)-2-{[(4-fluorobenzyl)amino]carbonyl}-9,9- dimethyl-4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidin-8-yl)acetate (1 eq.), acetamide oxime (6 eq.) and NaOEt (6 eq.) in EtOH was refluxed overnight to provide a crude which was directly purified by RP ΗPLC (C 18, 5 μm, H2OZMeCN with 1% of TFA as eluant) to afford the desired oxadiazole as TFA salt after lyophilisation of the desired fractions. 1H-NMR (400 MHz, dβ-DMSO) δ 12.20 (br. s, 1 H), 9.44 (t, J = 6.3 Hz, 1 H), 7.38 (dd, J = 8.4 Hz, J = 5.8 Hz, 2 H), 7.18 (t, J = 8.8 Hz, 2 H), 4.49 (d, J = 6.3 Hz, 2 H), 4.09 (s, 2 H), 3.77 (t, J = 5-3 Hz, 2 H), 3.07 (t, J = 5.3 Hz, 2 H), 2.35 (s, 3 H), 1.55 (s, 6 H); MS (ES) C2iH23FN6O4 requires 442, found: 443 (M+Ff). EXAMPLE 26
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-(l,3,4-oxadiazol-2-ylmetl1yl)-4-oxo-6:,7,8,9-tetrahydro-4H- pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 82 in Table 1)
Step 1: Methyl (3-(benzyloxy)-2-{[(4-fluorobenzyl)amino]carbonyl}-9,9-dimethyl-4-oxo-
4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidin-8-yl)acetate
A mixture of 3-(benzyloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (prepared as described in Example 3, Step 1) (1 eq.), K2CO3 (2 eq.), methyl bromoacetate (2 eq.) in DMF was heated for 24 hours at 65 0C and then was cooled to room temperature. The solvent was removed under reduced pressure and the residue was taken up in EtOAc and washed with brine, dried (Νa2Sθ4), filtered and concentrated under reduced pressure to yield the desired ester as a brown oil. MS (ES) C27H29FN4O5 requires 508, found: 509 (M+H1").
Step 2: N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-(l,3,4-oxadiazol-2-ylmethyl)-4-oxo- 6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide
A mixture of methyl (3-(benzyloxy)-2-{[(4-fluorobenzyl)amino]carbonyl}-9,9-dimethyl- 4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidin-8-yl)acetate (1 eq.), NH2NH2-H2O (10 eq.) in MeOH was refluxed overnight. The volatiles were evaporated under reduced pressure and the residue dissolved in toluene. TsOH (0.2 eq.) and trimethyl orthoformate (ca. 10 eq.) were added and the mixture was heated at 1100C for 1 hour, then cooled to room temperature and concentrated under reduced pressure. The resulting residue was purified by flash chromatography on silica using 1% MeOH/DCM as eluant. The residue was dissolved in MeOH and the mixture was stirred 1 hour under an H2 atmosphere in the presence of 10% Pd/C. Catalyst was then filtered off using celite and the filtrate was concentrated under reduced pressure and triturated with diethyl ether to yield the desired oxadiazole. 1H-NMR (300 MHz, d6-DMSO) δ 12.17 (br. s,l H), 9.21 (s, 1 H), 7.35 (dd, J = 8.2 Hz, J = 5.8 Hz, 2 H), 7.16 (t, J = 8.7 Hz, 2 H), 4.46 (d, J = 6.0 Hz, 2 H), 4.05 (s, 2 H), 3.75-3.66 (m, 2 H), 3.04-2.94 (m, 2 H), 1.53 (s, 6 H); MS (ES) C20H2IFN6O4 requires 428, found: 429 (TVH-H+).
EXAMPLE 27 N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methyl-l,3,4-oxadiazol-2-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 85 in Table 1)
A mixture of methyl (3-(benzyloxy)-2-{[(4-fluorobenzyl)amino]carbonyl}-9,9-dimethyl- 4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[l,2-β]pyrimidin-8-yl)acetate (prepared as described in Example 26, Step 1) (1 eq.), NΗ2NΗ2.Η2O (10 eq.) in MeOH was refluxed overnight, then the volatiles were evaporated under reduced pressure. The residue dissolved in toluene, TsOH (0.2 eq.) and trimethyl orthoacetate (ca. 10 eq.) were added and the mixture was heated at 100 0C for 3 hours, then it was diluted with more toluene and more TsOH (0.2 eq.) was added. After stirring overnight at 100 0C, the resulting residue was cooled to room temperature, concentrated under reduced pressure and dissolved in MeOH. The mixture was stirred 1 hour under an H2 atmosphere in the presence of 10% Pd/C. Catalyst was then filtered off through celite and the filtrate was concentrated under reduced pressure and purified by RP HPLC (Cl 8, 5 μm, H2OZMeCN with 1% of TFA as eluant) to afford the desired oxadiazole as TFA salt after lyophilisation of the desired fractions. 1H-NMR (300 MHz, d6-DMSO) δ 12.17 (br. s,l H), 9.43 (t, J = 6.2 Hz, 1 H), 7.37 (dd, J = 8.0 Hz, J = 5.8 Hz, 2 H), 7.17 (t, J = 8.7 Hz, 2 H), 4.48 (d, J = 6.2 Hz, 2 H), 3.97 (s, 2 H), 3.75-3.66 (m, 2 H), 3.06-2.93 (m, 2 H), 2.50 (s, 3 H), 1.55 (s, 6 H); MS (ES) C2IH23FN6O4 requires 442, found: 443 (M+H÷).
EXAMPLE 28 N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methyl-l,2,4-oxadiazol-3-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 89 in Table 1)
A solution of KOΗ (2.2 eq.) in MeOH was added to a solution of NΗ2OΗ.ΗC1 (2.2 eq.) in MeOH and the mixture was stirred for 30 minutes, then filtered onto 3-(benzyloxy)-8-(cyanomethyl)- N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (prepared as described in Example 4, Step I) (I eq.). The solution was heated overnight at 60 °C, then cooled to room temperature and the solvent was removed under reduced pressure. Ac2O (3 eq.) was added to a solution of the residue in toluene and the mixture was heated at 65 0C for 30 min and then at 110 0C for 48 hours. The volatiles were removed under reduced pressure and the crude was dissolved in MeOH. The mixture was stirred 1 hour under an H2 atmosphere in the presence of 10% Pd/C. Catalyst was then filtered off through celite and the filtrate was concentrated under reduced pressure and purified by RP HPLC (C 18, 5 μm, H2OMeCN with 1 % of TFA as eluant) to afford the oxadiazole as TFA salt after lyophilisation of the desired fractions. 1H-NMR (300 MHz, d6-DMSO) δ 12.17 (br. s, 1 H), 9.43 (t, J = 6.0 Hz, 1 H), 7.37 (dd, J = 8.4 Hz, J = 5.7 Hz, 2 H), 7.17 (t, J = 8.8 Hz, 2 H), 4.48 (d, J = 6.2 Hz, 2 H), 3.81 (s, 2 H), 3.72 (t, J = 4.7 Hz, 2 H), 3.01 (t, J = 5.0 Hz, 2 H), 2.58 (s, 3 H), 1.56 (s, 6 H); MS (ES) C2]H23FN6O4 requires 442, found: 443 (M+lf).
EXAMPLE 29
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-l,2,3-triazol-4-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 75 in Table 1) and N-(4- FluorobenzyO-S-hydroxy-P^-dimethyl-S-CCl-methyl-lH-l^^-triazol-S-yOmethylJ^-oxo-ό,?^^- tetrahydro-4H-pyrazmo[l,2-α]pyrimidine-2-carboxamide (Entry No. 76 in Table 1)
To a solution of 3-(ben2yloxy)-N-(4-fluorobenzyl)-9,9-dimethyl-4-oxo-8-prop-2-yn-l-yl- 6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (prepared as described in Example 24, Step I) (I eq.) in toluene was added Me3SiCΗΝ2 (3 eq.) and the mixture was heated at 110 0C overnight. Additional Me3SiCH2N3 (ca. 20 eq.) was added and the mixture was heated further to ensure completion. The solvent was evaporated under reduced pressure and the residue was treated at -78 0C with a 1 M solution of TBAF in THF (0.6 eq.) and the mixture was allowed to warm to room temperature. After evaporation of volatiles under reduced pressure, two isomers were observed and directly separated by RP HPLC (C 18, 5 μm, H2OMeCN with 1 % of TFA as eluant) to afford the isomeric triazoles as TFA salts after lyophilisation of the desired fractions.
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-l,2,3-triazol-4-yl)methyl]- 4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (more polar): 1H-NMR (300 MHz, d6-DMSO) δ 12.19 (br. s,l H), 9.45 (t, J = 5.8 Hz, 1 H), 8.00 (s, 1 H), 7.37 (dd, J = 8.3 Hz, J = 5.8 Hz, 2 H), 7.17 (t, J = 8.8 Hz, 2 H), 4.48 (d, J = 6.2 Hz, 2 H), 4.02 (s, 2 H), 3.87 (br. s, 3 H), 3.79-3.71 (m, 2 H), 3.06-2.95 (m, 2 H), 1.61 (s, 6 H); MS (ES) C2iH24FN7O3 requires 441, found: 442 (M+Ff1").
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-l,2,3-triazol-5-yl)methyl]- 4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (less polar): 1H-NMR (300 MHz5 d6-DMSO) δ 12.17 (br. s,l H), 9.45 (t, J = 5.8 Hz, 1 H), 7.67 (s, 1 H), 7.37 (dd, J = 8.3 Hz, J = 5.8 Hz, 2 H), 7.17 (t, J = 8.8 Hz, 2 H), 4.49 (d, J = 6.2 Hz, 2 H), 4.00 (s, 2 H), 3.86 (br. s, 3 H), 3.77-3.67 (m, 2 H)5 2.81-2.73 (m, 2 H), 1.61 (s, 6 H); MS (ES) C21H24FN7O3 requires 441, found: 442 (M+Ff).
EXAMPLE 30
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methyl-l,3-oxazol-2-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-α]pyrimidine-2-carboxamide (Entry No. 91 in Table 1)
Step 1: Lithium (3-(benzyloxy)-2-{[(4-fluorobenzyl)amino]carbonyl}-9,9-dimethyl-4-oxo-
4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidin-8-yl)acetate To a solution of methyl (3-(benzyloxy)-2-{[(4-fluorobenzyl)amino]carbonyl}-9,9- dimethyl-4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidin-8-yl)acetate (prepared as described in
Example 26, Step 1) (1 eq.) in TΗF:Η2O (1:1) LiOH (1 eq.) was added and the mixture was stirred for 2 hours at room temperature. The resulting solution was directly lyophilized to afford the desired lithium salt. MS (ES) C26H27FN4O5 requires 494, found: 495 (M+H1). Step 2: N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methyl-l,3-oxazol-2-yl)methyl]-4- oxo-6,7,8,9-tetrahydro-4H-pyrazino[ 1 ,2-α]pyrimidine-2-carboxamide To a solution of lithium (3-(benzyloxy)-2-{[(4-fluorobenzyl)amino]carbonyl}-9,9- dimethyl-4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[l,2-α]pyrimidin-8-yl)acetate (1 eq.) in CHCl3, propargylamine (1.1), EDC (2 eq.) and HOBt (2 eq.) were added and the reaction mixture was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure and the residue was taken up in EtOAc, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. The resulting crude was directly dissolved in acetic acid and Hg(OAc)2 (0.1 eq.) was added. The mixture was heated at 100 0C overnight and was then concentrated under reduced pressure. The residue was directly purified by RP-HPLC and after lyophilisation of the desired fractions, the O-benzyl protected material was dissolved in MeOH and stirred 1 hour under an H2 atmosphere in the presence of 10% Pd/C. The catalyst was then filtered off through celite, the filtrate was concentrated under reduced pressure and then the residue was dissolved in MeCN and H2O and lyophilized to afford the titled oxazole. 1H-NMR (400 MHz5 de-DMSO) δ 12.17 (br. s,l H), 9.43 (t, J = 6.2 Hz, 1 H), 7.37 (dd, J = 8.1 Hz, J = 5.7 Hz, 2 H), 7.17 (t, J = 8.9 Hz, 2 H), 6.77 (s, 1 H), 4.47 (d, J = 6.2 Hz, 2 H), 3.80 (s, 2 H), 3.71 (t, J = 5.0 Hz, 2 H), 3.00 (t, J = 5.1 Hz, 2 H)5 2.27 (s, 3 H), 1.53 (s, 6 H); MS (ES) C22H24FN5O4 requires 441, found: 442 (M+H1").
The following Table 1 lists compounds of the present invention which have been prepared. The table provides the structure and name of each compound and the mass of its molecular ion plus 1 (M+ 1) as determined via ES-MS. When the compound was prepared as a salt, the identity of the salt is included in parentheses following the compound name for the free base. The synthetic scheme employed to prepare the compound is indicated in parentheses following the compound name.
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
EXAMPLE 31 Oral Compositions
As a specific embodiment of an oral composition of a compound of this invention, 50 mg of compound of Example 1 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0 hard gelatin capsule. Encapsulated oral compositions containing any one of the compounds in Table 1 can be similarly prepared.
EXAMPLE 32 HIV Integrase Assay: Strand Transfer Catalyzed by Recombinant Iπtegrase
Assays for the strand transfer activity of integrase were conducted in accordance with WO 02/30930 for recombinant integrase. Representative compounds of the present invention exhibit inhibition of strand transfer activity in this assay. For example, the compounds in Table 1 were tested in the integrase assay and found to have IC50 values of less than about 10 micromolar. Further description on conducting the assay using preassembled complexes is found in
Wolfe, A.L. et al, J. Virol. 1996, 70: 1424-1432, Hazuda et al., J. Virol. 1997, 7k 7005-7011; Hazuda et al., Drug Design and Discovery 1997, 15: 17-24; and Hazuda et al., Science 2000, 287: 646-650.
EXAMPLE 33 Assay for inhibition of BDV replication
Assays for the inhibition of acute HTV infection of T-lymphoid cells (alternatively referred to herein as the "spread assay") were conducted in accordance with Vacca, J.P. et al., Proc. Natl. Acad. ScL USA 199 A, 9V. 4096. Representative compounds of the present invention exhibit inhibition of HIV replication in this assay. For example, compounds 1, 2, 5, 6, 9, 27, 29, 30, 32, 35-39, 42-63, 65-92, 106-157, 160, 161, 163, 166, 170, 175, 176 and 179-185 in Table 1 were found to have CIC95 values of less than 1 micromolar, and compounds 11, 12, 15-19, 21-23, 28, 64, 105, 159, 169 were found to have CIC95 values in a range from 1 to 10 micromolar. The other compounds in Table 1 were tested in the spread assay up to 1 micromolar, but specific IC95 values were not obtained; i.e., the IC95 values were greater than 1 micromolar. It is believed, however, that the IC95 values of these compounds would be less than about 50 micromolar.
EXAMPLE 34 Cytotoxicity
Cytotoxicity was determined by microscopic examination of the cells in each well in the spread assay, wherein a trained analyst observed each culture for any of the following morphological changes as compared to the control cultures: pH imbalance, cell abnormality, cytostatic, cytopathic, or crystallization (i.e., the compound is not soluble or forms crystals in the well). The toxicity value assigned to a given compound is the lowest concentration of the compound at which one of the above changes is observed. Representative compounds of the present invention that were tested in the spread assay (see Example 33) were examined for cytotoxicity. For example, compounds 11, 12, 15-19, 21-23, 28, 64, 105, 159, 169 in Table 1 were tested up to 10 micromolar and exhibited no toxicity, and the other compounds in Table 1 were tested up to 1 micromolar and exhibited no toxicity.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, the practice of the invention encompasses all of the usual variations, adaptations and/or modifications that come within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof:
Figure imgf000127_0001
wherein:
X is N(RK), O, S, S(O), S(0)2,
Figure imgf000127_0002
, where each * denotes the point of attachment to the rest of the molecule;
RK is:
(1) H,
(2) Ci_6 alkyl,
(3) C 1.6 alkyl substituted with T, wherein T is Cθ2RA, CN, SO2RA, N(RD)RE3 C(O)N(RD)RE N(RA)-C(O)C(O)-N(RD)RE, N(RA)-C(O)RB, N(RA)-SO2RB, N(RA)-SO2N(RD)RE, or N(RA)-CO2RB,
(4) Ci_6 haloalkyl,
(5) C(O)RA
(6) C(0)-Ci-6 haloalkyl,
(7) CO2RA5 (8) C(O)-U,
(9) C(0)-Ci-6 alkylene-U,
(10) C(O)N(RD)RE,
(11) C(O)-Ci-6 alkylene-N(RD)REs
(12) C(O)C(O)-U, (13) C(0)C(0)-Ci-6 alkylene-U,
(14) C(O)C(O)-N(RD)RE
(15) C(O)C(O)-Ci-6 alkylene-N(RD)RE5 (16) SO2RA
(17) SO2-U5
(18) SO2-C1-6 alkylene-U,
(19) SO2N(RD)RE5
(20) CycB,
(21) C 1-6 alkyl substituted with U, or
(22) Ci-6 alkyl substituted with C(O)N(RA)-C i_6 alkylene-U, wherein U is CycB, AryB, or HetB;
m and n are each independently integers equal to zero, 1, or 2, with the proviso that m + n is zero, 1, or 2;
Rl is:
(1) H,
(2) Ci_6 alkyl, (3) Ci-6 haloalkyl,
(4) Ci-6 alkyl substituted with V, wherein V is OH, O-Ci_6 alkyl, O-Ci-6 haloalkyl, SRA5 S(O)RA SO2RA5 N(RD)RE, C(O)N(RD)RE N(RA)-C(0)C(0)-N(RD)RE5
N(RA)-C(O)RB, N(RA)-SO2RB, N(RA)-C1-6 alkylene-SO2RB, N(RA)C(O)-C1-O alkylene-SO2RB, N(RA)-SO2N(RD)RE, N(RA)-CO2RB, or N(RA)-C(O)N(RD)RE5 (5) Ci-6 alkyl substituted with W, wherein W is CycA, AryA, HetA, O-Ci-6 alkylene-CycA, O-Ci-g alkylene-AryA, O-Ci-6 alkylene-HetA, S(0)j-Ci_6 alkylene-CycA, S(0)j-Ci-6 alkylene-AryA, S(0)j-Ci_6 alkylene-HetA,
N(RA)-C(O)-AryA, or N(RA)-C(O)-HetA,
(6) N(RA)-SO2RB, (7) N(RA)-SO2N(RD)RE,
(8) N(RA)-CO2RB,
(9) N(RD)RE,
(10) N(RC)RA5
(11) N(RA)-C(O)RB, (12) N(RC)-C(O)RA
(13) S(O)jRF
(14) ORF
(16) CycA,
(17) AryA, (18) HetA,
(19) N(RA)-C(O)-CycA,
(20) N(RA)-C(O)-AiyA,
(21) N(RA)-C(O)-HeIA,
(22) N(RA)-C(O)-N(RD)RE,
(23) N(RC)-C(O)-CycA,
(24) N(RC)-C(O)-AryA,
(25) N(RC)-C(O)-HeIA,
(26) N(RC)-C(O)-N(RD)RE5
(27) N(RA)-C(O)C(O)-CycA,
(28) N(RA)-C(O)C(O)-AiyA,
(29) N(RA)-C(O)C(O)-HetA,
(30) N(RA)-C(O)C(O)-N(RD)RE5
(31) N(RC)-C(O)C(O)-CycA,
(32) N(RC)-C(O)C(O)-AryA,
(33) N(RC)-C(O)C(O)-HetA, or
(34) N(RC)-C(O)C(O)-N(RD)RE;
each j is independently an integer equal to zero, 1, or 2;
R2 is H or C 1-6 alkyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form (i) a 3- to 7-membered saturated carbocyclic ring or (ii) a 4- to 7-membered saturated heterocyclic ring containing 1 or 2 heteroatoms independently selected from N, O and S, where independently each N is optionally substituted with C\.β alkyl and each S is optionally oxidized to S(O) or S(O)2;
each R3 is independently H or Ci -6 alkyl, and each R4 is independently H or C\-β alkyl; or alternatively R3 and R4 attached to the same carbon atom together form oxo or thioxo;
each R5 is independently H or Ci -6 alkyl, and each R6 is independently H or C 1-6 alkyl; or alternatively R5 and R6 attached to the same carbon atom together form oxo or thioxo;
R7 is H or Ci_6 alkyl; R.8 is H or C 1-6 alkyl; or alternatively R7 and R.8 together form oxo or thioxo;
R9 is H or Ci-6 alkyl;
Rl 0 is C i -6 alkyl substituted with CycC, AryC or HetC;
each RA is independently H or C\.β alkyl;
each RB is independently H or C 1-6 alkyl;
RC is C 1-6 alkyl substituted with CycA, AryA, or HetA; or alternatively, when X is N(RK) and Rl includes the N(RC) moiety, RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- to 7-membered diazacycloalkyl ring, wherein the portion of the fused ring obtained from RC and RK is a 1- to 4- membered methylene chain optionally substituted with oxo or Ci_6 alkyl;
each RD and RE are each independently H or C 1-6 alkyl, or together with the nitrogen to which they are both attached form a 4- to 7-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to RD and RE selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently Ci_6 alkyl or S(O)2-Ci-6 alkyl;
RF is Ci-6 alkyl, or alternatively, when X is N(RK) and Rl is SRF or ORF, RF and RK together with (i) the N atom to which RK is attached, (ii) the S or O atom to which RF is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- to 7-membered oxyazacycloalkyl or thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is a 1- to 4-membered methylene chain;
each CycA is independently C3-8 cycloalkyl which is optionally substituted with a total of from 1 to 6 substituents, wherein:
(i) from zero to 6 substituents are each independently:
(1) halogen,
(2) CN (3) Ci-6 alkyl,
(4) OH,
(5) O-Ci-6 alkyl,
(6) Ci_6 haloalkyl, or
(7) OCi -6 haloalkyl, and
(ϋ) from zero to 2 substituents are each independently:
(D CycD,
(2) AryD,
(3) HetD, or
(4) Ci-6 alkyl substituted with CycD, AryD, or HetD;
CycB and CycC each independently have the same definition as CycA;
each AryA is independently aryl which is optionally substituted with a total of from 1 to 5 substituents, wherein:
(i) from zero to 5 substituents are each independently:
(1) Ci_6 alkyl,
(2) Ci-6 alkyl substituted with OH, O-Ci-6 alkyl, O-Ci-g haloalkyl, CN, NO2, N(RA)RB5 C(O)N(RA)RB, C(O)RA5 CO2RA SRA, S(O)RA, S(0)2RA, S(O)2N(RA)RB5 N(RA)C(O)RB, N(RA)C02RB, N(RA)S(0)2RB,
N(RA)S(0)2N(RA)RB, OC(O)N(RA)RB3 N(RA)C(O)N(RA)RB5 or
N(RA)C(O)C(O)N(RA)RB,
(3) O-Ci-6 alkyl,
(4) C i_6 haloalkyl, (5) O-Ci-6 haloalkyl,
(6) OH,
(7) halogen,
(8) CN,
(9) NO2, (10) N(RA)RB5
(11) C(O)N(RA)RB5
(12) C(O)RA5
(13) C(0)-Ci-6 haloalkyl,
(14) C(O)ORA5 (15) OC(O)N(RA)RB5
(16) SRA,
(IV) S(O)RA
(18) S(O)2RA
(19) S(O)2N(RA)RB5
(20) N(RA)S(O)2RB3
(21) N(RA)S(O)2N(RA)RB3
(22) N(RA)C(O)RB5
(23) N(RA)C(O)N(RA)RB5
(24) N(RA)C(O)-C(O)N(RA)RB5 Or
(25) N(RA)CO2RB5 and
(ϋ) from zero to 2 substituents are each independently:
(1) CycD,
(2) AryD,
(3) HetD, or
(4) C i_6 alkyl substituted with CycD, AryD, or HetD;
AryB and AryC each independently have the same definition as AryA;
each HetA is independently a heteroaryl which is optionally substituted with a total of from 1 to 5 substituents, wherein:
(i) from zero to 5 substituents are each independently:
(1) Ci-6 alkyl,
(2) Ci-6 alkyl substituted with OH, O-Ci-6 alkyl, O-Ci-6 haloalkyl, CN, NO2, N(RA)RB, C(O)N(RA)RB5 C(O)RA5 CO2RA SRA S(O)RA S(O)2RA,
S(O)2N(RA)RB5 N(RA)C(O)RB, N(RA)CO2RB5 N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB5 OC(O)N(RA)RB5 N(RA)C(0)N(RA)RBS or N(RA)C(O)C(O)N(RA)RB5
(3) O-Ci-6 alkyl, (4) Ci-6 haloalkyl,
(5) O-Ci-6 haloalkyl,
(6) OH,
(7) 0X0,
(8) halogen, (9) CN,
(10) NO2, (H) N(RA)RB,
(12) C(O)N(RA)RB5 (13) C(O)RA5
(14) C(O)-Ci_6 haloalkyl,
(15) C(O)ORA,
(16) OC(O)N(RA)RB5
(17) SRA, (18) S(O)RA3
(19) S(O)2RA
(20) S(O)2N(RA)RB5
(21) N(RA)S(O)2RB5
(22) N(RA)S(O)2N(RA)RB5 (23) N(RA)C(O)RB,
(24) N(RA)C(O)N(RA)RB5
(25) N(RA)C(O)-C(O)N(RA)RB5 or
(26) N(RA)CO2RB, and
(ii) from zero to 2 substituents are each independently: (1) CycD,
(2) AryD,
(3) HetD, or
(4) C i _6 alky 1 substituted with CycD, AryD, or HetD;
HetB and HetC each independently have the same definition as HetA;
each CycD is independently a C3.8 cycloalkyl which is optionally substituted with from 1 to 4 substituents each of which is independently halogen, Ci_6 alkyl, OH, O-Ci-g alkyl, or Ci_6 haloalkyl;
each AryD is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 5 substituents each of which is independently any one of the substituents (1) to (25) as set forth above in part (i) of the definition of AryA; each HetD is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, C 1-6 alkyl, Ci_6 haloalkyl, O-Ci-6 alkyl, O-Ci_6 haloalkyl, or hydroxy;
each aryl is independently (i) phenyl, (ii) a 9- or 10-membered bicyclic, fused carbocyclic ring system in which at least one ring is aromatic, or (iii) an 11- to 14-membered tricyclic, fused carbocyclic ring system in which at least one ring is aromatic;
each heteroaryl is independently (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein each N is optionally in the form of an oxide, or (ii) a 9- or 10-membered bicyclic, fused ring system containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein either one or both of the rings contain one or more of the heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2;
and provided that:
(A) when m is zero and X is O, then Rl is not H or C\.ζ alkyl;
(B) when m is zero, X is O, and the -X[-C(R5R6)QC(R7R8)]- moiety is -OCH2- or -OCH2CH2- or -OCH2CH2CH2-, then Rl and R2 do not together form a ring;
(C) when X is N(RK) and RK is:
(1) H,
(2) Ci_6 alkyl,
(3) Ci-6 alkyl substituted with T, wherein T is Cθ2RA, CN, Sθ2RA, N(RD)RE, C(O)N(RD)RE, or N(RA)-C(O)RB,
(4) C 1-6 haloalkyl,
(5) C(O)RA
(6) C(O)-C 1-6 haloalkyl,
(8) C(O)-U and U is AryB or HetB, (9) C(O)-Ci-6 alkylene-U
(10) C(O)N(RD)RE5
(11) C(O)-Ci-6 alkylene-N(RD)RE,
(14) C(O)C(O)-N(RD)RE (except when RD and RE together with the N to which they are both attached form a saturated heterocyclic ring),
Figure imgf000135_0001
( 18) SO2-C i .6 alkylene-U, or
(21) C i_6 alkyl substituted with U (except when C\-β alkyl substituted with
U is CH2-HetB, and HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group, and m is zero and the -C(R5R6)ΠC(R7R8)- moiety is -CH2CH2-), then Rl is:
(4) C 1.6 alkyl substituted with V, wherein V is S(O)RA, N(RA)-C(O)C(O)-N(RD)RE, N(RA)-Sθ2RB, N(RA)-CI_6 alkylene-SO2RB, N(RA)C(O)-C i_6 alkylene-SO2RB, N(RA)-SO2N(RD)RE N(RA)-CO2RB, or N(RA)-C(O)N(RD)RE when N(RA)-C(O)N(RD)RE is other than NH-C(O)NH2,
(5) Ci_6 alkyl substituted with W, wherein W is O-Ci-g alkylene-CycA, O-Cl-6 alkylene-AryA, O-Ci_6 alkylene-HetA, S(0)j-Ci_6 alkylene-CycA, S(0)j-Ci_6 alkylene-AryA, S(O)j-Ci_6 alkylene-HetA,
N(RA)-C(O)-AryA, or N(RA)-C(O)-HetA, (7) N(RA)-SO2N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring, (10) N(RC)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring, (12) N(RC)-C(O)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(13) S(O)jRP when RF and RK are involved in the formation of a fused thioazacycloalkyl ring,
(14) OR!7 when RF and RK are involved in the formation of a fused oxyazacycloalkyl ring,
(16) CycA,
(21) N(RA)-C(O)-HetA, (22) N(RA)-C(O)-N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring,
(23) N(RC)-C(O)-CycA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(24) N(RC)-C(O)- AryA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(25) N(RC)-C(O)-HetA,
(26) N(RC)-C(O)-N(RD)RE when (i) RD and RE together with the N to which they are both attached form a optionally substituted saturated heterocyclic ring or (ii) R^ and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring),
(27) N(RA)-C(O)C(O)-CycA,
(28) N(RA)-C(O)C(O)-AryA, (29) N(RA)-C(O)C(O)-HetA,
(30) N(RA)-C(O)C(O)-N(RD)RE
(31) N(RC)-C(O)C(O)-CycA,
(32) N(RC)-C(O)C(O)-AryA,
(33) N(RC)-C(O)C(O)-HetA, or (34) N(RC)-C(O)C(O)-N(RD)RE; or
(D) when m is zero, the -C(R5R6)QC(R7R8). moiery is -CH2CH2-, X is N(RK)5 RK is CH2-HetB, and HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiery via a ring carbon atom and is optionally substituted with a methyl group, then either:
(dl) Rl is as defined in proviso C, or
(d2) Rl and R2 are both methyl, R9 is H, and RlO is 4-fluorobenzyl.
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula:
Figure imgf000137_0001
3. A compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein X is N(RK) or O.
4. A compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein:
R9 is H; and
RlO is:
(1) CH2-phenyl or CH2-HetC, wherein the phenyl is optionally substituted with a total of from 1 to 3 substituents, wherein (i) from zero to 3 substituents are each independently bromo, chloro, fluoro, Ci-4 alkyl, CF3, C(O)NH2, C(O)NH(Ci.4 alkyl), C(O)N(Ci_4 alkyl)2, S-C1.4 alkyl, SO2-C1-.4 alkyl, or Sθ2N(Ci_4 alkyl)2, and (ii) from zero to 1 substituent is a heteroaromatic selected from the group consisting of imidazolyl, triazolyl, oxadiazolyl, pyrrolyl, and pyrazolyl, wherein the heteroaomatic ring is optionally substituted with 1 or 2 substituents each of which is independently Cl, Br, F, Ci-4 alkyl, CF3, O-C1.4 alkyl, OCF3, or OH,
(2) CH2-HetC, wherein HetC is a heteroaryl which is (i) a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero to 1 O atom, and zero to 1 S atom, or (ii) a 9 or 10-membered bicyclic, fused ring system in which one ring is a benzene ring and the other ring is a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from zero to 3 N atoms, zero to 1 O atom, and zero to 1 S atom, wherein the heteroaryl is optionally substituted with from 1 to 3 substituents each of which is independently Cl, Br, F, or C i_4 alkyl.
5. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
X is N(RK) or O;
RK is:
(1) H,
(2) CM alkyl,
(3) Ci-4 alkyl substituted with T, wherein T is Cθ2RA, CN, N(RD)RE, or C(O)N(RD)RE5 (4) C(O)RA
(5) C(O)-C 1-4 fluoroalkyl,
(6) CO2RA
(7) SO2RA
(8) SO2-AIyB, (9) SO2N(RD)RE,
(10) C(O)N(RD)RE,
(11) C(O)C(O)-N(RD)RE
(12) C(O)-Cl-4 alkylene-N(RD)RE5
(13) CycB, (14) Ci_4 alkyl substituted with U, wherein U is CycB, AryB, or HetB, or
(15) Ci_4 alkyl substituted with C(O)N(RA)-C 1.4 alkylene-HetB;
Rl is:
(1) H, (2) Ci_4 alkyl,
(3) Ci_4 alkyl substituted with V, wherein V is OH, O-C1.4 alkyl, SRA, S(O)RA, SO2RA, N(RD)RE C(O)N(RD)RE5 N(RA)-C(0)C(0)-N(RD)RE, N(RA)-C(O)RB, N(RA)-SO2RB, N(RA)-C1-4 alkylene-SO2RB, N(RA)C(O)-C 1.4 alkylene-SO2RB, N(RA)-SO2N(RD)RE5 or N(RA)-CO2RB, (4) Ci-4 alkyl substituted with W, wherein W is CycA, AryA, HetA, O-Ci-4 alkylene-AryA, O-C1.4 alkylene-HetA, or N(RA)-C(O)-HetA,
(5) N(RA)-SO2RB,
Figure imgf000139_0001
(8) N(RD)RE
(9) N(RC)RA
(10) N(RA)-C(O)RB,
(11) N(RC)-C(O)RA (12) SRF, S(O)RF or S(O)2RF,
(13) N(RA)-C(O)-HdA,
(14) N(RC)-C(O)-N(RD)RE5 Or
(15) N(RA)-C(O)C(O)-N(RD)RE5 Or
(16) N(RC)-C(0)C(0)-N(RD)RE;
R2 is H or C 1-4 alkyl; or alternatively Rl and R2 together with the ring carbon atom to which they are both attached form (i) a 3- to 6-membered saturated carbocyclic ring or (ii) a 6-membered saturated heterocyclic ring containing 1 heteroatom selected from N, O and S, where the N is optionally substituted with C i_4 alkyl and the S is optionally oxidized to S(O) or S(O)2;
each R3 is independently H or Cl .4 alkyl, and each R4 is independently H or Ci .4 alkyl; or alternatively
R3 and R4 attached to the same carbon atom together form oxo;
each R5 is independently H or Cl .4 alkyl, and each R^ is independently H or Ci .4 alkyl; or alternatively R5 and R6 attached to the same carbon atom together form oxo;
R7 is H or C1.4 alkyl;
R8 is H or C 1-4 alkyl; or alternatively R7 and R§ together form oxo;
R9 is H or Ci_4 alkyl;
RlO is C 1-4 alkyl substituted with CycC, AryC or HetC; each RA is independently H or C 1.4 alkyl;
each RB is independently H or C 1.4 alkyl;
RC is Ci_4 alkyl substituted with CycA, AryA, or HetA; or alternatively, when X is N(RK) and Rl includes the N(RC) moiety, RC and RK together with (i) the N atom to which RK is attached, (ii) the N atom to which RC is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered diazacycloalkyl ring; wherein the portion of the fused ring obtained from RC and RK. is a 1- to 3- membered methylene chain optionally substituted with oxo or Cl .4 alkyl;
each RD and RE are independently H or C 1.4 alkyl, or together with the nitrogen to which they are both attached form a 5- or 6-membered saturated heterocyclic ring optionally containing a heteroatom in addition to the nitrogen attached to RC and RD selected from N, O, and S, where the S is optionally oxidized to S(O) or S(O)2, and wherein the saturated heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl or S(O)2-Ci_4 alkyl;
RF is C 1.4 alkyl, or alternatively, when X is N(RK) and Rl is SRF, RF and RK together with (i) the N atom to which RK is attached, (ii) the S atom to which RF is attached, (iii) the ring carbon to which Rl is attached, and (iv) the zero, 1 or 2 ring carbons between X and the ring carbon to which Rl is attached, form a fused 5- or 6-membered thioazacycloalkyl ring, wherein the portion of the fused ring obtained from RF and RK is a 1- to 3 -membered methylene chain;
each CycA is independently a C3-6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C1.4 alkyl, OH, or O-C1.4 alkyl;
CycB is a C3.6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl, OH, or O-Ci-4 alkyl;
CycC is a C3-6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently C 1.4 alkyl, OH, or O-Cχ_4 alkyl;
each AryA is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 3 substituents each of which is independently: (1) C i_4 alkyl, which is optionally substituted with OH, O-Cχ.4 alkyl, O-C1.4 haloalkyl,
CN, N(RA)RB5 C(O)N(RA)RB, C(O)RA CO2RA, SKA, S(O)RA, SO2RA, or
SO2N(RA)RB3
(2) O-Ci-4 alkyl,
(3) C i_4 haloalkyl,
(4) O-Ci-4 haloalkyl,
(5) OH,
(6) halogen,
(7) CN,
(8) NO2,
(9) N(RA)RB5
(10) C(O)N(RA)RB5
(H) C(O)RA5
(12) C(O)-C 1.4 haloalkyl,
(13) CO2RA,
(14) SRA,
(15) S(O)RA,
Figure imgf000141_0001
(17) SO2N(RA)RB5
AryB independently has the same definition as AryA;
AryC is phenyl or naphthyl, wherein the phenyl or naphthyl is:
(i) optionally substituted with from 1 to 3 substituents each of which is independently any one of the substituents (1) to (17) as set forth above in the definition of AryA, and
(ii) optionally substituted with:
(1) AryD,
(2) HetD,
(3) CycD, or (4) Ci_4 alkyl substituted with CycD, AryD or HetD;
each HetA is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, Cl .4 alkyl, or OH;
HetB is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, Ci .4 alkyl, or OH;
HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein each N is optionally in the form of an oxide, and wherein the heteroaromatic ring is:
(i) optionally substituted with from 1 to 3 substituents each of which is independently halogen, C 1.4 alkyl, or OH; and
(ii) optionally substituted with AryD, HetD, CycD, or Ci_4 alkyl substituted with AryD, HetD or CycD;
each CycD is independently a C3.6 cycloalkyl which is optionally substituted with 1 or 2 substituents each of which is independently Ci .4 alkyl, OH, or O-C1.4 alkyl;
each AryD is independently phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 3 substituents each of which is independently any one of the substituents (1) to (17) as set forth above in the definition of AryA; and
each HetD is independently a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from zero to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently halogen, C 1.4 alkyl, or OH;
and provided that: (A) when m is zero and X is O, then Rl is not H or C 1.4 alkyl;
(B) when m is zero, X is O, and the -X[-C(R5R6)nC(R7R8)]_ moiety is -OCH2- or -OCH2CH2- or -OCH2CH2CH2-, then Rl and R2 do not together form a ring;
(C) when X is N(RK) and RK is: (1) H, (2) Ci_4 alkyl,
(3) Ci-4 alkyl substituted with T, wherein T is Cθ2RA, CN, N(RP)RE, or C(O)N(RD)RE,
(4) C(O)RA (5) C(O)-Ci_4 fluoroalkyl,
(7) SO2RA
(10) C(O)N(RD)RE,
(11) C(O)C(O)-N(RD)RE (except when RD and RE together with the N to which they are both attached form a saturated heterocyclic ring), (12) C(O)-Ci-4 alkylene-N(RD)REs Or
(14) C i _4 alkyl substituted with U (except when C i .4 alkyl substituted with U is CH2-HeIB, and HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group, and m is zero and the -C(R5R6)QC(R7R8)- moiety is -CH2CH2-), then Rl is:
(3) Ci_4 alkyl substituted with V, wherein V is S(O)RA, N(RA)-C(O)C(O)-N(RD)RE N(RA)-SO2RB, N(RA)-C 1 -4 alkylene-SO2RB, N(RA)C(O)-C 1.4 alkylene-SO2RB, N(RA)-SO2N(RD)RE5 or N(RA)-CO2RB,
(4) C i_4 alkyl substituted with W, wherein W is O-Ci-4 alkylene-AryA, O-Ci-4 alkylene-HetA, or N(RA)-C(O)-HetA, (6) N(RA)-SO2N(RD)RE when RD and RE together with the N to which they are both attached form an optionally substituted saturated heterocyclic ring, (9) N(RC)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring, (11) N(RC)-C(O)RA when RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring,
(12) SRF, S(O)RF, or S(O)2RF when RF and RK are involved in the formation of a fused thioazacycloalkyl ring,
(13) N(RA)-C(O)-HetA, (14) N(RC)-C(O)-N(RD)RE when (i) RD and RE together with the N to which they are both attached form a optionally substituted saturated heterocyclic ring or (ii) RC and RK are involved in the formation of an optionally substituted fused diazacycloalkyl ring),
(15) N(RA)-C(O)C(O)-N(RD)RE, or
(16) N(RC)-C(O)C(O)-N(RD)RE; or
(D) when m is zero, the -C(R5R6)ΠC(R7R8)- moiety is -CH2CH2-, X is N(RK), RK is CH2-HetB, and HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group, then either:
(dl) Rl is as defined in proviso C, or
(d2) Rl and R2 are both methyl, R9 is H, and Rl 0 is 4-fluorobenzyl.
6. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, which is a compound of formula:
Figure imgf000144_0001
7. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, which is a compound of Formula HI, wherein:
Rl and R^ are both methyl;
R5, R6, R7 and R8 are each H; RlO is 4-fluorobenzyl;
RK is CH2-HetB; and
HetB is a 5-membered heteroaromatic ring containing from 2 to 4 heteroatoms independently selected from 1 to 4 N atoms, zero or 1 O atom, and zero or 1 S atom, wherein the heteroaromatic ring is attached to the -CH2- moiety via a ring carbon atom and is optionally substituted with a methyl group.
8. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, which is a compound of Formula π, m, V, VI or VII; wherein
Rl is N(RA)-C(O)C(O)-N(RD)RE or N(RC)-C(O)C(O)-N(RD)RE; and
R2 is H.
9. A compound, or a pharmaceutically acceptable salt thereof, which is a compound selected from the group consisting of:
N-(4-fluorobenzyl)-3'-hydroxy-7'-methyl-4'-oxo-6I,7l-dihydro-4'H-spiro[cyclohexane-l,8'- imidazo[l,5-α]pyrimidme]-2'-carboxamide; N-[4-fluoro-2-(methylsulfonyl)benzyl]-3-hydroxy-7,8,8-trimethyl-4-oxo-4,6,7,8- tetrahydroimidazo[l,5-α]pyrimidine-2-carboxamide;
Ν-(4-fluorobenzyl)-8-hydroxy-7-oxo-2,3,7510b-tetrahydro[l,3]thiazolo[3',2':3,4]imidazo[l,5- α]pyrimidine-9-carboxamide;
3-hydroxy-7,8,8-trimethyl-N-[2-(methylthio)benzyl]-4-oxo-4,6,7,8-tetrahydroimidazo[l,5- fl]pyrimidine-2-carboxamide;'
N-(4-fluorobenzyl)-3-hydroxy-8,8-dimethyl-4-oxo-7-(pyridin-3-ylmethyl)-4,6,7,8- tetrahydroimidazo[l,5-α]pyrimidine-2-carboxamide;
Ν-(4-fluorobenzyl)-3-hydroxy-8,8-dimethyl-4,6-dioxo-4,6,7,8-tetrahydroimidazo[l,5- a]pyrimidine-2-carboxamide; 9-[(benzyloxy)methyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4Η-pyrazino[l,2- a]pyrimidine-2-carboxamide;
8-acetyl-N-(4-fluorobenzyl)-3-hydroxy-9-(hydroxymethyl)-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide; 9-[(benzyloxy)methyl]-N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2-carboxamide;
8-acetyl-9-[(ben2yloxy)methyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2-carboxamide; 9-[(dimethylamino)methyl]-8-[(dimethylamino)(oxo)acetyl]-N-(4-fluorobenzyl)-3-hydroxy-4- oxo-6, 7, 8,9-tetrahydro-4H-pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
8-acetyl-9-[(dimethylamino)methyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
9-[(dimethylamino)methyl]-N-(4-fluorobenzyl)-3-hydroxy-8-(l,3-oxazol-4-ylmethyl)-4-oxo- 6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
9-[(dimethylamino)methyl]-N-(4-fluoroben2yl)-3-hydroxy-8-[(l-methyl-lH-pyrazol-3- yl)methyl]-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
9-[(dimethylamino)methyl]-N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide; N-[(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-6,7,8;(9-tetrahydro-4H- ρyrazino[l,2-a]pyrimidin-9-yl)methyl]-N,Nl,Nl-trimethylethanediamide;
9-{[[(dimethylamino)sulfonyl](methyl)amino]methyl}-N-(4-fluorobenzyl)-3-hydroxy-8-methyl- 4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-8-methyl-9-({methyl[(methylsulfonyl)acetyl]amino}methyl)-4- oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3 -hydroxy-δ-methyl-θ- { [methyl(methylsulfonyl)amino]methyl} -4-oxo- 6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-8-methyl-9-{[methyl(pyridin-2-ylcarbonyl)amino]methyl}-4-oxo- 6,7,8,9-tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3 -hydroxy-8-methyl-9-( {methyl [( 1 -oxidopyridin-2- yl)carbonyl]amino}methyl)-4-oxo-657,8,9-tetrahydro-4H-pyrazino[l:,2-a]pyrimidine-2-carboxamide; methyl 9- [(dimethylamino)methyl] -2- { [(4-fluorobenzy l)amino] carbonyl } -3 -hydroxy-4-oxo- 4,6,7,9-tetrahydro-8H-pyrazino[l,2-a]pyrimidine-8-carboxylate;
9-[(dimethylamino)methyl]-N-(4-fluorobenzyl)-3-hydroxy-8-(methylsulfonyl)-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-a] pyrimidine-2-carboxamide;
9-[(dimethylamino)methyl]-Ν-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4Η- pyrazino[l,2-a]pyriniidine-2-carboxamide;
Ν-(4-fluorobenzyl)-3-hydroxy-9-[(methylthio)methyl]-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-8-methyl-9-[(methylsulfonyl)methyl]-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3'-hydroxy-4'-oxo-253,5,6,7',8'-hexaliydro-4'H,6'H-spiro[pyran-4,9'- ρyrazino[l,2-a]pyrimidine]-2'-carboxamide; N-(4-fluorobenzyl)-3l-hydroxy-8l-methyl-4'-oxo-2,3,5,6,7',8'-hexahydro-4'H,6Η-spiro[pyran-4,9'- pyrazino[ 1 ,2-a]pyrimidine]-2'-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l;,2-a]pyrimidine- 2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-8,9-dimethyl-4-oxo-6,7,859-tetrahydro-4H-pyrazino[l,2- a]pyrimidine-2-carboxamide;
8-acetyl-N-(4-fluorobenzyl)-3-hydroxy-9-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- a]pyrimidine-2-carboxamide;
8-[(dimethylamino)(oxo)acetyl]-N-(4-fluoroben2yl)-3-hydroxy-9-methyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide; N-(4-fluoroben2yl)-3-hydroxy-9-methyl-8-[(l-methyl-lH-pyrazol-5-yI)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9-methyl-8-(l,3-oxazol-4-ylmethyl)-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3I-hydroxy-8I-[(l-methyl-lH-pyrazol-3-yl)methyl]-4'-oxo-2,3,5,6,7',8'- hexahydro-4'H,6'H-spiro[pyran-4,9'-pyrazino[l,2-a]pyrimidine]-2'-carboxamide;
N-(4-fluorobenzyl)-3'-hydroxy-8'-[(l-methyl-lH-pyrazol-3-yl)methyl]-4'-oxo-7',8I-dihydro- 4'H,6'H-spiro[cyclopropane-l,9'-pyrazino[l,2-a]pyrimidine]-2'-carboxamide;
N-(4-fluorobenzyl)-3'-hydroxy-8?-(l,3-oxazol-4-ylmethyl)-4'-oxo-7',8'-dihydro-4'H,6'H- spiro[cyclopropane- 1 ,9'-pyrazino[ 1 ,2-a]pyrimidine]-2'-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetraliydro-4H-pyrazino[l,2- σ]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-8,9,9-trimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- α]pyrimidine-2-carboxamide;
8-[(dimethylamino)(oxo)acetyl]-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-α] pyr imidine-2-carboxamide;
8-acetyl-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- α]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-(methylsulfonyl)-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[ 1 ,2-α]pyrimidine-2-carboxamide; N-(3-chloro-4-fluoroben2yl)-3-hydroxy-8,9,9-trimethyl-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[ 1 ,2-α]pyrimidine-2-carboxamide;
N-μ-fluoro^-CmethylsulfonyObenzylj-S-hydroxy-S^^-trimethyl^-oxo-βJ^^-tetrahydro^H- pyrazino[l,2-α]pyrimidine-2-carboxamide; N-(3-bromo-4-fluorobenzyl)-3-hydroxy-8,9,,9-trimethyl-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
N-{4-fluoro-2-[(methylamino)carbonyl]benzyl}-3-hydroxy-8,9,9-trimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(lH-pyrazol-5-ylmethyl)-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(pyrazin-2-ylmethyl)-6,7,8,9-tetrahydro-4H- pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-(l,3-oxazol-4-ylmethyl)-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-(l,3-oxazol-5-ylmethyl)-4-oxo-6,7,8,9-tetrahydro-
4H-pyrazino[l,2-a]pyrimidine-2-carboxainide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-(2-morpholin-4-ylethyl)-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(lH-l,2,3-triazol-5-ylmethyl)-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
N8-ethyl-N2-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-4,6,7,9-tetrahydro-8H- pyrazino[l,2-a]pyrimidine-2,8-dicarboxamide;
8-[(dimethylamino)sulfonyl]-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(pyridin-2-ylmethyl)-6,7,8,9-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(2-pyridin-2-ylethyl)-6,7,859-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-pyrazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluoroben2yl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-pyrazol-3-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-ρyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(lH-pyrazol-4-ylmethyl)-6,7,8,9-tetrahydro- 4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide; N-(4-fluoroberi2yl)-3-hydroxy-9,9-dime1iiyl-4-oxo-8-(l,3-thiazol-4-ylmethyl)-6,7,8,9-tetraliydro- 4H-pyrazino[l,2-a]pyrimidine-2-carboxatnide;
8-[2-(dimethylamino)-2-oxoethyl]-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide; 8-[2-(dimethylamino)ethyl]-N-(4-fluoroben2yl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
8-[2-(dimethylammo)-l-oxoethyl]-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methylisoxazol-3-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-a]pyrimidme-2-carboxamide;
8-[2-(diethylamino)ethyl]-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-l,2,4-triazol-3-yl)methyl]-4-oxo- 6,7,8,9-tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(2-methyl-l,3-thiazol-4-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(3-methylisoxazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(3-methyl-l,2,4-oxadiazol-5-yl)methyl]-4-oxo- 6, 7, 8,9-tetrahydro-4H-pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
8-(cyanomethyl)-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimetliyl-4-oxo-6J7,8,9-tetrahydro-4H- pyrazino[ 1 ,2-a]pyrimidme-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-(lH-tetrazol-5-ylmethyl)-6,7,8,9-tetrahydro- 4H-pyrazmo[l,2-a]pyrimidine-2-carboxamide; N-(4-fluoroben2yl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-l,2,3-triazol-4-yl)methyl]-4-oxo-
6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-l,2,3-triazol-5-yl)methyl]-4-oxo- 6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-(2-morpholin-4-yl-2-oxoethyl)-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[l,2-a]pyrimidme-2-carboxamide;
N-(4-fluoroben2yl)-3-hydroxy-959-dimethyl-4-oxo-8-(2-oxo-2-pyrrolidin-l-ylethyl)-6,7,8,9- tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[2-(methylamino)-2-oxoethyl]-4-oxo-6,7,8,9- tetrah.ydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide; (2-{[(4-fluoroben2yl)amino]carbonyl}-3-hydroxy-9,9-dimethyl-4-oxo-456,7,9-tetrahydro-8H- pyrazino[l,2-a]pyrimidin-8-yl)acetic acid;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[2-(4-methylpiperazin-l-yl)-2-oxoethyl]-4-oxo- 6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide; N-(4-fluoroben2yl)-3-hydroxy-9,9-dimethyl-8-(l,3,4-oxadiazol-2-ylmethyl)-4-oxo-6, 7,8,9- tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8-{2-oxo-2-[(pyridin-4- ylmethyl)amino]ethyl}-657,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-(l,3-oxazol-2-ylmethyl)-4-oxo-6,758,9-tetrahydro- 4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methyl-l,3,4-oxadiazol-2-yl)methyl]-4-oxo- 6,7,8,9-tetrahydro-4H-pyrazmo[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(l-methyl-lH-tetrazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(2-methyl-lH-tetrazol-5-yl)methyl]-4-oxo-6, 7,8,9- tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
8-benzyl-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2- a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(5-methyl-l,2,4-oxadiazol-3-yl)methyl]-4-oxo- 6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
8-(2-amino-2-oxoethyl)-N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimetliyl-8-[(5-methyl-l53-oxazol-2-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(4-methyl-l,3-oxazol-2-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino [ 1 ,2-α]pyrimidine-2-carboxamide;
(2- { [(4-fluorobenzyl)amino]carbonyl} -3-hydroxy-4-oxo-4,6,7,9-tetrahydro-8H-pyrazino[ 1 ,2- a]pyrimidin-8-yl)acetic acid;
8-benzyl-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine- 2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine-2- carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-4-oxo-8-(lH-l,2,3-triazol-5-ylmethyl)-6,7,8,9-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]pyrimidine- 2-carboxatnide;
8-[(dimethylarnino)(oxo)acetyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H- pyrazino[l,2-a]pyrimidine-2~carboxamide; S-acetyl-N-(4-fluorobenzyl)-3 -hydroxy-4-oxo-6, 7, 8,9-tetrahydro-4H-pyrazino [ 1 ,2-a]pyrimidine-
2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-4-oxo-8-(trifluoroacetyl)-6,7,8,9-tetrahydro-4H-pyrazino[l,2- a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-8-[(4-methylphenyl)sulfonyl]-4-oxo-6:,7,8,9-tetrahydro-4H- pyrazino [ 1 ,2-a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-4,7-dioxo-6,7,8,9-tetrahydro-4H-pyrazino[l,2-a]ρyrimidine-2- carboxamide;
7-benzyl-N-(4-fluorobenzyl)-3-hydroxy-4,6-dioxo-6,7,8,9-tetrahydro-4H-pyrimido[l,6- a]pyrimidine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-7-methyl-4,6-dioxo-6,7,8,9-tetrahydro-4H-pyrimido[l,6- a]pyrimidine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-8,9-dihydro-4H-pyrimido[2,l- d] [ 1 ,2,5]thiadiazine-2-carboxamide 7,7-dioxide;
(+) N-[2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-8-(2-phenylethyl)-4,6,7,8,9,10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepin- 10-yl]-N,N',N -trimethylethanediamide;
(-) N-[2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-8-(2-phenylethyl)-4,6,7,8,9,10- hexahydropyrimido[l,2-uT|[l,4]diazepin-10-yl]-N,N'N'-trimethylethanediamide;
Ν-(8-[(dimethylamino)(oxo)acetyl]-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-d][l,4]diazepin-10-yl)-N,N\N'-trimethylethanediamide; N-(cyclohexylmethyl)-N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-
4,6,7,8,9,10-hexahydropyrimido[l,2-d][l,4]diazepin-10-yl)-N',N'-dimethylethanediamide;
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-N-benzyl-N',N'-dimethylethanediamide;
N-(8-benzyl-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-N,N',N'-trimethylethanediamide;
N-[2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-(methylsulfonyl)-4-oxo-4,6, 7,8,9, 10- hexahydropyrimido[l,2-(i][l,4]diazepin-10-yl]-N,N'N-trimethylethanediamide;
(+)N-(2- { [(3 -chloro-4-fluorobenzyl)amino]carbonyl} -S-cyclopropyl-S -hydroxy-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-<5θ[l,4]diazepin-10-yl)-N,NJV'-trimethylethanediamide; (-)N-(2- { [(3 -chloro-4-fluorobenzyl)amino] carbonyl} -δ-cyclopropyl-3 -hydroxy-4-oxo- 4,6J,8,9,10-hexahydropyrimido[l,2-^[l,4]diazepin-10-yl)-N^,N'-trimethylethanediamide;
(+) N-(2-{[(3-chloro-4-methylbenzyl)atnino]carbonyl}-8-cyclopropyl-3-hydroxy-4-oxo- 4,6,7,8,9510-hexahydropyrimido[l,2-d][l,4]diazepin40-yl)-N^^4rimethylethanediamide; (-) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-8-cyclopropyl-3-hydroxy-4-oxo-
4,6,7,8,9,10-hexahydropyrimido[l,2-£/][l,4]dia2epin-10-yl)-Nr/V^V-trimethylethanediaxnide;
(+) N-(8-(cyclopropylmethyl)-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-_f][l,4]diazepin-10-yl)-N,N',N'-trimethylethanediamide;
(-) N-(8-(cyclopropylmethyl)-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-<fl[l,4]diazepin-10-yl)-N,N',N'-trimethylethanediamide;
(+) N-(8-cyclopentyl-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6, 7,8,9, 10- hexahydropyrimido[l,2-t/][l,4]diazepin-10-yl)-N,N'iV'-trimethylethanediamide;
(-) N-(8-cyclopentyl-2-{[(4-fluoroben2yl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-cf][l54]diazepin-10-yl)-N,N',Λr'-trimethylethanediamide; N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l ,2-d] [ 1 ,4]diazepin- 10-yl)-N-isobutyl-N', N'-dimethylethanediamide;
(+) N-(2-{[(4-fluoro-3-meth.ylbenzyl)amino]carbonyl}-3-hydroxy-8-isopropyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-(JJ [ 1 ,4] diazepin- 10-yl)-N,N JV-trimethylethanediamide;
(-) N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-8-isopropyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido [ 1 ,2-d] [1 ,4] diazepin- 10-yl)-N,N,A''-tπmethylethanediarmde;
N-(4-fluorobenzyl)-3 -hydroxy-8-methyl- 10- {methyl[morpholin-4-yl(oxo)acetyl] amino } -4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-JJ[l,4]diazepine-2-carboxamide;
(+) N-(8-(cyclopropylmethyl)-2-{[(4-fluorobenzyl)ammo]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9,l0-hexahydropyrimido[l,2-^[l54]diazepin-l0-yl)-N,N',N'-1τimethylethanediamide; (-) N-(8-(cyclopropylmethyl)-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-
4,6,7,8,9,10-hexahydropyrimido[l,2-J][l,4]diazepin-10-yl)-N,N',N'-trimethylethanediamide;
(+) N-(8-cyclopropyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-<5θ[l,4]diazepin-10-yl)-NyA''τΛ''-trimethylethanediamide;
(-) N-(8-cyclopropyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9,l0-hexahydropyrimido[l,2-(fl[l,4]diazepin-l0-yl)-N^^-1rime1iιylethanediamide;
N-(2-{[(3-chloro-4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6, 7,8,9, 10- hexahydropyrimido[l,2-^[l,4]diazepm-10-yl)-N,Nl,N-trimethylethanediamide;
(+) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10-
Figure imgf000152_0001
(-) N-(2-{[(3-chloro-4-methylben2yl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l:,2-(f][l,4]dia2:epm-10-yl)-N,N'y/V-trimethylethanediamide;
(+) N-(8-ethyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-<f][l,4]diazepin-10-yl)-N,N'N'-trimethylethanediamide; (-) N-(8-ethyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[ 1 ,2-d] [1 ,4]diazepin- 10-yl)-N,N' N'-trimethylethanediamide;
N-ethyl-N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo- 4,6,7,8,9, 10-hexahydropyrimido[l ,2-d\ [ 1 ,4]diazepin- 10-yl)-N,N-dimethylethanediamide;
(+) N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-isopropyl-4-oxo-4,657,8,9,10- hexahydropyrimido[l,2-c/][l,4]diazepin-10-yl)-N,N'rA/'-trimethylethanediamide;
(-) N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-isopropyl-4-oxo-4,6, 7,8,9, 10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-N,N,N-trimethylethanediamide;
N-(8-ace1yl-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,758,9,10- hexahydropyrimido[l,2-(/][l,4]diazepin-10-yl)-N,N',N-trimethylethanediamide; N-(4-fluorobenzyl)-3-hydroxy-8-methyl- 10- {methyl[oxo(pyrrolidin- 1 -yl)acetyl]amino} -4-oxo-
4,6,7,8,9, 10-hexahydropyrimido[ 1 ,2-d] [1 ,4]diazepine-2-carboxamide;
10-[acetyl(cyclohexylmethyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4] diazepine-2-carboxamide;
10-[acetyl(benzyl)amino]-Ν-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[l,2-ύf][l,4]diazepine-2-carboxamide;
8-acetyl- 10-[ben2yl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9, 10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepine-2-carboxamide;
(+) N-(2- { [(3-chlorobenzyl)amino]carbonyl} -3-hydroxy-8-methyl-4-oxo-4,6,7,8,9, 10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-N,N,N-trimethylethanediamide; (-) N-(2-{[(3-chlorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-c(][l,4]diazepin-10-yl)-N,N,N-trimethylethanediamide;
(+) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-<fl[l,4]diazepin-10-yl)-NJV'^'-trimethylethanediainide;
(-) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimidof 1 ,2-d] [1 ,4]diazepin- 10-yl)-NNI^V-trimethylethanediamide;
(-) N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-NJV^V-trimethylethanediamide;
(+) N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-cT|[l,4]diazepm-10-yl)-N,N^V-trimethylethanediamide; (+) N-(8-ethyl-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 1 O-yI)-N,N,N-trimethylethanediamide;
(-) N-(8-ethyl-2- { [(4-fluorobenzyl)amino]carbonyl} -3 -hydroxy-4-oxo-4,6,7,8,9, 10- hexahydropyrimido[ 1 ,2-d] [1 ,4]diazepin- 1 O-yl)-N,N,N-trimethylethanediamide; N-ethyl-N-(2-{[(4-fluorobenzyl)ammo]carbonyl}-3-hydroxy-8-methyl-4-oxo-4>6,7;8J9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 1 O-yl)-N,N'-dimethylethanediamide;
(-) N-(4-fluorobenzyl)-3-hydroxy-8-methyl-10-{methyl[(5-methyl-l,3,4-oxadiazol-2- yl)carbonyl]amino}-4-oxo-4,6,7, 8,9, 10-hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepine-2-carboxamide;
(+) N-(4-fluorobenzyl)-3 -hydroxy-8-metliyl- 10- {methyl[(5-methyl- 1 ,3 ,4-oxadiazol-2- yl)carbonyl]amino}-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2-uT][l,4]diazepine-2-carboxainide;
10-[[(dimethylamino)sulfonyl](methyl)ammo]-Ν-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo- 4,6,7,8,9, 10-hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepine-2-carboxamide;
(+)N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 10-y I)-NJV JV-trimethylethanediamide; (-) N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin-l 0^I)-N5N1 JV-trimethylethanediamide;
(+) N-(2-{[(4-fluoro-3-metb.ylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [1,4] diazepin- 10-y^-NJVjN-trimethylethanediamide;
(-)N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-i/][l,4]diazepin-10-yl)-NyN'yN'-trimethylethanediamide; l l-[(dimethylamino)(oxo)acetyl]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,9, 10, 11,12- hexahydro-4H-8,12-methanopyrimido[l,2-α][l,4,7]triazonine-2-carboxamide;
10-[benzyl(methyl)amino]-Ν-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9, 10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepine-2-carboxamide; N'-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-£/][l,4]diazepin-10-yl)-N,N-dimethylethanediamide;
10-[acelyl(isobutyl)amino]-Ν-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-4, 6,7,8,9, 10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepine-2-carboxamide;
10-[(cyclohexylmethyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-4,657,8,9,10- hexahydropyrimido[l ,2-d] [ 1 ,4]diazepine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-8-methyl-10-[methyl(methylsulfonyl)amino]-4-oxo-4,6, 7,8,9, 10- hexahydropyrimido[ 1 ,2-d] [1,4] diazepine-2-carboxamide;
10-(benzylamino)-N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9, 10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-8-methyl-10-[(methylsulfonyl)amino]-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4] diazepine-2-carboxamide; methyl (2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)methylcarbamate; 8-[(dimethylamino)(oxo)acetyl]-N-(4-fluoroben2yl)-3-hydroxy-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepine-2-carboxamide;
8-ben2yl-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimJdo[l,2- d] [ 1 ,4]diazepine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-10-(isobutylamino)-8-methyl-4-oxo-4,6, 7,8,9.10- hexahydropyrimidof 1 ,2-d] [1,4] diazeρine-2-carboxamide;
10-[acetyl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[l,2-d][l,4]diazepine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-8-(methylsulfonyl)-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2- d] [ 1 ,4] diazepine-2-carboxamide; 10-(acetylamino)-N-(4-fluorobenzyl)-3-hydroxy-8-methyl-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[l ,2-d][l ,4]diazeρine-2-carboxamide;
N-(4-fluorobenzyl)-3 -hydroxy- 1 l-methyl-4, 10-dioxo-6,7,9, 10, 11 , 12-hexahydro-4H-8, 12- methanopyrimido[ 1 ,2-α] [ 1 ,4,7]triazonine-2-carboxamide;
8-acetyl-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-4,6,7,8,9, 10-hexahydropyrimido[ 1,2- <s(][l,4]diazepine-2-carboxamide;
Ν-(4-fluorobenzyl)-3-hydroxy-10,10-dimethyl-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2- α] [ 1 ,4] diazepine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-9,10,10-trimethyl-4-oxo-4,6,7,8,9,10-hexahydropyrimido[l,2- α][l ,4]diazepine-2-carboxamide; N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4Η-pyrimido[l,2-c(][l,4]oxazepine-2- carboxamide;
10-(dimethylamino)-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4H-pyrimido[l,2- d] [ 1 ,4]oxazepine-2-carboxamide;
10-[acetyl(methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,759,10-tetrahydro-4H- pyrimidof 1 ,2-d] [1,4] oxazepine-2-carboxarrήde;
(+) N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4h- pyrimido[ 1 ,2-d] [ 1 ,4]oxazepin- 10-yl)-N,N' N'-trimethylethanediamide;
(-)N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4h- pyrimido[ 1 ,2-d] [ 1 ,4]oxazepin- 10-yl)-N,N',N -trimethylethanediamide; 10-[[(dimethylamino)sulfonyl](methyl)amino]-N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,9,10- tetrahydro-4h-pyrimido[ 1 ,2-d] [1,4] oxazepine-2-carboxamide;
N-(4-fluorobenzyl)-3-hydroxy-10-{methyl[(5-methyl-l,3,4-oxadiazol-2-yl)carbonyl]ammo}-4- oxo-6,7,9, 10-tetrahydro-4h-pyrimido[ 1 ,2-d\ [1 ,4]oxazepine-2-carboxamide; N-(4-fluoroben2yl)-3-hydroxy-10-{methyl[(4-methylpiperazm-l-yl)(oxo)acetyl]ainino}-4-oxo-
6,7,9, 10-tetrahydro-4H-pyrimido[ 1 ,2-d] [ l,4]oxazepine-2-carboxamide; and
N-(4-fluorobenzyl)-3 -hydroxy- 10- {methyl[(4-methylpiperazin- 1 -yl)sulfonyl]amino} -4-oxo- 6,7,9, 10-tetrahydro-4H-pyrimido[ 1 ,2-d] [ 1 ,4] oxazepine-2-carboxamide .
10. A compound according to claim 9, or a pharmaceutically acceptable salt thereof, which is a compound selected from the group consisting of:
Ν-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(2-methyl-lΗ-tetrazol-5-yl)methyl]-4-oxo-6,7,8,9- tetrahydro-4H-pyrazino[ 1 ,2-a]pyrimidine-2-carboxamide;
(-) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-8-cyclopropyl-3-hydroxy-4-oxo- 4,6,7,8,9, 10-hexahydropyrimido[ 1 ,2-d\[l ,4]diazepin- 10-yl)-N^V,N-trimethylethanediamide;
(+) N-(8-(cyclopropylmethyl)-2-{[(4-fluoro-3-methylben2yl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7, 8,9, 10-hexahydropyrimido[l ,2-d\[l ,4]diazepin- 10-yl)-N,N',N-trimethylethanediamide;
(-) N-(8-(cyclopropylmethyl)-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-^I[l,4]diazepm-10-yl)-N,N')N'-trimethylethanediamide; (+) N-(8-cyclopentyl-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-c(][l,4]diazepin-10-yl)-N,N',N'-trimethylethanediamide;
N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin-l 0-yl)-N-isobutyl-N',N -dimethylethanediamide;
(-) N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-8-isopropyl-4-oxo-4,6,7,8,9,10- hexahydropyrimidof 1 ,2-d] [ 1 ,4] diazepin- 10-yl)-N,N,N-1rimethylethanediamide;
N-(4-fluorobenzyl)-3-hydroxy-8-methyl-10-{methyl[moφholin-4-yl(oxo)acetyl]ammo}-4-oxo- 4,6,7,8,9,10-hexahydropyrimido[l,2-J][l,4]diazepine-2-carboxamide;
(+) N-(8-(cycloproρylmethyl)-2- { [(4-fluorobenzyl)amino]carbonyl } -3 -hydroxy-4-oxo- 4,6,7,8,9, 10-hexahydropyrimido[ l,2-d] [ 1 ,4]diazepin-l O-yl)-N,N',N'-trimethylethanediamide; (-) N-(8-(cyclopropylmethyl)-2- { [(4-fluorobenzyl)amino]carbonyl} -3-hydroxy-4-oxo-
4,6,7,8,9, 10-hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin-l O-yl)-N,N',N'-trimethylethanediamide;
(+) N-(8-cyclopropyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9, 10-hexahydropyrimido[ 1 ,2-d] [1 ,4]diazepin-l O-y^-N.N'^V-trimethylethanediamide; (-) N-(8-cyclopropyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo- 4,6,7,8,9, 10-hexahydropyrimido[l ,2-fiTJ[l,4]diazepm- 1 O-yl)-N,N,N-trimethylethanediamide;
N-(2-{[(3-chloro-4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepin- 10-y^-NjJVJV-trimethylethanediamide; (+) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[ 1 ,2-d] [1 ,4]diazepin- 1 O-yl)-N,N,N-trimethylethanediaπiide;
(-) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6, 7,8,9,10- hexahydropyrimidof 1 ,2-d] [ 1 ,4]diazepin-l O-yl)-N,N,N-trimethylethanediaπiide;
(+) N-(8-ethyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l ,2-d][ 1 ,4]diazepin- 10-yl)-N,N' N'-trimethylethanediamide;
(-) N-(8-ethyl-2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[ 1 ,2-d] [1 ,4]diazepin- 10-yl)-N,N' N'-trimethylethanediamide;
N-ethyl-N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo- 4,6,7,8,9,10-hexahydroρyrimido[l,2-c/][l,4]diazepin-10-yl)-N,N-dimethylethanediamide (HCl salt); (+) N-(2-{[(4-fluoroben2yl)amino]carbonyl}-3-hydroxy-8-isopropyl-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[ 1 ,2-d][l ,4]diazepin- 10-yl)-N,N,N-trimethylethanediamide;
(-) N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-isopropyl-4-oxo-4, 6, 7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 10-y^-NJV^-trimethylethanediamide;
(+)N-(2-{[(3-chlorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-NNI rN-trimethylethanediamide;
(-) N-(2-{[(3-chlorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimidof 1 ,2-^fJ[1 ,4]diazepin- 10-y^-N^VjiV-trimethylethanediamide;
(+) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimido [ 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-NN',N-trimethylethanediamide; (-) N-(2-{[(3-chloro-4-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6, 7,8,9,10- hexahydropyrimido[l,2-cd[l,4]diazepin-10-yl)-N,N5N-trimethylethanediamide;
(-) N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6, 7,8,9,10- hexahydropyrimidotl^-cdtl^ldiazepin-lO-y^-NjN^-trimethylethanediamide;
(+) N-(2- { [(4-fluoro-3-methylben2yl)amino]carbonyl} -S-hydroxy-S-methyR-oxo^^Jjδ^, 10- hexahydropyrimido[l ,2-d] [ 1 ,4]diazepin- 10-yl)-N,N,N-trimethylethanediamide;
(+) N-(8-ethyl-2- { [(4-fluorobenzyl)amino]carbonyl} -S-hydroxy^-oxo^^J^^, 10- hexahydropyrimidof 1 ,2-d] [ 1 ,4]diazepin- 10-y^-N^VjTV-trimethylethanediamide;
(-) N-(8-ethyl-2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimidof 1 ,2-d] [ 1 ,4]diazepin- 10-yl)-N,N',N'-trimethylethanediamide; N-ethyl-N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-cTl[l,4]diazepin-10-yl)-N'^V-dimethylethanediamide;
(+)N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido[l,2-c(l[l54]diazepin-10-yl)-N,N,N-trimethylethanediamide; 5 (-) N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-8-methyl-4-oxo-4,6,7,8,9,10- hexahydropyrimido [ 1 ,2-d\ [ 1 ,4] diazepin- 10-yl)-N,N^-trknethylethanediamide;
(+) N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,6,7,8,9,10- hexahydropyrimidof 1 ,2-d\ [1,4] diazepin- 1 O-yl)-N,N,N-trimethylemanediamide;
(-) N-(2-{[(4-fluoro-3-methylbenzyl)amino]carbonyl}-3-hydroxy-4-oxo-4,657,8,9,10- 0 hexahydropyrimido[ 1 ,2-d] [ 1 ,4] diazepin- 10-yl)-NN'yΛ''-trimethylethanediamide;
(+) N-(2- { [(4-fluorobenzyl)amino] carbonyl} -3 -hydroxy-4-oxo-6,7,9, 10-tetrahydro-4h- pyrimido[ 1 ,2-d] [ 1 ,4]oxazeρin-l 0-yl)-N,N' N -trimethylethanediamide; and
(-)N-(2-{[(4-fluorobenzyl)amino]carbonyl}-3-hydroxy-4-oxo-6,7,9,10-tetrahydro-4h- pyrimido[l,2-rf][l,4]oxazepin-10-yl)-N,N',N-trimethylethanediamide. 5
11. A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
0 12. A method for the inhibition of HIV integrase in a subj ect in need thereof which comprises administering to the subject an effective amount of the compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof.
13. A method for the treatment or prophylaxis of infection by HIV or for the 5 treatment, prophylaxis, or delay in the onset of AIDS in a subject in need thereof, which comprises administering to the subject an effective amount of the compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof.
14. Use of a compound according to any one of claims 1 to 10, or a pharmaceutically >0 acceptable salt thereof, for the inhibition of HIV integrase in a subject in need thereof.
15. Use of a compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of infection by HTV or for the treatment, prophylaxis, or delay in the onset of AIDS in a subject in need thereof.
5
16. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for the inhibition of HTV integrase in a subject in need thereof.
17. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS in a subject in need thereof.
PCT/GB2006/001062 2005-03-31 2006-03-22 Hiv integrase inhibitors WO2006103399A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2006228278A AU2006228278C1 (en) 2005-03-31 2006-03-22 HIV integrase inhibitors
CN200680009660XA CN101146811B (en) 2005-03-31 2006-03-22 Hiv integrase inhibitors
JP2008503572A JP5116660B2 (en) 2005-03-31 2006-03-22 HIV integrase inhibitor
EP06726483A EP1866313A1 (en) 2005-03-31 2006-03-22 Hiv integrase inhibitors
CA2600832A CA2600832C (en) 2005-03-31 2006-03-22 Hiv integrase inhibitors
US11/887,305 US7981879B2 (en) 2005-03-31 2006-03-22 HIV integrase inhibitors
US13/172,393 US20110257162A1 (en) 2005-03-31 2011-06-29 Hiv integrase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66689705P 2005-03-31 2005-03-31
US60/666,897 2005-03-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/172,393 Division US20110257162A1 (en) 2005-03-31 2011-06-29 Hiv integrase inhibitors

Publications (2)

Publication Number Publication Date
WO2006103399A1 true WO2006103399A1 (en) 2006-10-05
WO2006103399A8 WO2006103399A8 (en) 2007-11-01

Family

ID=36648790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001062 WO2006103399A1 (en) 2005-03-31 2006-03-22 Hiv integrase inhibitors

Country Status (7)

Country Link
US (2) US7981879B2 (en)
EP (1) EP1866313A1 (en)
JP (1) JP5116660B2 (en)
CN (1) CN101146811B (en)
AU (1) AU2006228278C1 (en)
CA (1) CA2600832C (en)
WO (1) WO2006103399A1 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118589A1 (en) 2004-05-28 2005-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2007061714A1 (en) * 2005-11-17 2007-05-31 Bristol-Myers Squibb Company Hiv integrase inhibitors
JP2007537251A (en) * 2004-05-12 2007-12-20 ブリストル−マイヤーズ　スクイブ　カンパニー HIV integrase inhibitor: cyclic pyrimidinone compound
WO2008077188A1 (en) * 2006-12-22 2008-07-03 Avexa Limited Bicyclic pyrimidinones and uses thereof
US7491819B1 (en) 2004-05-28 2009-02-17 Bristol-Myers Squibb Company N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
WO2009117540A1 (en) * 2008-03-19 2009-09-24 Bristol-Myers Squibb Company Bridged heterocycles as hiv integrase inhibitors
WO2010042391A2 (en) * 2008-10-06 2010-04-15 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2010088167A1 (en) * 2009-01-28 2010-08-05 Merck Sharp & Dohme Corp. Bridged compounds as hiv integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7897592B2 (en) 2005-11-15 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2291377A1 (en) * 2008-07-02 2011-03-09 Avexa Limited Imidazopyrimidinones and uses thereof
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2470014A1 (en) * 2009-08-26 2012-07-04 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015048363A1 (en) 2013-09-27 2015-04-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
EP2871957A4 (en) * 2012-07-11 2016-01-27 Merck Sharp & Dohme Macrocyclic compounds as hiv integrase inhibitors
WO2016191239A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US9643982B2 (en) 2013-05-17 2017-05-09 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017116928A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
US9981964B2 (en) 2013-12-17 2018-05-29 Agency For Science, Technology And Research Maleimide derivatives as modulators of wnt pathway
WO2018102485A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018102634A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
US10208017B2 (en) 2012-06-01 2019-02-19 Nogra Pharma Limited Heterocycles capable of modulating T-cell responses, and methods of using same

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2009062288A1 (en) 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
CN102336751A (en) * 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 Novel antiviral agent
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
CN105523998B (en) * 2015-12-16 2019-12-17 杨冰 preparation process of methimazole
PT3938047T (en) * 2019-03-22 2022-10-03 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
TWI843506B (en) 2022-04-06 2024-05-21 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058756A1 (en) * 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2005061490A1 (en) * 2003-12-22 2005-07-07 Shionogi & Co., Ltd. Hydroxypyrimidinone derivative having hiv integrase inhibitory activity
US20050256109A1 (en) * 2004-05-12 2005-11-17 Naidu B N HIV integrase inhibitors: cyclic pyrimidinone compounds
US20050267132A1 (en) * 2004-05-28 2005-12-01 Jacques Banville Bicyclic heterocycles as HIV integrase inhibitors
US20050267105A1 (en) * 2004-05-28 2005-12-01 Naidu B N Bicyclic heterocycles as HIV integrase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262055B1 (en) 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
US6306891B1 (en) 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
US6380249B1 (en) 1998-06-03 2002-04-30 Merck & Co., Inc. HIV integrase inhibitors
EP1196384A4 (en) 1999-06-25 2002-10-23 Merck & Co Inc 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
EP1326611B1 (en) 2000-10-12 2007-06-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
NZ525088A (en) 2000-10-12 2004-11-26 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
JP2004517860A (en) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Aza- and polyaza-naphthalenylcarboxamides useful as HIV integrase inhibitors
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
EP2181985B1 (en) 2001-08-10 2011-10-26 Shionogi & Co., Ltd. Antiviral Agent
CN102219750B (en) 2001-10-26 2013-05-29 P.安杰莱蒂分子生物学研究所 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
WO2003035076A1 (en) 2001-10-26 2003-05-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US7279487B2 (en) 2002-01-17 2007-10-09 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
US7135467B2 (en) 2003-01-13 2006-11-14 Bristol-Myers Squibb Company HIV integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
US20040229982A1 (en) * 2003-05-14 2004-11-18 Goossens Danielle F. Stabilized flame retardant additives and their use
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7491819B1 (en) 2004-05-28 2009-02-17 Bristol-Myers Squibb Company N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2007064316A1 (en) 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058756A1 (en) * 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2005061490A1 (en) * 2003-12-22 2005-07-07 Shionogi & Co., Ltd. Hydroxypyrimidinone derivative having hiv integrase inhibitory activity
US20050256109A1 (en) * 2004-05-12 2005-11-17 Naidu B N HIV integrase inhibitors: cyclic pyrimidinone compounds
US20050267132A1 (en) * 2004-05-28 2005-12-01 Jacques Banville Bicyclic heterocycles as HIV integrase inhibitors
US20050267105A1 (en) * 2004-05-28 2005-12-01 Naidu B N Bicyclic heterocycles as HIV integrase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THORNBER C W: "ISOSTERISM AND MOLECULAR MODIFICATION IN DRUG DESIGN", CHEMICAL SOCIETY REVIEWS, CHEMICAL SOCIETY, LONDON, GB, vol. 8, no. 4, 1979, pages 563 - 580, XP000953019, ISSN: 0306-0012 *

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537251A (en) * 2004-05-12 2007-12-20 ブリストル−マイヤーズ　スクイブ　カンパニー HIV integrase inhibitor: cyclic pyrimidinone compound
US7511037B2 (en) 2004-05-28 2009-03-31 Bristol-Myers Squibb Company N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1753767A1 (en) * 2004-05-28 2007-02-21 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1753767A4 (en) * 2004-05-28 2010-06-30 Bristol Myers Squibb Co Bicyclic heterocycles as hiv integrase inhibitors
WO2005118589A1 (en) 2004-05-28 2005-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
US7491819B1 (en) 2004-05-28 2009-02-17 Bristol-Myers Squibb Company N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
US10927129B2 (en) 2005-04-28 2021-02-23 Shinogi & Co., Ltd. N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
US11267823B2 (en) 2005-04-28 2022-03-08 Shionogi & Co., Ltd. Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity
US8410103B2 (en) 2005-04-28 2013-04-02 Shionogi & Co., Ltd. (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
US8778943B2 (en) 2005-04-28 2014-07-15 Shionogi & Co., Ltd. Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-α]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides
US9051337B2 (en) 2005-04-28 2015-06-09 Shionogi & Co., Ltd. Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
US9273065B2 (en) 2005-04-28 2016-03-01 Shionogi & Co., Ltd. Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
US7897592B2 (en) 2005-11-15 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007061714A1 (en) * 2005-11-17 2007-05-31 Bristol-Myers Squibb Company Hiv integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
JP2009515981A (en) * 2005-11-17 2009-04-16 ブリストル−マイヤーズ スクイブ カンパニー HIV integrase inhibitor
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
US8143268B2 (en) 2006-12-22 2012-03-27 Avexa Limited Bicyclic pyrimidinones and uses thereof
WO2008077188A1 (en) * 2006-12-22 2008-07-03 Avexa Limited Bicyclic pyrimidinones and uses thereof
US8859563B2 (en) 2006-12-22 2014-10-14 Avexa Limited Bicyclic pyrimidinones and uses thereof
US8207334B2 (en) 2006-12-22 2012-06-26 Avexa Limited Bicyclic pyrimidinones and uses thereof
EP2269992A1 (en) * 2006-12-22 2011-01-05 Avexa Limited Bicyclic pyrimidinones for the treatment of viral infections
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
JP2011515412A (en) * 2008-03-19 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Bridged heterocycles as HIV integrase inhibitors
WO2009117540A1 (en) * 2008-03-19 2009-09-24 Bristol-Myers Squibb Company Bridged heterocycles as hiv integrase inhibitors
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2291377A1 (en) * 2008-07-02 2011-03-09 Avexa Limited Imidazopyrimidinones and uses thereof
EP2291377A4 (en) * 2008-07-02 2011-10-05 Avexa Ltd Imidazopyrimidinones and uses thereof
US8431581B2 (en) 2008-07-02 2013-04-30 Avexa Limited Imidazopyrimidines and uses thereof
WO2010042391A3 (en) * 2008-10-06 2010-06-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
WO2010042391A2 (en) * 2008-10-06 2010-04-15 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
WO2010042392A2 (en) * 2008-10-06 2010-04-15 Merck & Co., Inc. Hiv integrase inhibitors
JP2012504648A (en) * 2008-10-06 2012-02-23 メルク・シャープ・エンド・ドーム・コーポレイション HIV integrase inhibitor
WO2010042392A3 (en) * 2008-10-06 2010-06-03 Merck & Co., Inc. Hiv integrase inhibitors
AU2009302663B2 (en) * 2008-10-06 2012-11-08 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US8513234B2 (en) 2008-10-06 2013-08-20 Merck Sharp & Dohme Corp. HIV integrase inhibitors
EP2391212A4 (en) * 2009-01-28 2012-08-08 Bridged compounds as hiv integrase inhibitors
WO2010088167A1 (en) * 2009-01-28 2010-08-05 Merck Sharp & Dohme Corp. Bridged compounds as hiv integrase inhibitors
EP2391212A1 (en) * 2009-01-28 2011-12-07 Merck Sharp & Dohme Corp. Bridged compounds as hiv integrase inhibitors
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2470014A4 (en) * 2009-08-26 2013-01-16 Merck Sharp & Dohme Hiv integrase inhibitors
EP2470014A1 (en) * 2009-08-26 2012-07-04 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
US8664248B2 (en) 2010-01-22 2014-03-04 Taimed Biologics, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
US10562883B2 (en) 2012-06-01 2020-02-18 Nogra Pharma Limited Heterocycles capable of modulating T-cell responses, and methods of using same
US10208017B2 (en) 2012-06-01 2019-02-19 Nogra Pharma Limited Heterocycles capable of modulating T-cell responses, and methods of using same
EP2861575B1 (en) * 2012-06-01 2019-02-27 Nogra Pharma Limited Heterocycles capable of modulating t-cell responses, and methods of using same
EP2871957A4 (en) * 2012-07-11 2016-01-27 Merck Sharp & Dohme Macrocyclic compounds as hiv integrase inhibitors
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9643982B2 (en) 2013-05-17 2017-05-09 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
EP3330272A1 (en) 2013-05-17 2018-06-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US9861620B2 (en) 2013-09-27 2018-01-09 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
WO2015048363A1 (en) 2013-09-27 2015-04-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
US10201533B2 (en) 2013-09-27 2019-02-12 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
US9981964B2 (en) 2013-12-17 2018-05-29 Agency For Science, Technology And Research Maleimide derivatives as modulators of wnt pathway
WO2016191239A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017116928A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2018102634A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018102485A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
US7981879B2 (en) 2011-07-19
WO2006103399A8 (en) 2007-11-01
EP1866313A1 (en) 2007-12-19
US20090253681A1 (en) 2009-10-08
CA2600832C (en) 2011-12-13
JP2008534561A (en) 2008-08-28
US20110257162A1 (en) 2011-10-20
JP5116660B2 (en) 2013-01-09
CN101146811B (en) 2012-01-11
CA2600832A1 (en) 2006-10-05
CN101146811A (en) 2008-03-19
AU2006228278B2 (en) 2010-07-22
AU2006228278C1 (en) 2011-06-23
AU2006228278A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CA2600832C (en) Hiv integrase inhibitors
CN111936475B (en) Immunomodulator, composition and preparation method thereof
AU2003292436B2 (en) Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors
AU2007246850B2 (en) Pentacyclic indole derivatives as antiviral agents
US7348425B2 (en) Inhibitors of HCV replication
AU2005274959A1 (en) Inhibitors of HCV replication
PT2989106T (en) Fused heterocyclic compounds as protein kinase inhibitors
EP1725102A1 (en) Hiv integrase inhibitors
WO2007092000A1 (en) Inhibitors of hcv replication
AU2008212645A1 (en) 2-Amino-5, 7-dihydro-6H-pyrrolo[3, 4-d]pyrimidine derivatives as HSP-90 inhibitors for treating cancer
US20080221090A1 (en) HCV NS5B Inhibitors
CA3176635A1 (en) Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2007050510A2 (en) Hiv integrase inhibitors
WO2015193169A1 (en) Fused bicyclic heteroaromatic derivatives as kinase inhibitors
ES2529205T3 (en) Pyrimidine derivatives as mTOR inhibitors
WO2009154870A1 (en) Hiv integrase inhibitors
AU2004208890A1 (en) Novel tricyclic azepine derivatives, method for production therof and pharmaceutical compositions comprising the same
CA2542047A1 (en) Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006228278

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2006726483

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006726483

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2600832

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2006228278

Country of ref document: AU

Date of ref document: 20060322

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006228278

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680009660.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11887305

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008503572

Country of ref document: JP

Ref document number: 7479/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006726483

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)